8-K/A
Enovis CORP true 0001420800 0001420800 2024-01-03 2024-01-03

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K/A

(Amendment No. 1)

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 3, 2024

 

 

Enovis Corporation

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-34045   54-1887631

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

2711 Centerville Road, Suite 400

Wilmington, DE 19808

(Address of principal executive offices) (Zip Code)

(302) 252-9160

(Registrant’s telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, par value $0.001 per share   ENOV   New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


Item 2.01.

Completion of Acquisition or Disposition of Assets.

As previously reported, on January 3, 2024, Enovis Corporation (the “Company” or “Enovis”) completed its previously announced acquisition of LimaCorporate S.p.A. (“Lima”) from Emil Holding II S.à r.l (“Seller”). Pursuant to the Share Purchase Agreement, dated September 22, 2023, between Seller and the Company, the Company acquired all of the issued and outstanding share capital of Lima from the Seller.

This Amendment No. 1 to Current Report on Form 8-K/A (“Amendment No. 1”) is filed to amend the Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) by the Company on January 3, 2024 (the “Initial Report”) to include the historical financial statements of Lima and certain pro forma financial information required by Item 9.01 (a) and (b) of Form 8-K.

The pro forma financial information included in this Amendment No. 1 has been presented for informational purposes only. It does not purport to represent the actual results of operations that Enovis and Lima would have achieved had the companies been combined during the periods presented in the pro forma financial information and is not intended to project the future results of operations that the combined company may achieve after the consummation of the acquisition. Except as described above, all other information in the Initial Report remains unchanged and is incorporated by reference herein.

 

Item 9.01.

Financial Statements and Exhibits.

(a) Financial Statements of Businesses Acquired.

The audited consolidated financial statements of Lima as of and for the years ended December 31, 2022 and December 31, 2021, together with the notes related thereto and the Independent Auditors’ Report thereon, are filed as Exhibit 99.1 to this Amendment No. 1 and included herein.

The unaudited condensed consolidated financial statements of Lima as of September 30, 2023 and for the nine months ended September 30, 2023 and 2022, together with the notes thereto, are filed as Exhibit 99.2 to this Amendment No. 1 and included herein.

(b) Pro Forma Financial Information.

The Company’s unaudited pro forma condensed combined balance sheet as of September 30, 2023 and unaudited pro forma condensed combined statement of operations for the year ended December 31, 2022 and the nine months ended September 30, 2023, together with the notes related thereto, are filed as Exhibit 99.3 to this Amendment No. 1 and included herein.

(d) Exhibits.

 

23.1    Consent of KPMG S.p.A., independent auditors of Lima.
99.1    Audited consolidated financial statements of Lima as of and for the years ended December 31, 2022 and December 31, 2021, including the notes related thereto and the Independent Auditors’ Report thereon.
99.2    Unaudited condensed consolidated financial statements of Lima, as of September 30, 2023 and for the nine months ended September 30, 2023 and 2022, together with the notes thereto.
99.3    Unaudited pro forma condensed combined financial information, giving effect to the acquisition of Lima, including the condensed combined balance sheet as of September 30, 2023 and unaudited pro forma condensed combined statement of operations for the year ended December 31, 2022 and the nine months ended September 30, 2023, together with the notes related thereto.
104    Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: February 21, 2024   ENOVIS CORPORATION
    By:  

/s/ Phillip B. Berry

    Name:   Phillip B. Berry
    Title:   Senior Vice President and Chief Financial Officer
EX-23.1

Exhibit 23.1

Consent of Independent Auditors

We consent to incorporation by reference in the registration statements (No.’s 333-150710, 333-173883, 333-183115, 333-211357, 333-238564, 333-266526, 333-272340) on Form S-8 and in the registration statement (No. 333-253236) on Form S-3 of Enovis Corporation of our report dated February 1, 2024, with respect to the consolidated financial statements of Limacorporate S.p.A., which report appears in the Form 8-K/A of Enovis Corporation dated February 20, 2024.

/s/ KPMG S.p.A.

Padua, Italy

February 20, 2024

 

KPMG S.p.A. è una società per azioni di diritto italiano e fa parte del network KPMG di entità indipendenti affiliate a KPMG International Limited, società di diritto inglese.   

Ancona Bari Bergamo

Bologna Bolzano Brescia

Catania Como Firenze Genova

Lecce Milano Napoli Novara

Padova Palermo Parma Perugia

Pescara Roma Torino Treviso

Trieste Varese Verona

  

Società per azioni

Capitale sociale

Euro 10.415.500,00 i.v.

Registro Imprese Milano Monza Brianza Lodi

e Codice Fiscale N. 00709600159

R.E.A. Milano N. 512867

Partita IVA 00709600159

VAT number IT00709600159

Sede legale: Via Vittor Pisani, 25

20124 Milano MI ITALIA

EX-99.1

Exhibit 99.1

 

LOGO

Consolidated financial statements restated as at 31 December 2022

 

LOGO


Contents

 

Consolidated financial statements restated as at 31 December 2022 of the Limacorporate Group

     3  

Notes to the Consolidated financial statements restated as at 31 December 2022

     8  

Other information

     48  

 

2022    2


Consolidated financial statements restated as at 31 December 2022 of the Limacorporate Group

Statement of financial position

 

(€‘000)

                   
     Note     31/12/2022
restated
    31/12/2021
restated
    01/01/2021  

ASSETS

 

     

Non-current assets

  

Other intangible assets

     [3.1     58,234       53,595       44,477  

Goodwill

     [3.2     384,216       398,305       396,900  

Property, plant and equipment

     [3.3     79,837       81,773       85,288  

Equity investments

     [3.4     2       2       402  

Deferred tax assets

     [3.5     31,709       33,462       31,895  

Other non-current assets

     [3.6     861       705       663  
    

 

 

   

 

 

   

 

 

 

Total non-current assets

       554,859       567,843       559,625  
    

 

 

   

 

 

   

 

 

 

Current assets

        

Inventories

     [3.7     86,728       87,421       84,166  

Trade receivables

     [3.8     70,161       66,891       63,070  

Current tax assets

     [3.9     2,087       2,554       4,361  

Other current assets

     [3.10     14,192       11,247       11,469  

Cash and cash equivalents

     [3.11     25,920       21,503       26,273  
    

 

 

   

 

 

   

 

 

 

Total current assets

       199,088       189,617       189,340  
    

 

 

   

 

 

   

 

 

 

TOTAL ASSETS

       753,947       757,461       748,965  
    

 

 

   

 

 

   

 

 

 

EQUITY AND LIABILITIES

        

Equity

        

Share capital

     [3.12     9,868       9,868       9,868  

Share premium reserve

     [3.12     14,425       14,425       14,425  

Other reserves

     [3.12     323,510       317,570       310,762  

Retained earnings (accumulated deficit)

     [3.12     (21,966     (18,862     (6,380

Profit (loss) for the year

     [3.12     (19,273     (2,539     (12,482
    

 

 

   

 

 

   

 

 

 

Total equity attributable to the owners of the parent

       306,564       320,463       316,194  
    

 

 

   

 

 

   

 

 

 

Total equity

       306,564       320,463       316,194  
    

 

 

   

 

 

   

 

 

 

Non-current liabilities

        

Non-current financial liabilities

     [3.15     10,165       283,573       287,407  

Employee benefits

     [3.14     1,296       1,442       1,421  

Deferred tax liabilities

     [3.5     19,275       17,296       12,986  

Provisions for risks and charges

     [3.13     17,156       15,314       12,847  

Other non-current liabilities

     [3.16     649       5,250       5,476  
    

 

 

   

 

 

   

 

 

 

Total non-current liabilities

       48,541       322,875       320,137  
    

 

 

   

 

 

   

 

 

 

Current liabilities

        

Current financial liabilities

     [3.15     336,659       61,536       61,156  

Trade payables

     [3.17     36,564       32,343       28,941  

Current tax liabilities

     [3.18     877       202       491  

Other current liabilities

     [3.19     24,742       20,041       22,047  
    

 

 

   

 

 

   

 

 

 

Total current liabilities

       398,842       114,123       112,635  
    

 

 

   

 

 

   

 

 

 

TOTAL EQUITY AND LIABILITIES

       753,947       757,461       748,965  
    

 

 

   

 

 

   

 

 

 

 

2022    3


Income statement

 

(€‘000)

      
     Note     2022 restated     2021 restated  

Revenue

     [3.20     245,669       210,543  

Other revenues and income

     [3.20     5,798       3,973  
    

 

 

   

 

 

 

Total revenue and income

       251,467       214,517  
    

 

 

   

 

 

 

Raw materials, consumables, supplies and goods

     [3.21     (56,391     (53,530

Services

     [3.22     (81,645     (69,910

Change in w.i.p., semi-finished products and finished goods

     [3.23     (887     2,058  

Personnel expenses

     [3.24     (76,858     (60,773

Amortisation and Depreciation

     [3.25     (35,408     (32,517

Impairment losses on trade receivables

     [3.25     (502     (429

Impairment losses on fixed assets

     [3.25     (16,152     (209

Other operating costs

     [3.26     (1,857     (1,509

Internal work capitalised

     [3.27     13,532       16,250  
    

 

 

   

 

 

 

Operating costs

       (256,167     (200,570
    

 

 

   

 

 

 

Operating profit

       (4,700     13,947  
    

 

 

   

 

 

 

Financial income

     [3.28     14,561       7,829  

Financial expense

     [3.28     (22,609     (20,785
    

 

 

   

 

 

 

Net financial expense

       (8,048     (12,956
    

 

 

   

 

 

 

Pre-tax income (loss)

       (12,748     991  
    

 

 

   

 

 

 

Income tax benefit (expense)

     [3.29     (6,526     (3,529
    

 

 

   

 

 

 

Profit (loss) for the year

       (19,273     (2,539
    

 

 

   

 

 

 

of which attributable to the owners of the parent

       (19,273     (2,539
    

 

 

   

 

 

 

 

2022    4


Statement of comprehensive income

 

(€‘000)

             
     Note     2022 restated     2021 restated  

Profit (loss) for the year

       (19,273     (2,539
    

 

 

   

 

 

 

Other comprehensive income (expense)

      

Items that will never be reclassified to profit or loss (A)

      

Remeasurements of the net defined benefit liability (asset)

     [3.14     71       3  

Related tax

     [3.14     (17     (1
    

 

 

   

 

 

 
       54       2  
    

 

 

   

 

 

 

Items that are or may be reclassified to profit or loss (B)

      

Exchange differences on translation of foreign operations

     [3.12     871       1,842  
    

 

 

   

 

 

 
       871       1,842  
    

 

 

   

 

 

 

Other comprehensive income (expense), net of tax (A+B)

       925       1,844  
    

 

 

   

 

 

 

Comprehensive income (expense) for the year

       (18,348     (695
    

 

 

   

 

 

 

Comprehensive income (expense) attributable to:

      

Owners of the parent

       (18,348     (695
    

 

 

   

 

 

 

 

2022    5


Statement of changes in equity

 

(€‘000)

 
    Note     Share
capital
    Share premium
reserve
    Legal
reserve
    Merger
reserve
    Equity
Injections
    Translation
reserve
    Actuarial
reserve
    Other
reserves
    Retained earnings
including Profit (loss) for
the year
    Total equity
attributable to the
owners of the

parent
    Total
equity
 

Balance at 1 January 2021 as previously reported

      9,868       14,425       2,101       288,261       23,088       (334     (25     (2,328     (11,917     323,139       323,139  
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Impact of correction of errors

                      (6,945     (6,945     (6,945
                   

 

 

   

 

 

   

 

 

 

Restated balance at 1 January 2021

      9,868       14,425       2,101       288,261       23,088       (334     (25     (2,328     (18,862     316,194       316,194  
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Statement of comprehensive income

                       

Profit for the year

    [3.12     —        —        —        —        —        —        —        —        (2,539     (2,539     (2,539

Other comprehensive income

    [3.12     —        —        —        —        —        1,842       2       —        —        1,844       1,844  

Comprehensive income

      —        —        —        —        —        1,842       2       —        (2,539     (694     (694

Owner transactions

                       

Allocation of the loss for the previous year

    [3.12     —        —        —        —        —        —        —        —        —        —        —   

Other owner transactions

    [3.12     —        —        —        —        4,963       —        —          —        4,963       4,963  

Total owner transactions

      —        —        —        —        4,963       —        —        —        —        4,963       4,963  

Other changes

    [3.12     —        —        —        —        —        —        —        —        —        —        —   
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

At 31 December 2021 restated

      9,868       14,425       2,101       288,261       28,051       1,508       (23     (2,328     (21,401     320,463       320,463  
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Statement of comprehensive income

                       

Profit for the year

    [3.12     —        —        —        —        —        —        —        —        (19,273     (19,273     (19,273

Other comprehensive income

    [3.12     —        —        —        —        —        871       54       —        —        925       925  

Comprehensive income

      —        —        —        —        —        871       54       —        (19,273     (18,349     (18,349

Owner transactions

                       

Allocation of the loss for the previous year

    [3.12     —        —        —        —        —        —        —        565       (565     —        —   

Other owner transactions

    [3.12     —        —        —        —        —        —        —          —        —        —   

Total owner transactions

      —        —        —        —        —        —        —        565       (565     —        —   

Other changes

    [3.12     —        —        —        —        —        —        —        4,450       —        4,450       4,450  
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

At 31 December 2022 restated

      9,868       14,425       2,101       288,261       28,051       2,379       31       2,687       (41,239     306,564       306,564  
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

2022    6


Statement of cash flows

 

(€‘000)

      
     Note     2022 restated     2021 restated  

Operating activities

      

Profit (loss) for the year

     [3.12]       (19,273     (2,539

Income tax (benefit)/expense

     [3.29]       6,526       3,529  

Net financial (income)/expense

     [3.28]       10,809       13,979  

Amortisation, depreciation and impairment losses

     [3.25]       50,649       32,726  

Accruals/(Release) to provisions

     [3.26]       1,842       3,204  

Net (gains)/loss on disposals

     [3.20] [3.26]       (629     (550

FX on contingent consideration

     [3.28]       1,031       1,384  

Cash flows from operating activities before changes in working capital

       50,955       51,734  

Change in inventories

     [3.7]       693       (3,255

Change in trade receivables

     [3.8]       (3,270     (3,502

Change in trade payables

     [3.17]       4,220       3,402  

Change in other assets/liabilities

     [3.10] [3.16] [3.19]       316       523  

Change in non-current assets

     [3.6]       (156     358  

Income taxes paid

       (2,019     (846
    

 

 

   

 

 

 

Cash flows from operating activities A)

       50,739       48,414  
    

 

 

   

 

 

 

Investing activities

      

Acquisitions of property, plant and equipment

     [3.3]       (25,234     (21,983

Disposal of property, plant and equipment

     [3.3]       1,418       2,108  

Acquisitions of intangible assets

     [3.1]       (12,229     (14,229

Disposal of intangible assets

     [3.1]       955       47  
    

 

 

   

 

 

 

Cash flows used in investing activities B)

       (35,090     (34,056
    

 

 

   

 

 

 

Financing activities

      

Third party funds

      

Net change in current financial liabilities

     [3.15]       8,916       805  

Gross change in non-current financial liabilities

     [3.15]       (0     (572

Decrease in lease liabilities

     [3.15]       (4,401     (3,384

Net interest income

     [3.28]       163       154  

Net interest paid

     [3.28]       (15,911     (16,131
    

 

 

   

 

 

 

Cash flows from (used in) in financing activities C)

       (11,231     (19,127
    

 

 

   

 

 

 

Increase (decrease) in liquid funds (A ± B ± C)

       4,417       (4,770
    

 

 

   

 

 

 

Opening cash and cash equivalent

       21,503       26,273  

Closing cash and cash equivalent

       25,920       21,503  
    

 

 

   

 

 

 

Increase (decrease) in cash and cash equivalents

       4,417       (4,770
    

 

 

   

 

 

 

 

2022    7


Notes to the Consolidated financial statements restated as at 31 December 2022

[2.1] General information

The Limacorporate Group (the “group”) designs, creates and sells joint implants and repair solutions in the medical sector.

The parent, Limacorporate S.p.A. (“Limacorporate” or the “parent”), was set up and is domiciled in Italy. Its registered office is at Via Nazionale 52, San Daniele del Friuli (Udine) and its company registration number is 173824.

The group carries out most of its business at its registered office while some activities are also performed by the subsidiaries.

The consolidated financial statements restated as at and for the year ended 31 December 2022 include the financial statements of the parent and the subsidiaries (together the “group”).

These consolidated financial statements as at 31 December 2022 were approved by the parent’s board of directors at its meeting on January 31, 2024.

The parent is managed and coordinated by Emil Holding II S.à.r.l., whose details are provided below:

 

   

Registered office: 26A, Boulevard Royal, L-2449 Luxembourg.

 

   

Legal form: limited liability company.

 

   

Description of its business activities and main operations: holding company

 

   

Ultimate parent’s name: Emil NewCo S.à.r.l.

 

   

Name of the ultimate indirect parent: EQT Luxembourg Management S.à r.l.

[2.2] Basis of presentation

The consolidated financial statements restated as at 31 December 2022 is prepared in accordance with the IFRS issued by International Accounting Standards Board (IASB).

The Group’s equity and profit for the year previously reported, were restated in accordance with IAS 8 due to a correction of error related to the payback mechanism accounted in compliance with IFRS 15, retrospectively, as reduction of revenue (variable consideration). The note [4.1] Correction of errors describes the corrected error and includes the reconciliation schedules of the Group’s equity and profit both for the current year and for the comparative periods.

These consolidated financial statements restated as at 31 December 2022 comprise the statement of financial position, income statement, statement of comprehensive income, statement of changes in equity, statement of cash flows and these notes. They comply with the provisions of IAS 1 Presentation of financial statements and the general principle of historical cost, except for those items that, pursuant to the IFRS, are measured at fair value, as explained in the accounting policies of the individual captions in note 2.4 Basis of preparation. The statement of financial position has been prepared by separating assets and liabilities into current and non-current, whereas costs are classified in the income statements on the basis of their nature. The statement of cash flows has been prepared using the indirect method.

The notes to the consolidated financial statements restated as at 31 December 2022 include the information generally required by ruling legislation and the IFRS, suitably presented with reference to the financial statements schedules used.

The consolidated financial statements restated as at 31 December 2022 have been prepared on a going concern basis, as the related assumptions are deemed to be met.

All figures are in thousands of Euros, unless indicated otherwise. The Euro is the parent’s functional and presentation currency. For each financial statements caption, the corresponding amount of the previous year is provided for comparative purposes.

 

2022    8


[2.3] Consolidation scope

The consolidated financial statements restated of the Limacorporate Group as at 31 December 2022 include the financial statements of the parent and the Italian and foreign subsidiaries at 31 December 2022.

Subsidiaries are those companies over which the group has control, as defined by IFRS 10 consolidated financial statements restated as at 31 December 2022. Control exists when the group has the power to, directly or indirectly, govern the financial and operating policies of an entity so as to obtain benefits from its activities. The financial statements of subsidiaries are included in the Consolidated financial statements restated as at 31 December 2022 starting from when control is assumed and until such control ceases to exist.

The table below lists the companies included in the consolidation scope at 31 December 2022.

Subsidiaries are included in the consolidation scope from when the group acquires control, as defined above, and are excluded from when the group no longer has control.

Amounts in thousands (of the stated currency)

 

    

Registered office

  

Currency

   Share/quota
capital
     Equity      Profit (Loss)
for the year
     %  

LIMA AUSTRIA GmbH

   Seestadtstrasse 27 Top 6-7, 1220 Vienna (Austria)    (EUR)      35        1,278        172        100

LIMA BELGIUM SRL

  

Chaussée de Wavre 504, boîte 5A - 1390 Grez

Doiceau (Belgium)

   (EUR)      30        -1,250        289        100

LIMA CZ s.r.o.

  

Do Zahràdek I., 157/5 - 155 21 Praha 5 - Třebonice -

(Czech Republic)

   (CZK)      200        116,390        16,178        100

LIMA DENMARK ApS

   Lyngebaekgards Alle 2, 2990 Niva (Denmark)    (DKK)      500        427        142        100

LIMA DEUTSCHLAND GmbH

   Kapstadtring 10, - 22297 Hamburg - (Germany)    (EUR)      25        5,291        1,674        100

LIMA DO BRASIL LTDA

  

Al. Campinas, 728 – 2° andar salas 201, 202, 203 e

204.- Jardim Paulista - Sao Paulo - SP - CEP:01404- 001 (Brazil)

   (BRL)      1,500        -10,475        7,754        100

LIMA FRANCE Sas

  

1, Allée des Alisiers - Immeuble “Le Galilée” - 69500

Bron - (France)

   (EUR)      40        440        161        100

LIMA IMPLANTES PORTUGAL S.U. LDA

  

Rua Pêro Vaz de Caminha 8 E 2660-441 Stº António

Cavaleiros - (Portugal)

   (EUR)      5        2,357        125        100

LIMA IMPLANTES Slu

   C/ Manuel Tovar, 33-35 28034 Madrid - (Spain)    (EUR)      200        1,089        29        100

LIMA JAPAN K.K.

  

Tokyo Front Terrace 13F 2-3-14 Higashi

Shinagawa, Shinagawa, Tokyo, 140-0002 , (Japan)

   (JPY)      10,000        -984,102        -34,681        100

LIMA KOREA Co., Ltd

  

Zero Building 11th Floor, 14 Teheran Ro 84 Gil,

Gangnam Gu, Seoul 06178 - (Korea)

   (KRW)      100,000        -1,932,158        299,988        100

LIMA NETHERLANDS B.V.

   Bergweg 153A, 3707AC Zeist - (Netherlands)    (EUR)      18        1,007        232        100

LIMA O.I. d.o.o. - ORTOPEDIJA I IMPLANTATI

   Ante Kovačića, 3 - 10000 Zagreb - (Croatia)    (HRK)      300        32,024        1,586        100

LIMA ORTHOPAEDICS AUSTRALIA Pty Ltd

  

Unit 1, 40 Ricketts Road - Mt Waverley, 3149 Victoria -

(Australia)

   (AUD)      0        21,875        405        100

LIMA ORTHOPAEDICS NEW ZEALAND Pty Ltd

  

20 Crummer Rd Grey Lynn 1021 Auckland 1021 - New

Zealand

   (NZD)      0        10,014        195        100

LIMA ORTHOPAEDICS SOUTH AFRICA (PTY) LTD

  

Northlands Deco Park, Stand 326, 10 Newmarket

Street, Design Boulevard, Northriding, 2186 (South Africa)

   (ZAR)      0        -11,459        -92        100

LIMA ORTHOPAEDICS UK Ltd

  

4 Office Village Forder Way Cygnet Park Hampton

Peterborough Peterborough PE7 8GX (United Kingdom)

   (GBP)      0        6,932        947        100

LIMA POLSKA SP. z.o.o.

   ul. Ul Lopuszanska 95 - 02-457 Warsaw (Poland)    (PLN)      5        472        1,126        100

LIMA SK S.r.o.

  

Cesta na Stadiòn 7 - 97404 Banska Banska Bystrica -

(Slovakia)

   (EUR)      7        6,371        313        100

LIMA SWEDEN AB

   Box 180 - SE-184 22 Akersberga - (Sweden)    (SEK)      100        1,678        666        100

LIMA SWITZERLAND SA

  

Birkenstrasse, 49 - 6343 Rotkreuz - Zug -

(Switzerland)

   (CHF)      100        2,084        328        100

TASFIYE HALINDE LIMA TURKEY ORTOPEDI AS

  

Serifali Mah. Hendem Cad.No: 54 Canan Residence

OFIS A-2,34775 - UMRANIYE - Istanbul - (Turkiye)

   (TRY)      50        -13,713        -11,252        100

LIMA USA Inc.

  

2001 NE Green Oaks Blvd, Suite 100 - Arlington, TX

76006 - (United States)

   (USD)      20        79,420        -1,368        100

LIMA SM S.p.A. in liquidazione

  

Strada Borrana, 38 - Serravalle 47899 - (Repubblica di

San Marino)

   (EUR)      2,701        4,051        -1,174        100

TechMah Medical LLC

  

2099 Thunderhead Road, Suite 302 - Knoxville, TN

37922 - (United States)

   (USD)      29,084        961        -8,268        100

LIMA (BEIJING) MEDICAL DEVICES CO., LTD.

  

Room 616, 6/F, Building 1, No.1, Lize Zhong 2 Road,

Chaoyang District, Beijing, China

   (CNY)      3,014        -3,784        -2,761        100

LIMA ORTHOPAEDICS CANADA INC.

  

3715 Laird Road Suite Unit 9, Mississauga, ON,

Canada

   (CAD)      200        221        28        100

Lima Orthopaedics Canada Inc. incorporated under Canadian law in October 2021 was included in the consolidation scope in 2022. It began operations in the first half of 2022 and was not consolidated in 2021 as it was not yet up and running and was immaterial.

The reporting date of all of the consolidated companies is 31 December.

 

2022    9


The basis of consolidation is set out below:

 

   

Adopting the line-by-line method, showing the portions of equity and profit or loss for the year attributable to non-controlling interests and recognising assets, liabilities, revenue and costs regardless of the percentage held in the subsidiaries.

 

   

Eliminating items deriving from intragroup transactions involving consolidated companies, including any unrealised gains and losses arising from intragroup transactions and recognising the resulting deferred tax effects.

 

   

Eliminating intragroup dividends and reallocating them to opening equity reserves.

 

   

Eliminating the carrying amount of investments in consolidated companies and the relevant portion of equity, allocating the resulting positive and negative differences to the relevant captions (assets, liabilities and equity), as defined at the time of acquisition of the investment and considering any subsequent variations. After control is acquired, any acquisitions of non-controlling interests or sales of shares to non-controlling interests that do not entail loss of control are recognised as owner transactions and the relevant effects are taken directly to equity. Any differences between the change in equity attributable to non-controlling interests and cash and cash equivalents exchanged are recognised under changes in equity attributable to the owners of the parent.

 

   

The financial statements of foreign operations are translated into Euros using the annual average rate for income statement items and the closing rate for statement of financial position items. The difference between the two rates along with the translation differences deriving from changes in opening and closing exchange rates are recognised as changes in equity.

The following rates were applied in translating the financial statements of foreign operations:

 

Currency

   Average Rate      Closing Rate  

AUD - Australian Dollar

     1.51670        1.56930  

BRL - Brazilian Real

     5.43990        5.63860  

CAD - Canadian Dollar

     1.36950        1.44400  

CHF - Swiss Franc

     1.00470        0.98470  

CZK - Czech Koruna

     7.07880        7.35820  

CNY - Yuan Renminbi

     24.56590        24.11600  

DKK - Danish Krone

     7.43960        7.43650  

GBP - Pound Sterling

     0.85276        0.88693  

HRK - Croatian Kuna

     7.53490        7.53650  

JPY - Japanese Yen

     138.0274        140.66  

KRW - South Korean Won

     1,358.07        1,344.09  

NZD - New Zealand Dollar

     1.65820        1.67980  

PLN - Polish Zloty

     4.68610        4.6808  

SEK - Swedish Krona

     10.62960        11.12180  

TRY - Turkish Lira

     17.40880        19.96490  

USD - US Dollar

     1.05300        1.06660  

ZAR - South African Rand

     17.20860        18.0986  

[2.4] Basis of preparation

[2.4.1] Business combinations and goodwill

Business combinations are recognised using the acquisition method under IFRS 3. To this end, the identifiable assets acquired and the liabilities assumed are recognised at their respective acquisition-date fair value. The consideration transferred in a business combination is the aggregate of the fair value, at the date of exchange, of assets acquired, liabilities assumed and equity instruments issued by the acquirer, in exchange for control of the acquiree.

 

2022    10


Goodwill is the positive difference between the consideration transferred, increased by both the fair value at the acquisition date of any non-controlling interests already held in the acquiree and the amount of non-controlling interests held in the acquiree by third parties (measured at fair value or based on the present value of the acquiree’s identifiable net assets), and the fair value of such assets and liabilities.

At the acquisition date, goodwill is allocated to each of the largely independent cash-generating units that are expected to benefit from the synergies of the business combination.

If the difference between the consideration transferred (increased by the above components) and the fair value of the net assets acquired is negative, this is recognised as a gain from a bargain purchase in the income statement in the year of acquisition.

Any goodwill related to non-controlling interests is included in the carrying amount of the relevant equity investments.

After initial recognition, goodwill is not amortised and is recognised net of any cumulative impairment losses, calculated using the methods set out in section [2.4.6] Impairment losses.

As set out in section [3.2] Goodwill of this report, the market multiples method is used to determine the fair value of goodwill, using listed comparable companies (these multiples are compared with the implicit multiple calculated using the group’s actual figures), except for CGU TechMah for which the value in use is defined using estimated future cashflows by applying a discount rate.

IFRS 3 is not applied retrospectively to business combinations that took place prior to 1 January 2018, i.e., the date of the parent’s transition to the IFRS. Accordingly, the amount of goodwill determined under the previous reporting standards, i.e., the carrying amount at such date, is maintained for such business combinations, subject to the recognition of any impairment losses.

[2.4.2] Intangible assets

An intangible asset is an identifiable asset without physical substance, controlled by the group and that generates future economic benefits, in addition to goodwill when acquired against consideration.

Identifiability is defined with reference to the possibility of distinguishing the intangible asset acquired from goodwill. An intangible asset is identifiable when it: (i) arises from a legal or contractual right or (ii) is separable, i.e., can be sold, transferred, licensed, rented, or exchanged, either individually or together with a related contract. An entity controls an asset if it has the power to obtain the future economic benefits flowing from the underlying resource and to restrict the access of others to such benefits.

Intangible assets are stated at cost, which is determined in the same manner as for property, plant and equipment.

Intangible assets with finite useful lives are amortised over their estimated useful lives starting from when they are available for use.

The amortisation rates adopted in 2022 are shown in the following table by asset category:

 

    

2022

Development expenditure    5 - 10 years
Industrial patents and intellectual property rights    10 - 20 years
Concessions, licences, trademarks and similar rights    3 - 4 - 5 years
Other    Contract term / maximum 6 years

Development expenditure

Development expenditure is expensed when incurred.

Development expenditure incurred for a specific project is only capitalised when the group can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use and for sale, its intention to complete such asset and use or sell it, how the intangible asset will generate probable future economic benefits, the availability of adequate technical, financial and other resources to complete the development and its ability to measure reliably the expenditure attributable to the intangible asset during its development.

 

2022    11


Subsequent to initial recognition, development expenditure is measured at cost less any accumulated amortisation and any accumulated impairment losses. Amortisation of the asset starts from when the development phase has been completed and the asset is available for use. The asset is amortised over the period for which the underlying project is expected to generate revenue for the group.

Industrial patents and intellectual property rights

Industrial patents and intellectual property rights refer to costs for patents owned by Limacorporate S.p.A..

Concessions, licences, trademarks and similar rights

This caption refers to costs to file and register trademarks and costs incurred to acquire commercial licences. The acquisition costs are amortised over a period equal to the useful life of the acquired right.

Other intangible assets

This caption refers to leasehold improvements. The capitalised costs are amortised on the basis of the residual term of the relevant lease contract.

[2.4.3] Property, plant and equipment

Property, plant and equipment are recognised at acquisition or production cost including directly attributable costs incurred to ready the asset for its intended use. Such cost includes costs to replace parts of equipment and plant when they are incurred if they meet the recognition requirements.

Assets acquired under business combinations before 1 January 2018 (the date of the parent’s transition to the IFRS) are recognised at their pre-existing carrying amount, determined within such business combinations in accordance with the previous reporting standards, i.e., at deemed cost.

The carrying amount (cost less accumulated depreciation and cumulative impairment losses) of the replaced parts of equipment and plant is taken to profit or loss at the time of replacement.

Maintenance and repair costs, which do not add to the value of the assets and/or prolong their residual useful lives, are expensed when incurred. Otherwise they are capitalised.

Property, plant and equipment are stated net of any accumulated depreciation and any cumulative impairment losses determined using the methods set out below. Depreciation is calculated on a straight-line basis over the estimated useful life of the asset for the group.

The depreciation rates used are shown in the following table by asset category:

 

     2022  

Buildings

     3%  

Light constructions

     10%  

General and specific plant

     10% - 15.5%  

Machinery

     15.5%  

Sundry and small equipment

     25%  

Production equipment

     10%  

Office furniture and machines

     12%  

Electronic office machines

     20%  

Transport vehicles

     20%  

Cars

     25%  

Right-of-use assets

     Lease term  

The residual value of the assets, the useful life and the depreciation method applied are reviewed at each year end and adjusted prospectively if necessary.

 

2022    12


If significant parts of an item of property, plant and equipment have different useful lives, such parts are recognised separately. Land, free of construction or annexed to buildings, is recognised separately and is not depreciated since it has an unlimited useful life.

The carrying amount of an item of property, plant and equipment and every significant part initially recognised is eliminated on disposal or when no future economic benefits are expected from its use or disposal. The gain or loss arising from the derecognition of the item (calculated as the difference between the carrying amount of the asset and the net disposal proceeds) is included in profit or loss when the item is derecognised.

[2.4.4] Leases

IFRS 16 defines the recognition, measurement, presentation and disclosure requirements for leases. Under IFRS 16, lessees are required to recognise all leases using a single accounting model similar to that used to recognise finance leases under IAS 17.

If a contract contains a lease, at the commencement date, the lessee shall recognise an asset representing its right to use the underlying leased asset and a lease liability representing its obligation to make lease payments. The lessee shall recognise interest on the lease liability and depreciation of the right-of-use asset separately. At inception of a contract, the entity shall assess whether the contract is, or contains, a lease. The contract is, or contains, a lease if it conveys the right to control the use of an identified asset for a period of time in exchange for consideration. An entity shall determine the lease term as the non-cancellable period of a lease, together with both periods covered by an option to extend the lease if the lessee is reasonably certain to exercise that option and periods covered by an option to terminate the lease if the lessee is reasonably certain not to exercise that option.

[2.4.5] Equity investments

Investments in associates and joint ventures are measured using the equity method, recognising the group’s share of the profits or losses for the year in the income statement, with the exception of the effects related to other changes in the equity of the investee, other than owner transactions, that are directly recognised in other comprehensive income.

In the event of losses exceeding the carrying amount of the equity investment, the excess is recognised in a specific provision to the extent the parent is obliged to fulfil legal or constructive obligations to the investee or to cover its losses.

Investments in other companies are measured at fair value and the fair value gains and losses are taken to equity. If fair value cannot be reliably determined, they are measured at cost, adjusted for any impairment losses.

[2.4.6] Impairment losses

At the reporting date, the carrying amount of property, plant and equipment, intangible assets, financial assets and equity investments is tested for indicators of impairment. Should such indicators exist, the group estimates the recoverable amount of the asset to check the recoverability of the carrying amount and determine any impairment loss to be recognised. Intangible assets with indefinite useful lives or not yet available for use are tested for impairment at least annually, irrespective of whether any indication of impairment exists, or more frequently if an indication of impairment exists.

In order to identify impairment losses, assets are grouped into the smallest identifiable group of assets that generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets (the cash-generating unit, CGU). Reference should be made to section [3.2] Goodwill for details of the group’s CGU. The goodwill generated by business combinations is allocated to the CGU that is expected to benefit from the combinations’ synergies. The recoverable amount of an asset or a CGU is the higher of its value in use and its fair value less costs to sell.

 

2022    13


Multiples are compared with the implicit multiple calculated using the group’s actual figures. When the carrying amount of an asset or a CGU exceeds its recoverable amount, the group recognises an impairment loss in profit or loss. Impairment losses on the CGU are allocated first to reduce the carrying amount of any goodwill allocated to it and then to the other assets of the CGU pro rata on the basis of their carrying amounts. Impairment losses on goodwill cannot be reversed. Impairment losses on other assets are reversed to the carrying amount that would have been determined (net of amortisation and depreciation) had no impairment losses been recognised in prior years.

The market multiples method is used to determine the value in use using listed comparable companies for the group’s CGU except for TechMah CGU where the value in use of the CGU Techmah is defined using estimated future cashflows by applying a discount rate (weighted average cost of capital).

[2.4.7] Financial instruments

The financial instruments held by the group are described below.

Financial assets

Financial assets include equity investments, current securities, loans and borrowings, as well as derivatives with a positive fair value, trade receivables and other assets, in addition to cash and cash equivalents.

Specifically, cash and cash equivalents include cash, bank deposits and highly marketable securities that are readily convertible to cash and are subject to an immaterial risk of changes in value.

Current securities include short-term or marketable securities which represent temporary investments of available funds and do not meet the requirements to be classified as cash and cash equivalents. Financial assets represented by debt instruments are classified in the consolidated financial statements restated as at 31 December 2022 and measured using the business model adopted by the group for managing financial assets and based on the cash flows related to each financial asset. Financial assets also include equity investments not held for trading. Such assets are strategic investments and the group has opted to recognise fair value gains or losses thereon through profit or loss (fair value through profit or loss, FVTPL).

Financial assets are tested for impairment using a model based on expected credit losses.

Financial liabilities

Financial liabilities include loans and borrowings, as well as derivatives with a negative fair value, trade payables and other liabilities.

Financial liabilities are classified and measured at amortised cost, with the exception of those initially measured at fair value, e.g., financial liabilities related to earn-out considerations for business combinations and derivatives and financial liabilities for options on non-controlling interests.

Derecognition of financial assets and liabilities

A financial asset or liability (or, where applicable, part of a financial asset/liability or part of a group of similar financial assets/liabilities) is derecognised when the group unconditionally transfers the contractual rights to receive the cash flows of the financial asset or the obligation to make payments or fulfil other obligations related to the liability.

[2.4.8] Inventories

Raw materials and packaging are measured at the lower of purchase cost and estimated replacement value based on market trends. The cost is calculated using the weighted average cost for the year.

Semi-finished products and finished goods are measured at purchase or production cost, considering their stage of completion, or their realisable value based on market trends, if lower. The production cost includes the reasonably attributable portion of direct and indirect manufacturing costs.

 

2022    14


The resulting amount is written down through the allowance for inventory write-down to account for items whose expected realisable value is lower than their cost.

[2.4.9] Trade receivables and other assets and trade payables and other liabilities

Trade receivables and other assets that derive from the supply of credit facilities, goods or services to third parties are classified under current assets, except when they are due after one year of the reporting date with reference to loans and receivables. If they have a set due date, current and non-current loan assets, other current and non-current assets and trade receivables, with the exception of derivatives, are measured at amortised cost calculated using the effective interest method. If they do not have a set due date, financial assets are measured at cost. Loans and receivables due after one year that are non-interest bearing or accruing interest lower than market rates are discounted using market rates.

The above financial assets are measured using the expected credit loss impairment model introduced by IFRS 9.

Trade payables and other liabilities that arise from the acquisition of credit facilities, goods or services from a third party supplier are classified under current liabilities, except when they are due after one year of the reporting date with reference to loans and borrowings.

On initial recognition, current and non-current loans and borrowings, other current and non-current liabilities and trade payables are stated at fair value, which normally coincides with the transaction price including transaction costs. Subsequently, all financial liabilities are measured at amortised cost calculated using the effective interest method.

[2.4.10] Employee benefits

The liability related to short-term employee benefits paid during the employment relationship is recognised on an accruals basis at the amount accrued at the reporting date.

The liability related to employee benefits paid upon or after termination of the employment relationship via defined benefit plans, is recognised at the amount accrued at the reporting date.

The liability related to employee benefits paid upon or after termination of the employment relationship via defined benefit plans, net of any plan assets and advances granted, is calculated using actuarial assumptions and recognised on an accruals basis in line with the service needed to obtain the benefits. Such liability is calculated by independent actuaries. The gain or loss deriving from the actuarial calculation is fully recognised in the statement of comprehensive income for the relevant year.

Defined benefit plan liabilities are measured using the actuarial assumptions set out in section [3.14] Employee benefits of the notes to the consolidated financial statements restated as at 31 December 2022.

[2.4.11] Provisions for risks and charges

The provisions for risks and charges are recognised when the group has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation.

The amount recognised as a provision is the best estimate of the expenditure required to settle the present obligation or transfer it to third parties at the reporting date. Where the effect of the discounting is material, the provisions are calculated by discounting the estimated future cash flows at a rate that reflects current market assessments of the time value of money. When discounting is used, the carrying amount of the provision increases to reflect the passage of time and this increase is recognised as borrowing cost.

 

2022    15


[2.4.12] Share-based payments

The grant-date fair value of equity-settled share-based payment arrangements agreed with employees is generally recognised as an expense, with a corresponding increase in equity, over the vesting period of the awards. The amount recognised as an expense is adjusted to reflect the number of awards for which the related service and non-market performance conditions are expected to be met, such that the amount ultimately recognised is based on the number of awards that meet the related service and non-market performance conditions at the vesting date. For share-based payment awards with non-vesting conditions, the grant-date fair value of the share-based payment is measured to reflect such conditions. With regard to non-vesting conditions, any differences between expected and actual outcomes do not have an impact on the consolidated financial statements restated as at 31 December 2022.

The fair value of the amount payable to employees in respect of cash-settled share-based payments is recognised as an expense with a corresponding increase in liabilities, over the period during which the employees become unconditionally entitled to payment. The liability is remeasured at each reporting date and at the settlement date based on the fair value of the share-based payments. Any fair value gains or losses are recognised in profit or loss.

The parent has had agreements with some managers for the award of options and/or shares for several years (see section [4.8] Incentive plans).

[2.4.13] Revenue and expense

Based on the five-step model introduced by IFRS 15, the group recognises revenue after identifying the contract(s) with a customer and the performance obligations in the contract (transfer of goods and/or services), determining the transaction price to which it expects to be entitled in exchange for fulfilling performance obligations (at a point in time or over time). Revenue is measured on the basis of the transaction price excluding amounts collected on behalf of third parties. Based on the group’s internal analysis of contracts with customers, the group has not identified any performance obligations that are satisfied over time and, therefore, the group recognises revenue upon the transfer of control of the promised goods or services to the customer. Revenue is measured to the extent that it is probable that the economic benefits will flow to the group and the amount can be measured reliably.

Revenue is adjusted for any discounts and volume rebates allowed by the group in contracts with customers and for the payback (variable considerations) see [3.20] Revenue and other revenue and income and [3.13] Provisions for risks and charges for payback system.

Expense is recognised when the goods and services are sold or consumed during the year or by systematic allocation, or when it is not possible to identify their future use.

Expense items are classified by nature in accordance with the applicable IFRS.

[2.4.14] Government grants

Grants related to income are taken to profit or loss in the year in which the relevant expense is recognised.

Grants related to assets received for projects and development activities are recognised under liabilities and subsequently recognised under operating revenue in line with the amortisation and depreciation of the relevant assets.

Grants due for investments in research and development are recognised in line with the progress of the research, calculated on the basis of the progress reports issued to the relevant bodies and the stage of completion reported by those in charge of the research, if all requirements for their disbursement are met.

[2.4.15] Financial income and expense

Financial income and expense are recognised on an accruals basis on the basis of interest accrued on the net amount of the relevant financial assets and liabilities, using the effective interest method.

 

2022    16


[2.4.16] Dividends

Dividends are recognised when the shareholder’s right to receive payment is established.

[2.4.17] Income taxes

Income taxes recognised in profit or loss are the sum of current and deferred taxes.

Income taxes for the year are determined on the basis of ruling legislation. They are recognised in profit or loss, except for those related to items recognised directly in equity, for which the tax effect is accounted for directly in equity.

Income tax liabilities are recognised under current tax liabilities, net of advances paid. Any tax credits are recognised under current tax assets.

Deferred tax assets and liabilities are calculated on the temporary differences between the carrying amounts of assets and liabilities (resulting from the application of the accounting policies set out in note [2.4] Basis of preparation) and their tax bases (deriving from the application of the tax legislation ruling in the country of the subsidiaries). Current and deferred tax assets and liabilities are offset when the group has the legally enforceable right to offset.

Deferred taxes are calculated using the tax rates expected to be enacted in the years in which the temporary differences will be recovered or settled. Deferred tax assets and liabilities are not discounted.

Deferred tax assets are recognised on temporary differences and to the extent that it is probable the group will have future taxable profits that will allow their recovery.

[2.4.18] Fair value

IFRS 13 is a common framework for fair value measurement and relevant disclosure when this measurement is required or allowed by other IFRS. Specifically, the standard sets out the definition of fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

IFRS 13 establishes a hierarchy that categorises the inputs used in the valuation techniques adopted to measure fair value into different levels, as follows:

 

   

level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity has the ability to access at the measurement date;

 

   

level 2: inputs other than quoted prices included in level 1 that are observable for the assets or liabilities, either directly or indirectly;

 

   

level 3: unobservable inputs for the assets or liabilities.

In some cases, the inputs used to measure the fair value of an asset or a liability might be categorised within different levels of the fair value hierarchy. In those cases, the fair value measurement is categorised in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement.

The group recognises transfers among the different levels of the fair value hierarchy at the end of the year in which the transfer took place.

Reference should be made to the notes to the individual financial statements items for the definition of the fair value hierarchy level used to classify the individual instruments measured at fair value or whose fair value is disclosed.

The fair value of derivatives is calculated by discounting estimated cash flows using the market interest rates at the reporting date and the credit default swaps issued by the counterparty and group companies, to include the non-performance risk explicitly provided for under IFRS 13.

Where market prices are not available, the fair value of non-derivative medium/long-term financial instruments is calculated by discounting estimated cash flows using the market interest rates at the reporting date and considering counterparty risk for financial assets and credit risk for financial liabilities.

 

2022    17


[2.4.19] Use of estimates

In preparing the consolidated financial statements restated as at 31 December 2022, the directors were required to apply accounting policies that are, at times, based on judgements or past experience or assumptions deemed reasonable and realistic at the time, depending on the relevant circumstances. The application of such estimates and assumptions impacts the carrying amounts recognised in the statement of financial position, income statement, statement of comprehensive income and statement of cash flows, in addition to the disclosure provided. The end results of the assessments in which such estimates and assumptions were used may differ from those recognised in the consolidated financial statements restated as at 31 December 2022 due to the inherent uncertainty of the assumptions and the conditions underlying the estimates.

Actual results may differ from those estimated. Estimates and assumptions are reviewed on an ongoing basis. The effect of a change in accounting estimates is recognised in profit or loss in the period of the change, if the change affects that period only, or the period of the change and future periods, if the change affects both.

Estimates mainly refer to the following captions:

 

   

Impairment losses on non-current assets and goodwill;

 

   

loss allowance;

 

   

allowance for inventory write-down;

 

   

recoverability of deferred tax assets;

 

   

estimate of the provisions for risks and contingent liabilities;

 

   

financial liabilities;

 

   

employee incentive plans.

Impairment losses on non-current assets and goodwill

Non-current assets include property, plant and equipment, intangible assets including goodwill and other financial assets.

Management periodically revises the carrying amount of non-current assets held and used and assets held for sale when events and circumstances require such revision. This is performed using the estimates of cash flows the group expects to derive from using or selling the asset and suitable discount rates for calculating the present value.

When the carrying amount of a non-current asset has been impaired, the group recognises an impairment loss equal to the excess between the carrying amount and the amount to be recovered through use or sale of the asset, determined using the parent’s or group’s most recent plans. Reference should be made to note [2.4.6] Impairment losses.

Loss allowance

The loss allowance is management’s best estimate of the potential credit losses on trade receivables from end customers. Reference should be made to note [2.4.8] Trade receivables and other assets and trade payables and other liabilities for a description of the criteria used in estimating the allowance.

Allowance for inventory write-down

Inventories of slow-moving raw materials and finished goods are periodically analysed on the basis of historical data and the possibility of selling them at prices lower than normal market transactions. If, as a result, the carrying amount of inventories needs to be written down, the group recognises a specific allowance for inventory write-down.

Recoverability of deferred tax assets

The group pays taxes in numerous countries and some estimates are required to calculate the taxes in each jurisdiction. It recognises deferred tax assets to the extent that it is probable that future taxable profits will be available and over a period of time compatible with the time horizon implicit in the management estimates.

 

2022    18


Estimate of the provisions for risks and contingent liabilities

The group could be subject to legal and tax disputes regarding a vast range of issues that are subject to the jurisdiction of various countries. Disputes and litigation against the group are subject to a different degree of uncertainty, including the facts and circumstances inherent to each dispute, the jurisdiction and different applicable laws. In the ordinary course of business, management consults its legal consultants and legal and tax experts. The group recognises a liability for such disputes when it is deemed probable that they will result in an outflow of resources and when the amount of the resulting losses can be reasonably estimated. If an outflow of resources is possible but the amount cannot be determined, such fact is disclosed in the notes to the consolidated financial statements restated as at 31 December 2022.

Employee incentive plans and financial liabilities

Reference is made to section [4.8] Incentive plans for a description of the calculation of the fair value of share-based payments as part of group management incentive plans. Section [3.15] Current and non-current financial liabilities provides details of the calculation of fair value of the group’s financial liabilities.

[2.4.20] Translation of foreign currency items

The financial statements of each consolidated company are prepared using the functional currency related to the economy where each company operates. Transactions in currencies other than the functional currency are recognised at the exchange rate at the date of the transaction. Foreign currency monetary assets and liabilities are subsequently translated at the closing rate and any exchange differences are taken to profit or loss. Foreign currency non-monetary assets and liabilities recognised at historical cost are translated using the exchange rate at the date of the transaction.

For consolidation purposes, the foreign currency reporting packages of consolidated companies are translated using the closing rates for asset and liability captions, including goodwill and consolidation adjustments, and the average rate for the year (if similar to the respective transaction-date rates) or the period under consolidation, if lower, for income statement captions. The relevant exchange differences are taken directly to the statement of comprehensive income and reclassified to profit or loss when control over the investee is lost and, thus, it is deconsolidated.

[2.4.21] Operating segments

An operating segment is a component of an entity:

 

   

that engages in business activities from which it may earn revenue and incur expenses (including revenue and expenses relating to transactions with other components of the same entity);

 

   

whose operating results are regularly reviewed by the entity’s chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance; and

 

   

for which discrete financial information is available.

Note [4.2] Operating segments provides information about the single operating segment identified.

[2.4.22] New standards and interpretations, revisions and amendments to existing standards

As required by IAS 8 Accounting policies, changes in accounting estimates and errors, below are the new standards and interpretations, in addition to amendments to existing and applicable standards and interpretations, applicable starting from 1 January 2022 and not yet in effect at the reporting date.

 

2022    19


[2.4.22.1] New standards and interpretations applicable from 1 January 2022

The amendments to the IFRS adopted during the year included:

On 14 May 2020, the IASB published the following amendments:

 

   

Amendments to IFRS 3 Business combinations: which update the reference in IFRS 3 to the revised conceptual framework without significantly changing its requirements.

 

   

Amendments to IAS 16 Property, plant and equipment: which prohibit deducting from the cost of an item of property, plant and equipment any proceeds from selling items produced during the testing of such item. An entity recognises the proceeds from selling such items, and the cost of producing those items, in profit or loss.

 

   

Amendments to IAS 37 Provisions, contingent liabilities and contingent assets: which specify that the cost of fulfilling a contract comprises the costs that relate directly to the contract. Costs that relate directly to a contract can either be incremental costs of fulfilling that contract (e.g., direct labour, materials) or an allocation of other costs that relate directly to fulfilling contracts (e.g., the allocation of the depreciation charge for an item of property, plant and equipment used in fulfilling the contract).

 

   

Annual Improvements 2018-2020: which amend IFRS 1 First-time adoption of International Financial Reporting Standards, IFRS 9 Financial instruments, IAS 41 Agriculture and the illustrative examples of IFRS 16 Leases.

All of the amendments are effective for annual periods beginning on or after 1 January 2022.

The adoption of the other standards and interpretations detailed above has not had a material impact on the measurement of the group’s asset, liabilities, costs and revenue.

[2.4.22.2] Standards, amendments and interpretations not yet mandatory and not adopted early at 31 December 2022

On 18 May 2017, the IASB published IFRS 17 Insurance contracts which will replace IFRS 4 Insurance contracts.

The objective of the new standard is to ensure that an entity provides relevant information that faithfully represents the rights and obligations deriving from insurance contracts issued. The IASB developed the standard to eliminate inconsistencies and deficiencies in existing accounting standards, providing a single principle-based framework covering all types of insurance contracts, including reinsurance contracts held by an insurance company.

The new standard also sets out presentation and disclosure requirements to improve the comparability between entities operating in the insurance industry.

Under IFRS 17, an entity measures an insurance contract using a general accounting model or a simplified version called the premium allocation approach.

The main features of the general model are:

 

   

estimates and assumptions of future cash flows are always current;

 

   

measurement reflects the time value of money;

 

   

estimates make maximum use of observable market data;

 

   

there is a current and explicit measurement of risk;

 

   

expected profit is deferred and aggregated in groups of insurance contracts at initial recognition; and

 

   

expected profit is recognised over the coverage period after adjustments from changes in the cash flows assumptions related to each group of contracts.

Under the premium allocation approach, an entity measures the liability for the remaining coverage of a group of insurance contracts on the condition that, at initial recognition, the entity reasonably expects that this will be an approximation of the general model. Contracts with a coverage period of one year or less are automatically eligible for PAA. The simplifications arising from PAA do not apply to the measurement of the liability for incurred claims, measured under the general model. However, there is no need to discount those cash flows if the balance is expected to be paid or received in one year or less from the date the claims are incurred.

 

2022    20


An entity shall apply the new standard to issued insurance contracts, including reinsurance contracts issued, reinsurance contracts held and also to investment contracts with a discretionary participation feature (DPF).

The standard is effective for annual periods beginning on or after 1 January 2023. Early application is permitted only for entities that apply IFRS 9 Financial instruments and IFRS 15 Revenue from contracts with customers.

The directors do not expect the adoption of this standard to have a significant effect on the group’s consolidated financial statements restated as at 31 December 2022.

On 9 December 2021, the IASB published “Amendments to IFRS 17 Insurance contracts: Initial application of IFRS 17 and IFRS 9 – Comparative information”. The amendment is a transition option relating to comparative information about financial assets presented on initial application of IFRS 17. The amendment is aimed at helping entities to avoid temporary accounting mismatches between financial assets and insurance contract liabilities, and therefore improve the usefulness of comparative information for users of financial statements. IFRS 17 incorporating the amendment is effective for annual reporting periods beginning on or after 1 January 2023.

On 12 February 2021, the IASB published “Disclosure of accounting policies—Amendments to IAS 1 and IFRS Practice statement 2” and “Definition of accounting estimates—Amendments to IAS 8”. These amendments will help companies improve accounting policy disclosures so that they provide more useful information to investors and other primary users of the financial statements and distinguish changes in accounting estimates from changes in accounting policies. The amendments are effective for annual reporting periods beginning on or after 1 January 2023 and early adoption is permitted.

On 7 May 2021, the IASB published “Amendments to IAS 12 Income taxes: Deferred tax related to assets and liabilities arising from a single transaction” which clarify how companies account for deferred tax on transactions such as leases and decommissioning obligations. The amendments are effective for annual reporting periods beginning on or after 1 January 2023 and early adoption is permitted.

Limacorporate S.p.A. did not opt for early adoption of these standards.

Other standards, amendments and interpretations

 

   

On 23 January 2020, the IASB published “Amendments to IAS 1 Presentation of financial statements: classification of liabilities as current or non-current” and, on 31 October 2022, “Amendments to IAS 1 Presentation of financial statements: non-current liabilities with covenants” which clarify how an entity classifies debt and other financial liabilities as current or non-current. The amendments are effective for annual reporting periods beginning on or after 1 January 2024 and early adoption is permitted.

 

   

On 22 September 2022, the IASB published “Amendments to IFRS 16 Leases: lease liability in a sale and leaseback” which requires a seller-lessee to measure lease liabilities arising from a sale and leaseback in a way that it does not recognise any amount of the gain or loss that relates to the right of use it retains. The amendments are effective for annual reporting periods beginning on or after 1 January 2024 and early adoption is permitted.

 

   

On 30 January 2014, the IASB published IFRS 14 Regulatory deferral accounts permits a first-time adopter of IFRS Standards to continue to recognise its rate regulation activities in accordance with its previous GAAP. As the parent and group are not a first-time adopter, this standard is not applicable.

The group will adopt such new standards and amendments, on the basis of the relevant application date, and will assess the potential impacts on the consolidated financial statements restated as at 31 December 2022 when they are endorsed by IASB.

 

2022    21


[3] Notes to the consolidated financial statements restated as at 31 December 2022

Below are comments on the statement of financial position captions as at 31 December 2022. For details on statement of financial position captions deriving from related party transactions, reference should be made to note [4.6] Related party transactions.

[3.1] Other intangible assets

Other intangible assets at 31 December 2022 amount to €58,234 thousand, up €4,639 thousand on the previous year end (€53,595 thousand). Changes in other intangible assets in 2021 and 2022 and a breakdown of historical cost, accumulated amortisation and any cumulative impairment losses are summarised in the following tables.

 

(€‘000)

                                                
     01/01/2021      Exchange
difference
     Increases      Reclassifications      Decreases      Amortisation      31/12/2021
restated
 

Development expenditure

     664        1,414        7,322        28,340        0        -3,858        33,882  

Industrial patents and intellectual property rights

     1,181        0        413        924        0        -455        2,063  

Concessions, licences, trademarks and similar rights

     5,016        10        2,411        1,722        0        -2,914        6,245  

Assets under development and payments on account

     37,267        1,041        3,893        -30,987        -38        0        11,176  

Other

     349        2        53        1        -9        -167        229  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     44,477        2,467        14,092        0        -47        -7,394        53,595  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

(€‘000)

                                                
     31/12/2021
restated
     Exchange
difference
     Increases      Reclassifications      Decreases      Amortisation      31/12/2022
restated
 

Development expenditure

     33,882        2,057        5,132        943        0        -4,896        37,118  

Industrial patents and intellectual property rights

     2,063        0        485        0        0        -339        2,208  

Concessions, licences, trademarks and similar rights

     6,245        51        2,322        446        0        -3,165        5,900  

Assets under development and payments on account

     11,176        19        3,911        -1,646        -953        0        12,507  

Other

     229        2        271        257        -2        -257        500  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     53,595        2,129        12,121        0        -955        -8,657        58,234  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

€‘000

                    
     01/01/2021  
     Historical cost      Accumulated amortisation      Carrying amount  

Development expenditure

     1,639        975        664  

Industrial patents and intellectual property rights

     2,984        1,802        1,181  

Concessions, licences, trademarks and similar rights

     18,905        13,889        5,016  

Assets under development and payments on account

     37,267        —         37,267  

Other

     1,207        859        348  
  

 

 

    

 

 

    

 

 

 

Total

     62,002        17,525        44,477  
  

 

 

    

 

 

    

 

 

 

 

2022    22


€‘000

                    
     31/12/2021 restated  
     Historical cost      Accumulated amortisation      Carrying amount  

Development expenditure

     38,593        4,711        33,882  

Industrial patents and intellectual property rights

     3,904        1,841        2,063  

Concessions, licences, trademarks and similar rights

     21,272        15,027        6,245  

Assets under development and payments on account

     11,176        0        11,176  

Other

     1,246        1,017        229  
  

 

 

    

 

 

    

 

 

 

Total

     76,191        22,596        53,595  
  

 

 

    

 

 

    

 

 

 

 

€‘000

                    
     31/12/2022 restated  
     Historical cost      Accumulated amortisation      Carrying amount  

Development expenditure

     46,425        9,307        37,118  

Industrial patents and intellectual property rights

     3,663        1,455        2,208  

Concessions, licences, trademarks and similar rights

     22,359        16,458        5,901  

Assets under development and payments on account

     12,507        0        12,507  

Other

     1,731        1,231        500  
  

 

 

    

 

 

    

 

 

 

Total

     86,685        28,451        58,234  
  

 

 

    

 

 

    

 

 

 

Intangible assets with an indefinite useful life only comprise goodwill, while the other assets (development expenditure, industrial patents and intellectual property, concessions, licences, trademarks and similar rights, other intangible assets and assets under development and payments on account) all have a finite life. More information on each item is provided below.

Development expenditure, amounting to €37,118 thousand, comprises:

 

   

€1,060 thousand incurred by the parent mainly related to Physica and Hybrid Glenoid;

 

   

€14,424 thousand related to the allocation of part of the goodwill arising on consolidation transferred at the acquisition date for TechMah Medical LLC (resulting from a step acquisition achieved in stages but consolidated at 100% as per the anticipated acquisition method). Such goodwill was partly allocated to development expenditure and partly to goodwill. The relevant estimated useful life is ten years;

 

   

€1,382 thousand for the recognition of the additional new milestone agreed with the sellers of such company in June 2020 via an addendum to the initial agreement, for the development of an additional implant technology to those agreed at the acquisition;

 

   

€20,252 thousand related to costs capitalised by TechMah Medical LLC for the development of its products which will enrich the group’s portfolio with digital solutions designed to assist surgeons with operations. The same applies as for the second point regarding amortisation.

The significant increase on the previous year end is due to the costs incurred by TechMah Medical LLC in 2022 to develop products. The recoverability of TechMah costs is supported by the result of the discounted cash flow method applied to test the TechMah CGU; based on the impairment test exercise at 31 December 2022 the VIU is lower than the carrying amount of the CGU so, as provided for IAS 36, management fully impaired firstly the goodwill. The carrying amount of the CGU after the impairment of goodwill is recoverable by the VIU defined.

In summer 2023 the Management of Limacorporate took the strategic decision to stop the Spart Space project (TechMah business). All digital activities and resources have been refocused on other projects (please refer to Events after the reporting date paragraph).

Amortisation of this caption amounts to €4,896 thousand.

Industrial patents and intellectual property rights, amounting to €2,208 thousand, are comprised of costs incurred by Limacorporate S.p.A. to acquire patents in 2022 and previous years.

 

2022    23


Concessions, licences, trademarks and similar rights of €5,900 thousand are comprised of costs incurred by:

 

   

the parent (€2,861 thousand) for costs to register Lima products on the European, US, Chinese, Korean and Japanese markets;

 

   

other group companies (€448 thousand) for costs mainly to register products on the Brazilian market;

 

   

the parent (€2,336 thousand) for costs incurred to purchase commercial licences (€1,146 thousand), software programs (€1,086 thousand) and to register trademarks (€104 thousand);

 

   

other group companies (€255 thousand). Amortisation of this caption amounts to €3,165 thousand.

Assets under development and payments on account, amounting to €12,507 thousand, is comprised of the following:

 

   

€12,107 thousand for costs incurred by Limacorporate S.p.A. for development activities, payments on account for software licences, costs to register the Lima products and costs incurred to acquire patents;

 

   

€400 thousand related to other group companies.

“Other”, amounting to €500 thousand, refers to the following companies for leasehold improvements:

 

   

Limacorporate S.p.A. for €19 thousand;

 

   

Lima USA for €269 thousand;

 

   

Lima Orthopaedics Australia for €23 thousand;

 

   

Lima Implantes for €56 thousand;

 

   

Lima Korea for €115 thousand;

 

   

other group companies for €18 thousand.

The capitalised costs are amortised over the residual term of the relevant lease contract and amortisation of this caption amounts to €257 thousand.

Total amortisation of intangible assets taken to profit or loss amounts to €8,657 thousand.

[3.2] Goodwill

Goodwill amounts to €384,216 thousand.

Pursuant to IAS 36, goodwill is not subject to amortisation, but is tested for impairment at least annually or more frequently if events or circumstances indicate that it might be impaired. With regard to testing goodwill for impairment, the group identified two CGUs for its operations,-one for the Group except TechMah (“Group CGU”) and one related to TechMah . It considered the sources of information set out by IAS 36 such as the fact that management monitors the group’s performance and takes strategic decisions about its product offering and investments at group level, except for TechMah business which is a separate CGU.

The goodwill recognised in the consolidated financial statements restated as at 31 December 2022 in relation to the above-mentioned merger, together with other items of goodwill, was tested for impairment at the reporting date. Specifically, the recoverable amount of the group’s assets was calculated by estimating their fair value and comparing it with the carrying amount of consolidated net invested capital at 31 December 2022 in order to examine whether recognised amounts had been impaired.

The market multiples method is used to determine the fair value of goodwill of the Group CGU, using listed comparable companies. These multiples are compared with the implicit multiple calculated using the group’s actual figures. The market multiples analysis based on companies operating in sectors comparable to those of Limacorporate (performed on the date the impairment test was carried out on seven comparable companies) provides supporting evidence about the carrying amount of goodwill recognised in the 2022 consolidated financial statements restated as at 31 December 2022. This is because the market multiples (which show an average enterprise value of between 15 and 17 times gross operating profit) are higher and/or in line with the multiple obtained by comparing the group’s actual net invested capital at the end of 2022 (i.e., including goodwill) to consolidated gross operating profit.

 

2022    24


As a result of such checks, based on market references (i.e., market multiples) compared with the group’s implicit multiple, no impairment indicators have been detected to date for goodwill allocated to the Group CGU.

The group separately measured TechMah Medical LLC’s business related to the Smart SPACE digital solution.

The recoverable value of the TechMah CGU was determined as its value in use, on the basis of the cashflows discounted using a rate that reflects the risk conditions (WACC of 13.5%). The recoverable amount determined with aforementioned method led to the full impairment of goodwill (€ 15,109 thousand) allocated to the CGU.

[3.3] Property, plant and equipment

Property, plant and equipment and other assets amount to €79,837 thousand, down €1,936 thousand compared to 31 December 2021 (€81,773 thousand).

Changes in property, plant and equipment in 2021 and 2022 and a breakdown of historical cost, accumulated depreciation and any cumulative impairment losses are summarised in the following tables:

 

(€‘000)

                                                       
     01/01/2021      Exchange
difference
     Increases      Decreases      Depreciation      Reclassifications      Other changes      31/12/2021
restated
 

Land and buildings

     15,907        0        508        0        -703        34        0        15,746  

Leased land and buildings

     9,364        377        827        -78        -2,539        0        -880        7,071  

Plant and equipment

     17,945        14        1,753        -754        -4,282        343        0        15,019  

Leased plant and equipment

     26        0        0        0        -15        0        2        13  

Industrial and commercial equipment

     35,489        670        15,676        -626        -14,967        578        0        36,820  

Leased industrial and commercial equipment

     15        0        935        0        -315        0        0        635  

Other assets

     1,605        35        643        -22        -576        0        0        1,683  

Other leased assets

     2,695        7        1,221        0        -1,726        0        -52        2,145  

Assets under construction and payments on account

     2,244        81        1,349        -78        0        -955        0        2,641  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     85,288        1,184        22,912        -1,558        -25,123        0        -930        81,773  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

(€‘000)

                                                       
     31/12/2021
restated
     Exchange
difference
     Increases      Reclassifications      Decreases      Other changes      Depreciation      31/12/2022
restated
 

Land and buildings

     15,746        0        456        35        -67        0        -674        15,496  

Leased land and buildings

     7,071        226        2,087        0        -5        623        -3,247        6,755  

Plant and equipment

     15,019        0        3,601        2,255        -17        0        -4,442        16,416  

Leased plant and equipment

     13        0        82        0        0        0        -16        79  

Industrial and commercial equipment

     36,820        258        14,647        -63        -1,156        0        -15,832        34,674  

Leased industrial and commercial equipment

     635        0        0        0        0        -58        -558        19  

Other assets

     1,683        15        706        3        -20        0        -600        1,787  

Other leased assets

     2,145        2        1,577        0        0        90        -1,514        2,299  

Assets under construction and payments on account

     2,641        64        1,991        -2,231        -154        0        0        2,311  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     81,773        566        25,145        0        -1,418        655        -26,884        79,837  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

(€‘000)

                           
     01/01/2021  
   Historical cost      Accumulated
depreciation
     Accumulated
impairment losses
     Carrying amount  

Land and buildings

     24,082        7,610        565        15,907  

Leased land and buildings

     18,471        9,107        —         9,364  

Plant and equipment

     53,382        35,437        —         17,945  

Leased plant and equipment

     117        91        —         26  

Industrial and commercial equipment

     116,513        80,857        167        35,489  

Leased industrial and commercial equipment

     30        15        —         15  

Other assets

     6,727        5,122        —         1,605  

Other leased assets

     6,176        3,481        —         2,695  

Assets under construction and payments on account

     2,244        —         —         2,244  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

     227,741        141,720        733        85,288  
  

 

 

    

 

 

    

 

 

    

 

 

 

 

2022    25


     31/12/2021 restated  
     Historical cost      Accumulated
depreciation
     Accumulated
impairment losses
     Carrying amount  

Land and buildings

     24,624        8,313        565        15,746  

Leased land and buildings

     17,344        10,273        0        7,071  

Plant and equipment

     54,318        39,299        0        15,019  

Leased plant and equipment

     119        106        0        13  

Industrial and commercial equipment

     132,183        95,196        167        36,820  

Leased industrial and commercial equipment

     966        331        0        635  

Other assets

     7,257        5,574        0        1,683  

Other leased assets

     6,016        3,871        0        2,145  

Assets under construction and payments on account

     2,641        0        0        2,641  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

     245,468        162,963        733        81,773  
  

 

 

    

 

 

    

 

 

    

 

 

 

 

     31/12/2022 restated  
     Historical cost      Accumulated
depreciation
     Accumulated
impairment losses
     Carrying amount  

Land and buildings

     23,870        8,374        0        15,496  

Leased land and buildings

     19,868        13,113        0        6,755  

Plant and equipment

     59,135        42,719        0        16,416  

Leased plant and equipment

     202        122        0        80  

Industrial and commercial equipment

     141,939        107,009        256        34,674  

Leased industrial and commercial equipment

     66        47        0        19  

Other assets

     7,937        6,150        0        1,787  

Other leased assets

     5,069        2,770        0        2,299  

Assets under construction and payments on account

     2,311        0        0        2,311  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

     260,397        180,304        256        79,837  
  

 

 

    

 

 

    

 

 

    

 

 

 

The €456 thousand increase in land and buildings during the year is chiefly due to costs incurred by the parent to build the new electrical substation at the Villanova production facility and to acquire land to extend the production facility.

The increase in plant and machinery mainly refers to the construction of plant for the new electrical substation, the completion of the new packaging line and investments made to purchase production machinery, specifically additive manufacturing machines.

Industrial and commercial equipment amounts to €34,674 thousand and is chiefly comprised of surgical instruments capitalised during the current and previous years.

Other assets include office furniture and machines, electronic office machines, transport vehicles and cars. Investments, amounting to €706 thousand, refer to purchases of electronic office machines and furniture.

The €1,991 thousand increase in assets under construction and payments on account during the year is chiefly due to costs incurred to expand the Villanova production facility and for the purchase of production equipment and machinery.

Some plant and machinery are subject to a special lien at the reporting dates. Additional information is provided in note [3.15] Current and non-current financial liabilities.

Changes in right-of-use assets deriving from the application of IFRS 16 are set out in the following tables, where such changes are shown for each asset category along with details on the historical cost and accumulated depreciation:

 

(€‘000)

                                                
     01/01/2021      Exchange
difference
     Increases      Decreases      Depreciation      Other
changes
     31/12/2021
restated
 

Right-of-use assets

                    

Leased land and buildings

     9,364        377        827        -78        -880        -2,539        7,071  

Leased plant and equipment

     26        0        0        0        2        -15        13  

Leased industrial and commercial equipment

     15        0        935        0        0        -315        635  

Other leased assets

     2,695        7        1,221        0        -52        -1,726        2,145  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     12,100        384        2,983        -78        -930        -4,595        9,864  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

2022    26


(€‘000)

                                                
     31/12/2021
restated
     Exchange
difference
     Increases      Decreases      Depreciation      Other
changes
     31/12/2022
restated
 

Right-of-use assets

                    

Leased land and buildings

     7,071        226        2,087        -5        623        -3,247        6,755  

Leased plant and equipment

     13        0        82        0        0        -16        79  

Leased industrial and commercial equipment

     635        0        0        0        -58        -558        19  

Other leased assets

     2,145        2        1,577        0        90        -1,514        2,300  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     9,864        228        3,746        -5        655        -5,335        9,153  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Lease liabilities deriving from the application of IFRS 16 are included under current and non-current financial liabilities (analysed in note [3.15] Current and non-current financial liabilities). Changes in current and non-current lease liabilities from 1 January 2021 to 31 December 2022 are set out below:

 

(€‘000)

                                
     01/01/2021      Increases      Decreases     Reclassifications     31/12/2021
restated
 

Lease liabilities as per IFRS 16 - non-current portion

     6,573        1,369        —        (3,518     4,423  

Lease liabilities as per IFRS 16 - current portion

     3,384        —         (3,384     3,518       3,518  
  

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Total

     9,957        1,369        (3,384     —        7,941  
  

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

 

(€‘000)

                                                
     31/12/2021
restated
     Exchange
difference
     Increases      Decreases      Other
changes
     Reclassifications      31/12/2022
restated
 

Lease liabilities as per IFRS 16 - non-current portion

     4,423        83        3,663        0        655        -4,273        4,552  

Lease liabilities as per IFRS 16 - current portion

     3,518        -7        40        -4,559        0        4,273        3,265  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     7,941        76        3,703        -4,559        655        0        7,817  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

[3.4] Equity investments

Equity investments amount to €2 thousand at 31 December 2022.

The following information is provided on direct and indirect equity investments in subsidiaries, associates and other companies.

Subsidiaries

All of the subsidiaries are included in the consolidation scope.

Other companies

Equity investments in other companies amount to €2 thousand and refer to CAAF Interregionale dipendenti S.r.l., Consorzio Friuli Energia, Terra degli Elimi and CE.R.ME.T..

[3.5] Deferred tax assets and liabilities

Deferred tax assets and liabilities are only offset when this is legally provided for within the same tax jurisdiction. The group recognised deferred tax assets and liabilities on the temporary differences between carrying amounts and tax bases. The latter were calculated using the rates ruling when the temporary differences will reverse in the different countries where the group operates.

 

2022    27


Deferred tax assets and liabilities are broken down as follows at 31 December 2022 and 2021:

 

(€‘000)

                                  
     31/12/2022
restated
     31/12/2021
restated
     01/01/2021      Variation
2022 vs 2021
     Variation
2021 vs 2020
 

Deferred tax assets

     11,558        11,947        12,758        -390        -811  

Deferred tax assets arising on consolidation

     20,151        21,515        19,137        -1,364        2,378  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     31,709        33,462        31,895        -1,754        1,567  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

(€‘000)

                                  
     31/12/2022
restated
     31/12/2021
restated
     01/01/2021      Variation
2022 vs 2021
     Variation
2021 vs 2020
 

Deferred tax liabilities

     9,414        7,931        5,461        1,483        2,470  

Deferred tax liabilities arising on consolidation

     9,861        9,364        7,525        497        1,839  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     19,275        17,295        12,986        1,980        4,309  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Reference should be made to section [3.29] of these notes for more details on deferred tax assets and liabilities and the differences that generated them.

The recoverability of DTA accrued at 31 December 2022 was based on the business plan prepared by the management which shows the recoverability considering the future taxable incomes.

[3.6] Other non-current assets

Other non-current assets, amounting to €861 thousand, mainly refer to guarantee deposits for lease contracts taken out by the group and prepayments (€162 thousand), mostly for insurance and maintenance.

[3.7] Inventories

A breakdown of inventories at 31 December 2022 and 2021 is provided below:

 

(€‘000)

                                  
     31/12/2022
restated
     31/12/2021
restated
     01/01/2021      Variation
2022 vs 2021
     Variation
2021 vs 2020
 

Raw materials and supplies

     6,272        6,094        6,106        178        -12  

Work in progress and semi-finished products

     11,533        12,861        14,344        -1,328        -1,483  

Contract work in progress

     0        0        0        0        0  

Finished goods

     79,583        77,993        74,875        1,590        3,118  

Payments on account

     0        0        0        0        0  

Goods in transit

     831        647        177        184        470  

Allowance for inventory write-down

     -11,492        -10,174        -11,336        -1,318        1,162  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     86,728        87,421        84,166        -693        3,255  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Inventories were measured using the cost of the production company for the consolidated companies.

 

2022    28


The allowance for inventory write-down, amounting to €11,492 thousand at 31 December 2022, changed as follows during the year:

 

(€‘000)

      

Balance at 01/01/2021

     11,336  
  

 

 

 

Exchange difference

     74  

Utilisations

     -1,952  

Accruals

     716  
  

 

 

 

Balance at 31/12/2021 restated

     10,174  
  

 

 

 

Exchange difference

     54  

Utilisations

     -1,883  

Accruals

     3,146  
  

 

 

 

Balance at 31/12/2022 restated

     11,491  
  

 

 

 

Utilisations of the allowance refer to the scrapping of obsolete goods by Limacorporate S.p.A. and subsidiaries during the year.

[3.8] Trade receivables

Trade receivables at 31 December 2022 amount to €70,161 thousand, compared to €66,891 thousand at the previous year end, and are broken down as follows:

 

(€‘000)

                    
     Gross amount      Loss allowance      Carrying amount
31/12/2021 restated
 

Trade receivables - third parties

     68,971        2,082        66,889  

Trade receivables - related parties

     2        —         2  
  

 

 

    

 

 

    

 

 

 

Total

     68,973        2,082        66,891  
  

 

 

    

 

 

    

 

 

 

 

(€‘000)

                    
     Gross amount      Loss allowance      Carrying amount
31/12/2022 restated
 

Trade receivables - third parties

     72,527        2,387        70,140  

Trade receivables - related parties

     21        —         21  
  

 

 

    

 

 

    

 

 

 

Total

     72,548        2,387        70,161  
  

 

 

    

 

 

    

 

 

 

Trade receivables originate from group activities and are broken down by geographical segment as follows:

 

(€‘000)

                           
     Total Italy
31/12/2021

restated
     Total EU
31/12/2021

restated
     Rest of world
31/12/2021 restated
     Total
31/12/2021

restated
 

Trade receivables

     21,642        20,938        24,309        66,889  

From subsidiaries

     0        0        2        2  

From associates

     0        0        0        0  

From parents

     0        0        0        0  

From subsidiaries of parents

     0        0        0        0  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

     21,642        20,938        24,311        66,891  
  

 

 

    

 

 

    

 

 

    

 

 

 

 

(€‘000)

                           
     Total Italy
31/12/2022

restated
     Total EU
31/12/2022

restated
     Rest of world
31/12/2022 restated
     Total
31/12/2022

restated
 

Trade receivables

     23,021        20,681        26,438        70,140  

From subsidiaries

     0        0        0        0  

From associates

     0        0        0        0  

From parents

     0        21        0        21  

From subsidiaries of parents

     0        0        0        0  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

     23,021        20,702        26,438        70,161  
  

 

 

    

 

 

    

 

 

    

 

 

 

Trade receivables in foreign currency are detailed in section [4.2] Financial instruments – Fair value and risk management under Other information, to which reference should be made.

 

2022    29


The loss allowance amounts to €2,387 thousand at 31 December 2022 (31 December 2021: €2,082 thousand).

The loss allowance is management’s estimate of the expected credit losses on trade receivables from customers. The estimate is based on the group’s expected credit losses, determined using past experience with similar receivables, current and historical overdue amounts, losses and collections, a careful monitoring of credit quality and forecasts of economic and market conditions.

Changes in the loss allowance in 2022 and 2021 are as follows:

 

(€‘000)

             
     2022
restated
     2021
restated
 

Opening balance

     2,082        1,940  

Exchange difference

     33        10  

Accruals

     519        544  

Utilisations

     -247        -412  
  

 

 

    

 

 

 

Closing balance

     2,387        2,082  
  

 

 

    

 

 

 

Specifically:

 

(€‘000)

                    
     Receivables impaired
individually
     Receivables impaired
collectively
     Total  

01/01/2021 restated

     1,660        280        1,940  
  

 

 

    

 

 

    

 

 

 

Utilisations

     -398        -14        -412  

Accruals

     406        138        544  

Exchange difference

     11        0        11  
  

 

 

    

 

 

    

 

 

 

31/12/2021 restated

     1,679        404        2,082  
  

 

 

    

 

 

    

 

 

 

Utilisations

     -230        -17        -247  

Accruals

     324        195        519  

Exchange difference

     -10        43        33  
  

 

 

    

 

 

    

 

 

 

31/12/2022 restated

     1,763        624        2,387  
  

 

 

    

 

 

    

 

 

 

A breakdown of the loss allowance by past due category is as follows:

 

(€‘000)

                                         
     Not yet due      Overdue      Total  
            <30 days      30 - 90 days      90 - 180 days      Over 180
days
        

Gross trade receivables at 01 January 2021 restated

     38,238        6,112        5,375        4,306        10,968        64,998  

Loss allowance

     0        0        0        64        1,876        1,940  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Net trade receivables at 01 January 2021 restated

     38,238        6,112        5,375        4,242        9,092        63,058  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Gross trade receivables at 31 December 2021 restated

     41,111        6,422        5,362        4,622        11,454        68,971  

Loss allowance

     0        0        0        24        2,059        2,082  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Net trade receivables at 31 December 2021 restated

     41,114        6,422        5,362        4,598        9,395        66,891  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Gross trade receivables at 31 December 2022 restated

     47,203        7,324        6,108        4,519        7,394        72,548  

Loss allowance

     0        0        1        1        2,385        2,387  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Net trade receivables at 31 December 2022 restated

     47,203        7,324        6,107        4,518        5,009        70,161  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

[3.9] Current tax assets

Tax assets at 31 December 2022 amount to €2,087 thousand and include direct taxes, particularly in relation to the parent’s IRES and IRAP for €1,619 thousand.

 

2022    30


[3.10] Other current assets

Other current assets at 31 December 2022 amount to €14,192 thousand, compared to €11,247 thousand at the previous year end, and are broken down as follows:

 

(€‘000)

                                  
     31/12/2022
restated
     31/12/2021
restated
     01/01/2021      Variation 2022
vs 2021
     Variation 2021
vs 2020
 

Grants

     5,281        4,976        4,807        305        169  

Other tax assets

     827        758        1,024        69        -266  

Advances to agents

     776        779        964        -3        -185  

VAT

     1,317        1,340        923        -23        417  

Advances to suppliers

     1,327        939        804        388        135  

Hire and maintenance

     873        657        669        216        -12  

Other sundry

     1,354        420        489        934        -69  

VAT to be offset

     325        118        461        207        -343  

Insurance premiums and sureties

     574        507        396        67        111  

Other

     676        239        349        437        -110  

VAT claimed for reimbursement

     289        289        289        0        0  

Other tax credit

     0        0        104        0        -104  

Rent

     32        112        88        -80        24  

Deductible taxes

     0        50        50        -50        0  

Social security institutions

     20        20        21        0        -1  

IRAP-IRES reimbursement

     18        18        18        0        0  

Tax withholdings

     2        8        7        -6        1  

Factoring interest

     40        10        3        30        7  

Accrued income

     3        3        3        0        0  

Tax assets - interest

     454        0        0        454        0  

Leasing fees

     0        0        0        0        0  

IRPEF reimbursement

     4        5        0        -1        5  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     14,192        11,247        11,469        2,945        -222  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Grants chiefly refer to the amount accrued by the parent (€5,281 thousand) and are broken down as follows:

 

   

SIB grant (€4,630 thousand);

 

   

MCBEES grant (€258 thousand);

 

   

AIM grant (€40 thousand);

 

   

IAREPAM grant (€158 thousand;

 

   

PROST3SIS grant (€195 thousand).

Other assets also include guarantee deposits on gas and electricity consumption (€472 thousand).

[3.11] Cash and cash equivalents

Cash and cash equivalents at 31 December 2022 amount to €25,920 thousand, compared to €21,503 thousand at the previous year end. This caption shows the group’s liquidity at the reporting date.

Reference should be made to the statement of cash flows for an analysis of changes in cash and cash equivalents.

 

(€‘000)

                                  
     31/12/2022
restated
     31/12/2021
restated
     01/01/2021      Variation 2022
vs 2021
     Variation 2021
vs 2020
 

Bank and postal accounts

     25,903        21,486        26,257        4,417        -4,771  

Cash-in-hand and cash equivalents

     17        17        16        0        1  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     25,920        21,503        26,273        4,417        -4,770  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

2022    31


[3.12] Equity

Equity attributable to the owners of the parent amounts to €306,564 thousand, and is broken down as follows:

 

     31/12/2022
restated
     31/12/2021
restated
     01/01/2021      Variation
2022 vs 2021
     Variation
2021 vs 2020
 

Share capital

     9,868        9,868        9,868        0        0  

Share premium reserve

     14,425        14,425        14,425        0        0  

Legal reserve

     2,101        2,101        2,101        0        0  

Equity injections

     28,051        28,051        23,088        0        4,963  

Merge reserve

     288,261        288,261        288,261        0        0  

Actuarial reserve

     31        -23        -25        54        2  

Translation reserve

     2,379        1,508        -334        871        1,842  

Other reserves

     2,687        -2,329        -2,329        5,016        0  

Retained earnings (losses carried forward)

     -21,966        -18,862        -6,380        -3,104        -12,482  

Profit (loss) for the year

     -19,273        -2,539        -12,482        -16,735        9,943  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Equity

     306,564        320,463        316,194        -13,899        4,269  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

The share capital at 31 December 2022 is €9,868 thousand and is fully subscribed and paid up. It is comprised of 9,989,718 ordinary shares without a nominal amount. It is unchanged on the previous year end.

The share premium reserve amounts to €14,425 thousand and is unchanged on the previous year end.

The legal reserve amounts to €2,101 thousand. This reserve is not distributable and did not change during the year.

Negative goodwill, amounting to €288,261 thousand, comprises the effects of the reverse merger between the parent and Emil Holding III S.p.A. in October 2016 on equity.

Capital injections for capital increase, amounting to €28,051 thousand, comprise the contribution in kind made in 2021 by the shareholder for the acquisition of TechMah Medical (€4,963 thousand), the capital injection made by the shareholder in June 2020 (€20,000 thousand) and the effects of a contribution in kind made in 2019 by the shareholder in relation to the transaction carried out by the subsidiary Lima USA with Hospital for Special Surgery (HSS) (€3,088 thousand).

The contribution in kind made by the shareholder in 2021 is directly related to the shared-based payment of certain milestones regarding the acquisition of TechMah Medical. Under the agreement signed in 2018, the subsidiary Lima USA would allocate the founding shareholders of TechMah Medical a set number of new EmilNewCo Sarl (indirect parent of Limacorporate S.p.A. with a 100% interest) shares upon reaching set targets regarding the development of new products benefiting the group.

The above-mentioned allocation of shares in October 2021 led to a share capital increase for EmilNewCo and the recognition of an amount due from the founding shareholders of TechMah Medical equal to the liability recognised by Lima USA for the contractual milestones to be settled. The two transactions between the founding shareholders of Techmah Medical and Lima Group (EmilNewCo Sarl, Limacorporate S.p.A. and Lima USA) were offset using claim notes, which generated the capital injection referred to above.

With a similar transaction, the collaboration agreement signed with HSS in January 2019 for the production of implants within the hospital led to the following agreements:

 

   

a six-year lease for the premises where Lima USA will produce the implants for HSS, of which payment for the first three years has been made by awarding HSS a fixed number of new EmilNewCo Sarl shares and the second three years will be paid by monthly instalments;

 

   

a clause which establishes that HSS will bear an agreed amount of the cost of any leasehold improvements made by Lima USA and will receive an agreed number of new EmilNewCo Sarl shares in return.

The above-mentioned allocation of shares led to a share capital increase for EmilNewCo and the recognition of an amount due from HSS. The prepaid lease instalments and the set amount related to the leasehold improvements generated a liability for Lima USA towards HSS. The two transactions between HSS and Lima Group (EmilNewCo, Limacorporate S.p.A. and Lima USA) have been offset using claim notes, which generated the capital injection referred to above.

 

2022    32


Other reserves also include:

 

   

the revaluation reserve, which arose from the merger of Lima S.p.A., amounts to €111 thousand and is recognised in compliance with Law no. 413 of 30 December 1991 in relation to deferred tax on the revalued amount of land and industrial buildings. There were no changes in the reserve during the year;

 

   

the reserve deriving from the application of IAS 19 Employee benefits amounting to €31 thousand;

 

   

the IFRS 2 reserve amounting to €4,650 thousand deriving from the accounting treatment of cash-settled share-based payment and equity-settled share-based payment arrangements;

 

   

the reserve for unrealised exchange rate gains of €1,764 thousand, comprising the net unrealised gains on the allocation of the parent’s profit for the previous year;

 

   

the translation reserve, with a positive balance of €2,379 thousand, reflects the changes in the group’s share of the equity of consolidated companies due to changes in exchange rates of such companies’ functional currencies compared to the presentation currency of the Consolidated financial statements restated as at 31 December 2022.

The correction of error on payback for €6.945 thousand has been recorded on retained earnings / losses carried forward.

The following table provides information on the possibility of use and distribution of each of the parent’s equity items, along with their utilisations in the last three years:

 

Description

   Amount      Possibility
of use
     Available
portion
     Utilisation in
the previous
three years
to cover

losses
     Utilisation in
the previous
three years
for other

reasons
 

Share capital

     9,868        B           

Share premium reserve

     14,425        A, B        14,425        

Legal reserve

     2,101        B        2,101        

Capital injections for capital increase

     28,051        A, B, C        28,051        9,215     

Merge reserve

     288,261        A, B, C        288,288        246     

Actuarial reserve

     31              

Translation reserve

     2,379              

Other reserves

     2,687              

Retained earnings (losses carried forward)

     -21,966           10,770        
  

 

 

       

 

 

    

 

 

    

 

 

 

TOTAL

     325,838           343,635        9,461        0  
  

 

 

       

 

 

    

 

 

    

 

 

 

Non-Distributable Portion (Legal Reserve)

           2,101        

Non-Distributable Portion (Reserve For Unrealised Exchange Rate Gains)

           1,199        

Capitalised Start-Up And Development Costs)

           14,387        
        

 

 

       

Residual Distributable Amount

           325,949        
        

 

 

       

 

*

A: for capital increases; B: to cover losses; C: dividends

The following supplementary information is provided on the parent’s reserves:

1) Reserves or other provisions that do not contribute to the taxable profit of shareholders in the event of distribution regardless of when they are formed.

 

(€‘000)

                    
     31/12/2022
restated
     31/12/2021
restated
     01/01/2021  

Emil Holding III merger reserve

     288,261        288,261        288,261  

Capital injections for capital increase

     28,051        28,051        23,088  

Share premium reserve

     14,425        14,425        14,425  
  

 

 

    

 

 

    

 

 

 

Total

     330,737        330,737        325,774  
  

 

 

    

 

 

    

 

 

 

 

2022    33


2) Reserves or other provisions that do contribute to the taxable profit of the parent in the event of distribution regardless of when they are formed.

 

(€‘000)

                    
     31/12/2022
restated
     31/12/2021
restated
     01/01/2021  

Revaluation reserve as per Law no. 413/1991

     111        111        111  

Reserve as per article 55 of Presidential decree no. 917/86

     —         —         —   
  

 

 

    

 

 

    

 

 

 

Total

     111        111        111  
  

 

 

    

 

 

    

 

 

 

3) Reserves included in share capital.

Reserves or other provisions that contribute to the taxable profit of shareholders in the event of distribution, irrespective of when they were set up, for a free share capital increase by using the reserve as per the shareholders’ resolution of 15 October 1999.

 

(€‘000)

                    
     31/12/2022
restated
     31/12/2021
restated
     01/01/2021  

Extraordinary reserve

     540        540        540  
  

 

 

    

 

 

    

 

 

 

Total

     540        540        540  
  

 

 

    

 

 

    

 

 

 

[3.13] Provisions for risks and charges

Details of this caption and changes therein during 2021 and 2022 are provided below:

 

(€‘000)

                                         
     01/01/2021      Exchange
differences
     Increases      Decreases      Reclassification      31/12/2021
restated
 

Pension and similar provisions

     889        0        198        -162        0        925  

Other provisions

     11,958        -4        4,226        -1,222        -569        14,389  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     12,847        -4        4,424        -1,384        -569        15,314  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

(€‘000)

                                         
     31/12/2021
restated
     Exchange
differences
     Increases      Decreases      Reclassification      31/12/2022
restated
 

Pension and similar provisions

     925        0        236        -576        0        585  

Other provisions

     14,389        14        4,166        -1,997        0        16,571  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     15,314        14        4,402        -2,573        0        17,156  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Agents’ termination indemnity (€585 thousand) is the estimated liability deriving from the application of ruling legislation and the contractual clauses in relation to the termination of agency contracts. Unlike accruals to the provision for risks, guarantees and other provisions, accruals to agents’ termination indemnity are classified by nature among costs for services. The decreases of the year refer to utilisations of the provision following the termination of agency contracts and the release of the provision when not due.

Other provisions, amounting to €16,571 thousand, are comprised as follows:

 

   

the provision for charges of €1,859 thousand, of which €1,460 thousand related to commission expense on revenue yet to be invoiced; and €399 thousand related to highly probable non-competition agreements the payment date of which is not yet known;

 

   

the provision related to the payback system for €14.3 million;

 

   

compensation for damage caused by products of €300 thousand;

 

   

other disputes/contingent liabilities of €95 thousand.

The decreases of the year mainly refer to the release of a provision following the signing of a settlement agreement with an agent.

The accruals of the year mainly refer to the best estimate of the amounts due under the payback system.

 

2022    34


The market in which the Group operates is strictly controlled by laws and regulations such as, e.g., the EU Medical Devices Regulation (‘MDR’) in Europe and the Federal Food, Drug and Cosmetic Act (‘FDCA’) in USA. In order to demonstrate adherence to regulatory requirements and to maintain the ability to sell its products, the Group must obtain and maintain authorisations and certifications from the relevant authorities. Discussions are currently underway with the Australian authority, the Therapeutic Goods Administration (the ‘TGA’), which has been provided with clarification regarding an observation made by the TGA on the high revision rate of certain elements of the ‘SMR’ shoulder solution.

[3.14] Employee benefits

Employee benefits chiefly refer to post-employment benefits recognised by the parent. These are defined benefit plans in accordance with IAS 19. Changes in the caption during the two years were as follows:

 

(€‘000)

                    
     31/12/2022
restated
     31/12/2021
restated
     Variation
2022 vs 2021
 

Balance at 1 January

     1,442        1,421        21  

Exchange difference

     (13      —         (13

Benefits settled/advances paid

     (189      (123      (66

Accruals

     1,716        1,651        65  

Cometa Fund, other pension funds

     (1,599      (1,376      (223

Post-employment benefits - Substitute tax on revaluation

     —         (132      132  

Interest

     10        4        6  

Actuarial (gain) loss

     (71      (3      (68
  

 

 

    

 

 

    

 

 

 

Total

     1,296        1,442        (146
  

 

 

    

 

 

    

 

 

 

The main actuarial assumptions used in determining the present value of post-employment benefits are set out below:

 

    

31/12/2022

  

31/12/2021

Actual mortality rate    RG48 tables determined by the State general accountant    RG48 tables determined by the State general accountant
Actual invalidity rate    INPS disability/invalidity tables    INPS disability/invalidity tables
Rate of early terminations (dismissals and resignations)    Constant annual average rate of 5%    Constant annual average rate of 5%
Rate of requests for advances of post-employment benefits   

- Constant annual average rate of 3%

 

- Average amount of 70% of post-employment benefits accrued

  

- Constant annual average rate of 3%

- Average amount of 70% of post-employment benefits accrued

Annual technical discount rate    3.6% - iBoxx index Eur Corporate AA 10    1% - iBoxx index Eur Corporate AA 10+
Annual future inflation rate    2.50%    1.50%
Pension dates    In line with ruling legislation    In line with ruling legislation
Annual increase in post-employment benefits    Fixed rate of 3.38% plus 75% of the inflation rate noted by ISTAT for December of the previous year    Fixed rate of 2.63% plus 75% of the inflation rate noted by ISTAT for December of the previous year

 

2022    35


The occurrence of reasonably possible changes in the actuarial assumptions at 31 December 2022 and 2021 would have impacted the defined benefit obligations by the amounts shown below:

 

2021 sensitivity analysis

 
(€‘000)    Defined benefit obligation  
     +      -  

Annual discount rate (+/- 0.50%)

     959        999  

Annual inflation rate (+/- 0.25%)

     991        967  

Annual turnover rate (+/- 2.00%)

     978        979  

2022 sensitivity analysis

 
(€‘000)    Defined benefit obligation  
     +      -  

Annual discount rate (+/- 0.50%)

     890        922  

Annual inflation rate (+/- 0.25%)

     915        896  

Annual turnover rate (+/- 2.00%)

     907        906  

The number of employees by category at the reporting date and the average for the year is set out below:

 

Workforce

   31/12/2020      Incoming      Outgoing      Other
changes
     Reclassifications      31/12/2021      2021 average  

Blue collars

     227        11        -18        0        0        220        224  

White collars

     589        108        -104        -1        -1        591        590  

Junior managers

     90        7        -9        0        -12        76        83  

Managers

     32        5        -9        0        13        41        37  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     938        131        -140        -1        0        928        933  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

Workforce

   31/12/2021      Incoming      Outgoing      Other
changes
     Reclassifications      31/12/2022      2022 average  

Blue collars

     220        22        -14        -20        -4        204        212  

White collars

     591        140        -132        1        -2        598        595  

Junior managers

     76        8        -14        15        5        90        83  

Managers

     41        4        -9        4        1        41        41  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     928        174        -169        0        0        933        931  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

[3.15] Current and non-current financial liabilities

Non-current financial liabilities, amounting to €10,165 thousand at 31 December 2022, comprise the portion of loans and borrowings due after one year and are broken down as follows:

 

(€‘000)

                                  
     31/12/2022
restated
     31/12/2021
restated
     01/01/2021      Variation
2022 vs 2021
     Variation
2021 vs 2020
 

Non-current bank loans and borrowings

     363        746        1,379        -383        -633  

Non-current bank loans and borrowings (due after five years)

     2        0        41        2        -41  

Bonds

     0        272,556        271,136        -272,556        1,420  

Other financial liabilities

     5,248        5,848        8,279        -600        -2,431  

Lease liabilities as per IFRS 16

     4,552        4,423        6,573        129        -2,150  

Derivatives

     0        0        0        0        0  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     10,165        283,573        287,407        -273,408        -3,834  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

2022    36


Current financial liabilities, amounting to €336,659 thousand, comprise the current portion of loans and borrowings and are broken down as follows:

 

(€‘000)

                                  
     31/12/2022
restated
     31/12/2021
restated
     01/01/2021      Variation
2022 vs 2021
     Variation
2021 vs 2020
 

Credit cards

     383        47,000        40,000        -46,617        7,000  

Advances on exports

     0        7,771        14,817        -7,771        -7,046  

Current bank loans and borrowings

     54,000        3,518        3,384        50,482        134  

Non-current bank loans and borrowings

     386        1,346        1,318        -960        28  

Bonds - current portion

     274,039        882        909        273,157        -27  

Accrued expenses on bonds - due within one year

     1,979        0        0        1,979        0  

Accrued financial expense - due within one year

     298        401        405        -103        -4  

Loans and borrowings with other financial backers

     2,310        280        211        2,030        69  

Lease liabilities as per IFRS 16

     3,265        338        112        2,927        226  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     336,659        61,536        61,156        275,123        380  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Current financial liabilities chiefly include the bonds issued by Limacorporate S.p.A. in 2017 equal to €274,039 thousand at the reporting date. They are senior secured bonds redeemable in 2023 for a total nominal amount of €275 million. The bonds were initially recognised at fair value, net of directly related costs, and measured at amortised cost applying the effective interest rate method.

The bonds have coupons based on the 3-month Euribor plus a 3.75% spread, with a Euribor floor threshold of 0.00%. They are listed on the Euro MTF market of the Luxembourg Stock Exchange and the professional section of the ExtraMOT market of the Italian Stock Exchange.

The coupons mature every three months on 15 February, 15 May, 15 August and 15 November each year starting from 15 November 2017.

The following guarantees were issued in relation to the bonds:

 

   

pledge on the shares of Limacorporate S.p.A.;

 

   

pledge on the shares of some subsidiaries;

 

   

pledge on some of the current accounts of the parent and some subsidiaries;

 

   

special lien on plant, machinery and other items of property, plant and equipment of the parent;

 

   

lien on certain categories of assets of some subsidiaries;

 

   

guarantees on some categories of assets of the parent and some subsidiaries.

In relation to the refinancing put in place in 2017, as well as the issue of bonds, Limacorporate also finalised an agreement for a new super senior revolving credit facility for a maximum of €60 million. It may also be used partially, in several instalments with set repayment terms. If the financial covenants are complied with, the interest rate is the same as the bonds, i.e., 3-month Euribor plus a 3.75% spread, with a Euribor floor threshold of 0.00%.

The same guarantees provided for the issue of the bonds were granted for this revolving credit facility; specifically:

 

   

pledge on the shares of Limacorporate S.p.A.;

 

   

pledge on the shares of some subsidiaries;

 

   

pledge on some of the current accounts of the parent and some subsidiaries;

 

   

special lien on plant, machinery and other items of property, plant and equipment of the parent;

 

   

lien on certain categories of assets of some subsidiaries;

 

   

guarantees on some categories of assets of the parent and some subsidiaries.

At the reporting date, €54 million of the revolving facility was used (31 December 2021: €47 million).

If more than 35% of the available amount of the revolving facility is used (i.e., draw-downs exceeding €21 million), a covenant related to the ratio of super senior net debt (the amount drawn down from the revolving facility net of liquid funds) to consolidated gross operating profit (as defined in the loan agreement), which cannot exceed 1.83, is activated under the terms of the contract. Such covenant was complied with at 31 December 2022.

On 3 February 2023, the parent issued new senior secured bonds redeemable in February 2028 for a total nominal amount of €295 million. In addition to the bond issue, the parent also signed a new super senior revolving facility for a maximum of €65 million expiring in November 2027.

 

2022    37


On 9 March 2023, the parent privately placed additional notes with the same terms and conditions as the bonds, for an amount of €15 million.

The pre-existing bonds and super senior revolving facility were fully redeemed and repaid.

The bonds have coupons based on the 3-month Euribor plus a 5.75% spread, with a Euribor floor threshold of 0.00%. They are listed on the Euro MTF market of the Luxembourg Stock Exchange.

The completion of the refinancing also saw a significant capital injection of €46,295 thousand by the parent’s shareholder.

The management, after having carefully assessed, and positively considered, the effects of the actions in progress have the reasonable expectation that the Company may continue to operate in the foreseeable future, consequently the management have prepared the financial statements as at 31 December 2022 on a going concern basis.

Non-current financial liabilities include loans and borrowings from other financial backers (€185 thousand) related to the amount due in 2024 for the acquisition of a business unit from the group’s Sicilian distributor.

On 25 September 2017, the parent entered into an agreement with the agency MT Ortho to acquire its business unit comprising the components organised for the marketing, sale and after-sales assistance of Lima medical devices in Sicily and Calabria. Specifically, the business unit included:

 

   

ongoing supply contracts with the healthcare facilities;

 

   

supply contracts under negotiation;

 

   

goodwill.

The consideration of €3.7 million was to be paid as follows:

 

   

€740 thousand when the contract was signed;

 

   

€2,960 thousand in six annual instalments (from 2018 to 2023), the payment of which depends on whether a certain level of sales is maintained in the region until the payment is complete.

The agreement was renegotiated in late 2020, accelerating the payment of the remaining 2021 instalments of €1,645 thousand against a €20 thousand decrease in the liability and the renegotiation of the commissions in the area.

Loans and borrowings from other financial backers also include amounts yet to be paid in relation to the acquisition of TechMah Medical LLC (contingent consideration). The difference on the previous year end is taken to profit or loss under financial income.

The caption also includes the non-current portion of the medium/long-term loans taken out by the parent for the SICAT and IAREPAM projects and by some branches in relation to the relief available for the Covid-19 pandemic, detailed as follows:

 

Description

  

Company

   Original
amount
    

Rate

   Expiry date    Residual
amount at

01/01/2021
    

Guarantee

SICAT sustainable growth fund 1st progress report

   Limacorporate S.p.A.      274      Fixed    30/06/2026      190      None

SICAT sustainable growth fund 2nd progress report

   Limacorporate S.p.A.      339      Fixed    30/06/2026      251      None

Covid-19 subsidised loan

   Lima France      500      Fixed    31/05/2024      500     

Government

guarantee

Covid-19 subsidised loan

   Lima Austria      200      0% until August 2022, then a floating loan    31/12/2024      200      None

Covid-19 subsidised loan

   Lima Switzerland      407      Fixed    31/03/2025      407      None
     

 

 

          

 

 

    

Total

        1,720              1,548     
     

 

 

          

 

 

    

 

2022    38


Description

  

Company

   Original
amount
    

Rate

   Expiry date    Residual
amount at

31/12/2021
    

Guarantee

SICAT sustainable growth fund 1st progress report

   Limacorporate S.p.A.      274      Fixed    30/06/2026      156      None

SICAT sustainable growth fund 2nd progress report

   Limacorporate S.p.A.      339      Fixed    30/06/2026      206      None

Covid-19 subsidised loan

   Lima France      500      Fixed    31/05/2024      512     

Government

guarantee

Covid-19 subsidised loan

   Lima Austria      200      0% until August 2022, then a floating loan    31/12/2024      150      None
     

 

 

          

 

 

    

Total

        1,313              1,024     
     

 

 

          

 

 

    

 

Company

  

Description

   Original
amount
    

Rate

   Expiry date      Residual
amount at

31/12/2022
    

Guarantee

Limacorporate S.p.A.

   SICAT sustainable growth fund 1st progress report      274      Fixed      30/06/2026        122      None

Limacorporate S.p.A.

   SICAT sustainable growth fund 2nd progress report      339      Fixed      30/06/2026        161      None

Limacorporate S.p.A.

   Sustainable growth fund “Project IAREPAM – Artificial Intelligence for the Efficient Development of an Implant in Additive Manufacturing” 1st progress report      6      Fixed      30/06/2031        6      None

Lima France

   Covid-19 subsidised loan      500      Fixed      31/05/2024        363      Government guarantee

Lima Austria

   Covid-19 subsidised loan      200      0% until August 2022, then a floating loan      31/12/2024        100      None
     

 

 

          

 

 

    

Total

        1,319              751     
     

 

 

          

 

 

    

Accrued financial expense and accrued expenses on bonds due within one year include interest accrued at each reporting date and not yet paid.

Finally, financial liabilities include lease liabilities deriving from the application of IFRS 16. The discount rate applied in 2022 was revised and modified to take into consideration the higher interest rates compared to previous years.

Changes in lease liabilities from 1 January 2021 to 31 December 2022 are set out below:

 

(€‘000)

                                                
     01/01/2021      Exchange
differences
     Increases      Decreases      Other
changes
     Reclassifications      31/12/2021
restated
 

Lease liabilities as per IFRS 16 - non-current portion

     6,573        0        1,369        0        0        -3,518        4,424  

Lease liabilities as per IFRS 16 - current portion

     3,384        0        0        -3,384        0        3,518        3,518  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     9,957        0        1,369        -3,384        0        0        7,941  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

(€‘000)

                                                
     31/12/2021
restated
     Exchange
differences
     Increases      Decreases      Other
changes
     Reclassifications      31/12/2022
restated
 

Lease liabilities as per IFRS 16 - non-current portion

     4,424        83        3,663        0        655        -4,273        4,552  

Lease liabilities as per IFRS 16 - current portion

     3,518        -7        40        -4,559        0        4,273        3,265  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     7,941        76        3,703        -4,559        655        0        7,817  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Lease liabilities are detailed by due dates as follows:

 

(€‘000)

                    
     31/12/2022
restated
     31/12/2021
restated
     01/01/2021  

Current liabilities - due within one year

     3,265        3,518        3,384  

Non-current liabilities - due from one to five years

     3,997        4,328        6,022  

Non-current liabilities - due after five years

     555        95        551  
  

 

 

    

 

 

    

 

 

 

Total

     7,817        7,941        9,957  
  

 

 

    

 

 

    

 

 

 

[3.16] Other non-current liabilities

Other non-current liabilities, amounting to €649 thousand (31 December 2021: €5,250 thousand), include incentive plans for some managers (€427 thousand) and the non-current portion of deferred income (€221 thousand), chiefly related to insurance costs.

The decrease on the previous year end is chiefly due to the pay-out of amounts to an outgoing manager and the fair value adjustment of the incentive plans.

 

2022    39


Reference should be made to note [4.8] incentive plans under section [4] Other information for further information about such plans.

[3.17] Trade payables

Trade payables amount to €36,564 thousand at 31 December 2022 (31 December 2021: €32,343 thousand) and refer to short-term obligations to suppliers of goods and services. They refer to positions payable in the short term and there are no amounts due after one year.

There are no differences between the carrying amount and fair value of such payables.

Trade payables at 31 December 2022 are broken down by geographical segment in the following table:

 

     Total Italy      Total EU      Rest of
world
     Total  

Trade payables

     19,196        8,941        8,077        36,214  

Commercial paper

     —         —         —         —   

Payable to subsidiaries

     —         —         —         —   

Payable to associates

     —         —         —         —   

Payables to parents

     —         350        —         350  

Payables to subsidiaries of parents

     —         —         —         —   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

     19,196        9,291        8,077        36,564  
  

 

 

    

 

 

    

 

 

    

 

 

 

Trade payables at 31 December 2021 are broken down by geographical segment in the following table:

 

     Total Italy      Total EU      Rest of
world
     Total  

Trade payables

     18,297        7,366        6,330        31,993  

Commercial paper

           —         —   

Payable to subsidiaries

     —         —         —         —   

Payable to associates

     —         —         —         —   

Payables to parents

     —         350        —         350  

Payables to subsidiaries of parents

     —         —         —         —   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

     18,297        7,716        6,330        32,343  
  

 

 

    

 

 

    

 

 

    

 

 

 

Trade payables at 01 January 2021 are broken down by geographical segment in the following table:

 

     Total Italy      Total EU      Rest of
world
     Total  

Trade payables

     16,316        6,208        5,491        28,016  

Payable to subsidiaries

     —         —         400        400  

Debiti verso Imprese Collegate

     —         —         —         —   

Payables to parents

     —         525        —         525  

Payables to subsidiaries of parents

     —         —         —         —   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

     16,316        6,733        5,891        28,941  
  

 

 

    

 

 

    

 

 

    

 

 

 

Trade payables do not accrue interest. The terms and conditions for related parties do not differ from those applied for third party suppliers. Trade payables in foreign currencies are analysed in section [4.2] Financial risk management Fair value and risk management to which reference should be made.

[3.18] Tax liabilities

Tax liabilities amount to €877 thousand at 31 December 2022 (31 December 2021: €202 thousand). Specifically, the caption is fully comprised of current taxes payable by foreign branches.

 

2022    40


[3.19] Other current liabilities

Other current liabilities are broken down in the following table. The main liabilities refer to payments on account, tax liabilities, social security charges payable, amounts due to employees and sundry liabilities mainly related to the payback system.

 

 

(€‘000)

                                  
     31/12/2022
restated
     31/12/2021
restated
     01/01/2021      Variation
2022 vs 2021
     Variation
2021 vs 2020
 

Wages and salaries

     1,848        2,347        3,386        -499        -1,039  

Employee and performance bonus

     8,911        6,064        6,197        2,847        -133  

Directors’ fees

     302        82        369        220        -287  

Statutory auditors’ fees

     34        35        18        -1        17  

Liabilities for the purchase of business units

     194        194        194        0        0  

Payables to factors for collections received

     7        2        5        5        -3  

Foreign commissions

     4        0        0        4        0  

Sundry other liabilities

     1,034        1,382        1,396        -348        -14  

Payments on account

     4,380        4,273        4,378        107        -105  

IRPEF withholdings

     1,241        978        812        263        166  

Other tax liabilities

     1,852        632        826        1,220        -194  

VAT

     1,280        1,384        1,344        -104        40  

INPS - Inpdai - Previndai

     2,390        1,616        2,048        774        -432  

INAIL

     19        18        3        1        15  

Cometa Fund, other pension funds

     292        255        226        37        29  

Enasarco for agents

     181        152        142        29        10  

Other social security charges payable

     612        425        442        187        -17  

Accrued expenses:

     0        0        0        0        0  

Insurance premiums

     5        9        10        -4        -1  

Interest on non-current loans

     0        9        0        -9        9  

Other

     80        152        189        -72        -37  

Deferred income:

     0        0        0        0        0  

Grants related to assets

     72        26        42        46        -16  

Rent

     1        0        0        1        0  

Other

     3        6        19        -3        -13  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     24,742        20,041        22,047        4,701        -2,006  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Payments on account amount to €4,380 thousand and include the following:

 

   

PON SIB grant advance of €3,773 thousand, unchanged on the previous year end;

 

   

MC BEES grant advance of €249 thousand, up €33 thousand on the previous year end;

 

   

IAREPAM grant advance of €11 thousand (nil balance at the previous year end);

 

   

advances received from customers of €340 thousand;

 

   

other payments on account of €7 thousand.

Liabilities for the purchase of business units of €194 thousand (unchanged from the previous year) refers to the acquisition of the Lima Brazil business unit. This liability dates back to 2011 when the Brazilian business unit was set up.

Other tax liabilities include taxes, fines and interest which arose from the parent signing a mutually-agreed assessment settlement procedure with the tax authorities (Friuli-Venezia Giulia regional tax authorities).

On 4 December 2019, the company was notified of a preliminary assessment report by tax authorities.

 

2022    41


On 3 February 2020, the company replied to such preliminary assessment report, asking the tax authorities to recognize the lack of grounds of some of the allegations set out in the report and, accordingly, not to issue the assessment notices, reserving its right to present further pleadings and start negotiations with the tax authorities.

No issue of the assessment notices has been notified. In this context the risk was difficult to quantify and of an indeterminate amount, in light of the deductions made by the company and the failure to establish a cross-examination on the matter with the Tax Authority.

The company’s management believed that if taken the claim to court, then it is probable that it will be able to defend its position, however, at the end of 2022 management changed the strategy and intended to take in consideration to settle the claim (although not in agreement on the legitimacy and grounds of the add-backs proposed by the tax authorities), in order to avoid a lengthy dispute and based on its assessments on the cost-effectiveness of the legal procedure.

On 11 January 2023 the tax authorities notified to the company an Invitation (pursuant to article 5-ter of Legislative decree no. 218 of 19 June 1997), the invitation is a communication to appear in order to try to reach an agreement. the Invitation has been issued with year protocol 2022 and notified in early January to the company.

In march 2023 the company decided to accept the amount of the settlement proposed by the tax authorities.

The amount due is of about €1,477 at 31 December 2022 and is included in the caption “Other current liabilities”.

[3.20] Revenue and other revenue and income

Revenue amounts to €245,669 thousand, compared to €210,543 thousand in 2021, a year-on-year increase of 16.7%.

Revenue derives from sales and distribution contracts with group customers essentially related to the sale of orthopaedic implants, mostly for shoulders, hips and knees.

In accordance with IFRS 15, revenues are stated net of discounts and allowances and are constrained in order to only represent the ones that are highly probable to be collected. The constraints related to variable consideration refer to payback, amounting to € 2.9 million at 31 December 2022 (€ 2.3 million at 31 December 2021), established in connection with the activation of the Italian government payback provision as a retroactive rebate (i.e. variable consideration). Such variable considerations were estimated based on the publicly available information. The Italian payback law is a mechanism to obtain from suppliers a contribution to offset variances occurring when Italian government expenditures exceed their ceiling for the purchase of medical devices.

It is broken down by geographical segment as follows:

 

(€‘000)

                    
     2022 restated      2021 restated      Variation  

Italy

     45,227        39,950        5,277  

Rest of Europe

     97,948        79,011        18,937  

APAC

     37,652        38,357        (705

United States

     43,111        35,283        7,828  

Rest of world

     21,731        17,942        3,789  
  

 

 

    

 

 

    

 

 

 

Total

     245,669        210,543        35,126  
  

 

 

    

 

 

    

 

 

 

Under Italian healthcare regulations, each region is allocated an annual budget for purchasing medical devices. Upon exceeding the assigned budget, the region can ask suppliers of medical devices to reimburse a portion of the excess amount in proportion to the annual market share of each supplier in the region involved (the payback system). Specifically, pursuant to Decree law no. 115 of 9 August 2022 (converted into Law no. 142/2022), the Ministry for Health, with Ministerial decree published on 15 September 2022 (“Decree 216/2022”), set the amounts exceeding the regional budgets for each year from 2015 to 2018 and, with Ministerial decree published on 6 October 2022 (“Decree 251/2022”), set out guidelines for the Italian regions to follow in requesting reimbursements under the payback system.

Under the payback system, each region issues payment orders to suppliers of medical devices. At the date of these consolidated financial statements restated as at 31 December 2022, Limacorporate S.p.A. and Lima SM in liquidation received payment orders for reimbursements under the payback system for amounts totalling €8.8 million for 2015, 2016, 2017 and 2018 which were recognised under provisions for risks and charges.

 

2022    42


Should a supplier not pay the requested amounts within 30 days, Decree 216/2022 provides that such amounts be offset against any amounts due to such suppliers from each region and/or body partnered with regional healthcare authorities. In addition, under Decree law no. 4 of 11 January 2023, the due date for the payment of such amounts was deferred to 30 April 2023. Decree law no. 34 of 30 March 2023 as modified by Law Decree n 132 of 15th november 2023 then further deferred the payment to 30th November 2023. On 24 November 2023 the Lazio regional administrative court has referred to the Italian Constitutional Court a series of points around the constitutional legitimacy of the legislation that disciplines the payback system for medical devices. As a consequence, al proceedings pending before the Lazio regional administrative court are, de facto, suspended until the Constitutional Court rules on the above.

Additionally, on 30 November 2023 the Lazio regional administrative court has issued a specific ruling to Limacorporate S.p.A., confirming that all requests for payment received from the regions are to be suspended until the Constitutional Court rules on the above.

In line with the approach adopted by other suppliers of medical devices, Limacorporate contested Decree 216/2022 and Decree 251/2022 before the Lazio regional administrative court, contesting, inter alia, whether the decrees comply with the constitution. The parent also contested the individual deeds through which the regions involved individually settled and requested the amounts deemed due to it.

Furthermore, as it cannot be excluded that the Italian Ministry for Health may deem that the regional budgets for each year from 2019 to 2022 have been exceeded and, thus, that the Italian regions may issue further payment orders for each of those years, the group has calculated its best estimate of amounts probably due, based on:

 

   

publicly available data on spending by the regions over the relevant budgets

 

   

Limacorporate’s turnover in the various regions;

 

   

Limacorporate’s market share in the various regions.

Other revenue and income are broken down as follows:

 

(€‘000)

                    
     2022 restated      2021 restated      Variation  

Service recharges

     2,805        2,048        757  

Lease income

     449        441        8  

Recharges to subsidiaries/associates

     24        1        23  

Gains

     863        675        188  

Release of the provision for risks

     106        0        106  

Other income

     535        489        46  

Grants related to income

     615        475        140  

Grants related to assets

     84        77        7  

Other revenute - previous years

     283        -249        532  

Other revenue

     33        16        17  
  

 

 

    

 

 

    

 

 

 

Total

     5,798        3,973        1,825  
  

 

 

    

 

 

    

 

 

 

The increase in revenue from recharges for services is linked to the rise in turnover and sales.

 

2022    43


[3.21] Raw materials, consumables, supplies and goods

This caption amounts to €56,391 thousand, compared to €53,530 thousand in 2021. It is broken down as follows:

 

(€‘000)

                    

Description

   2022 restated      2021 restated      Variation  

Purchase of raw materials

     9,350        9,038        312  

Purchase of semi-finished products

     21,353        21,567        -214  

Purchase of finished goods

     10,218        6,136        4,082  

Individual tool components

     13,501        15,135        -1,634  

Opening balance of raw materials, consumables, supplies and goods

     6,094        6,106        -12  

Closing balance of raw materials, consumables, supplies and goods

     -6,272        -6,094        -178  

Other purchases

     2,146        1,642        504  
  

 

 

    

 

 

    

 

 

 

TOTAL

     56,391        53,530        2,860  
  

 

 

    

 

 

    

 

 

 

[3.22] Services

Services amount to €81,645 thousand, up 16.8% on the €69,910 thousand of 2021. The caption is broken down as follows:

 

(€‘000)

                    

Description

   31/12/2022
restated
     31/12/2021
restated
     Variation  

Outsourced processing and analyses

     3,310        4,347        -1,037  

Transport costs for sales

     5,551        4,750        801  

Transport costs for purchases

     790        631        159  

Energy, power supply

     3,622        1,194        2,428  

Administrative services

     1,891        1,693        198  

Maintenance and repair

     2,226        1,825        400  

Maintenance of HW/SW/office equipment

     2,700        2,071        629  

Technical and commercial consultancy

     5,895        5,535        360  

Non-recurring consultancy

     635        5,386        -4,751  

Conferences and trade fairs

     2,354        1,026        1,328  

WorkShop

     2,812        1,414        1,399  

Enasarco commissions and charges

     28,074        23,670        4,405  

Travel costs

     4,561        2,670        1,892  

Insurance costs

     3,524        3,078        446  

Directors’ fees

     2,784        799        1,986  

Royalties

     1,360        936        424  

Others

     9,555        8,886        669  
  

 

 

    

 

 

    

 

 

 

TOTAL

     81,645        69,910        11,735  
  

 

 

    

 

 

    

 

 

 

The increase in this caption is chiefly due to fees directly related to the growth in turnover and higher energy costs tied to the rise in utilities costs.

Directors’ fees for 2022 include €941 thousand for management incentive plans (2021: €466 thousand). Reference should be made to section [4.8] Incentive plans for a description of such plans. The increase in directors’ fees is attributable to the costs incurred due to the CEO stepping down.

[3.23] Change in work in progress, semi-finished products and finished goods

This caption shows a negative balance of €887 thousand for 2022 (2021: positive balance of €2,058 thousand).

 

2022    44


[3.24] Personnel expenses

Personnel expenses amount to €76,858 thousand, compared to €60,773 thousand in 2021, and are broken down as follows:

 

(€‘000)

                    

Description

   31/12/2022
restated
     31/12/2021
restated
     Variation  

Wages and salaries

     63,080        48,151        14,928  

Social security contributions

     11,980        10,485        1,495  

Post-employment benefits

     1,716        1,726        -10  

Other costs

     82        411        -329  
  

 

 

    

 

 

    

 

 

 

Total

     76,858        60,773        16,085  
  

 

 

    

 

 

    

 

 

 

Reference should be made to note [3.14] Employee benefits for details on the workforce.

Personnel expenses for 2022 include €3,928 thousand for management incentive plans. Reference should be made to section [4.8] Incentive plans for a description of such plans and the related costs.

[3.25] Amortisation, depreciation and impairment losses

Amortisation, depreciation and impairment losses amount to €35,408 thousand in 2022, compared to €32,517 thousand in 2021, and include depreciation of right-of-use assets of €5,335 thousand (2021: €4,595 thousand). Reference should be made to note [3.3] Property, plant and equipment for details on the individual categories.

The caption is broken down as follows:

 

(€‘000)

                    

Description

   2022 restated      2021 restated      Variation  

Amortisation of intangible assets

     8,657        7,393        1,263  

Depreciation of property, plant and equipment

     21,416        20,529        887  

Depreciation of leased assets

     5,335        4,595        740  
  

 

 

    

 

 

    

 

 

 

Total

     35,408        32,517        2,891  
  

 

 

    

 

 

    

 

 

 

Other impairment losses of €16,152 thousand (2021: €209 thousand) refer to impairment losses on intangible assets and property, plant and equipment for which the related costs are not expected to be recovered as of the date of preparation of these consolidated financial statements restated as at 31 December 2022. The caption also includes the impairment loss on the goodwill generated by the acquisition of the subsidiary TechMah. Reference should be made to note [3.2] Goodwill for details.

The impairment losses on trade receivables of €502 thousand (2021: €429 thousand) include the net impairment losses on trade receivables recognised pursuant to IFRS 9.

[3.26] Other operating costs

Other operating costs amount to €1,857 thousand in 2022, compared to €1,509 thousand in 2021, and are broken down as follows:

 

(€‘000)

                    
     2022 restated      2021 restated      Variation  

Taxes and duties

     1,053        904        149  

Other costs

     18        16        2  

Losses on assets

     52        94        -42  

Gifts and donations

     670        490        180  

Sundry costs - previous years

     234        125        109  

Tax expense - previous years

     0        -51        51  

Provision for risks

     -170        -69        -101  
  

 

 

    

 

 

    

 

 

 

Total

     1,857        1,509        348  
  

 

 

    

 

 

    

 

 

 

 

2022    45


[3.27] Internal work capitalised

This caption amounts to €13,532 thousand for 2022 and €16,250 thousand for 2021. It may be broken down as follows:

 

(€‘000)

                    

Description

   31/12/2022
restated
     31/12/2021
restated
     Variation  

Increases in property, plant and equipment for capitalisation of equipment

     10,291        11,856        -1,565  

Increases in intangible assets for capitalisation of sundry costs

     759        1,826        -1,068  

Increases in property, plant and equipment for internal work

     2,483        2,568        -85  
  

 

 

    

 

 

    

 

 

 

Total

     13,532        16,250        -2,717  
  

 

 

    

 

 

    

 

 

 

Increases in property, plant and equipment for the capitalisation of surgical instruments and internal work both refer to the capitalisation of surgical instruments built internally. These surgical instruments are provided to hospitals on a free loan basis to be used to implant the group’s products.

Increases in non-current assets for capitalisation of costs (€759 thousand) refer to the capitalisation of internal and external costs incurred for product development projects.

[3.28] Financial income and expense

Net financial expense amounts to €8,048 thousand in 2022, compared to €12,956 thousand in 2021, and is broken down as follows:

 

(€‘000)

                    
     2022 restated      2021 restated      Variation  

Exchange gains

     -7,416        -6,986        -430  

Other interest income

     -163        -154        -9  

Fair value gain on liabilities

     -6,981        -688        -6,293  
  

 

 

    

 

 

    

 

 

 

Financial income

     -14,561        -7,829        -6,732  
  

 

 

    

 

 

    

 

 

 

Exchange losses

     6,478        5,645        833  

Interest on bonds

     11,320        10,484        835  

Other interest and financial expenses

     4,811        4,069        742  

Fair value losses on liabilities

     0        586        -586  
  

 

 

    

 

 

    

 

 

 

Financial expense

     22,609        20,785        1,824  
  

 

 

    

 

 

    

 

 

 

Total

     8,048        12,956        -4,908  
  

 

 

    

 

 

    

 

 

 

The €6,732 thousand increase in financial income during the year is chiefly due to fair value gains on the liability for the acquisition of TechMah.

The higher interest rates on bonds and the revolving credit facility in the second half of the year following the rise in the Euribor led to an increase in net borrowing costs.

 

2022    46


[3.29] Income taxes

Income taxes amount to €6,526 thousand compared to €3,529 thousand in 2021. The caption is broken down as follows:

 

€‘000

             
     2022 restated      2021 restated  

Pre-tax income (loss)

     -12,748        991  

Income taxes calculated using the the theorical IRES rate (24%)

     3,059        -238  

IRAP

     -252        -809  

Effect of different taxation of foreign companies

     -1,924        -673  

Patent Box effect

     0        0  

Other taxes

     5,642        5,249  
  

 

 

    

 

 

 

Income tax benefit (expense)

     6,526        3,529  
  

 

 

    

 

 

 

Taxes relative to previous years refer to taxes for 2016 defined with the mutually-agreed assessment settlement procedure (tax settlement). Reference should be made to section [3.19] Other current liabilities for more information.

The main temporary differences that led to the recognition of deferred tax assets and liabilities are set out in the following table along with relevant effects:

 

(€’000)         

Description

   31/12/2022 restated      31/12/2021 restated  
   Temporary
differences
     Tax
effect
     Temporary
differences
     Tax
effect
 

Change in deferred tax assets:

           

Provision for risks and charges

     14,682        -3,751        13,147        -3,207  

Allowance for inventory write-down

     6,178        -1,483        5,972        -1,443  

Amortisation of trademarks

     149        -42        128        -36  

Amortisation of goodwill

     670        -69        1,386        -387  

Unpaid directors’ fees

     262        -63        40        -10  

Agents’ termination indemnity

     97        -27        268        -75  

Exchange losses

     11,309        -2,713        10,007        -2,402  

Impairment losses on equity investments

     0        0        565        -136  

Impairment losses on intangible assets

     152        -37        222        -57  

ACE deduction

     8,966        -2,152        6,254        -1,501  

Non-deductible interest as per article 96 of the

     0        0        3,103        -745  

Consolidated income tax act

           

Fiscal losses

     979        -235        0        0  

Difference between carrying amount and tax base

     953        -229        640        -154  

IFRS 16

     99        -72        302        -87  

Incentive plans

     0        0        4,217        -1,012  

Post-employment benefits

     37        -19        76        -18  

Other variations

     532        -128        136        -34  

Deferred tax assets - subsidiaries (Lima AU, Lima ES,

     0        -538        0        -642  

Lima BR, Lima NZ, Lima DK, Lima PL)

           

Deferred tax assets on consolidation adjustments

     0        -20,151        0        -21,516  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total change in deferred tax assets

     45,068        -31,709        46,463        -33,462  
  

 

 

    

 

 

    

 

 

    

 

 

 

Change in deferred tax liabilities

           

Taxed grands

     3,692        886        3,754        901  

Exchange gains

     7,874        1,890        7,976        1,914  

Other variations

     641        154        456        117  

Deferred tax liabilities - subsidiaries (Lima AU, Lima ES,

     0        6,484        0        5,000  

Lima CZ, Lima JP, Lima NZ, Lima PL, Lima UK and

           

Lima USA)

           

Deferred tax assets on consolidation adjustments

     0        9,861        0        9,364  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total change in deferred tax liabilities

     12,207        19,275        12,186        17,296  
  

 

 

    

 

 

    

 

 

    

 

 

 

Net change in deferred tax (assets) liabilities

     32,861        -12,434        34,277        -16,166  
  

 

 

    

 

 

    

 

 

    

 

 

 

The deferred tax assets and liabilities includes the taxes calculated on the temporary differences arising between the book value of assets and liabilities and the corresponding tax values (especially for taxed funds and non-deductible interest). Considering 3 years history, 2020,2021, 2022 the fiscal year 2022 was the first year of fiscal losses of the Group. The tax rate for the fiscal year 2022 is mainly impacted by the full impairment of the Goodwill related to TechMah CGU as described in paragraph [3.2].

 

2022    47


Other information

[4.1] Correction of errors

The accounting policies set out in the relevant section of these notes have been applied to prepare the Consolidated financial statements restated at 31 December 2022 following the correction of error related to the payback mechanism accounted according to IFRS 15, Revenue from Contracts with Customers, retrospectively, as reduction of revenue (variable consideration).

Although the correction did not result in an application of a new accounting standard, it impacted the one adopted in relation to the payback mechanism as described in paragraph [3.20] Revenue and other revenue and income. The error has been corrected by restating each of the affected financial statement line items for the current period and the previous one.

As per the IAS.8, par. 49, the following tables show the amounts of the error correction for previously reported amounts . The error refers to the payback system accounted for as variable consideration under IFRS15 instead of IAS37. The correction of error has been accounted for retrospectively at 1 January 2021.

The information presented covers the impact of the correction, in 2021 and 2022, on the financial position and financial performance.

The effect of the restatement on the 2021 figures is a decrease on the opening balances of Retained earnings (accumulated deficit) for €6,945 thousand related to the correction of error of previous years and an increase of the period loss for €1,713 thousand. The table reported below summarize the effects of the restatement on the financial statements as at 1 January 2021 and 31 December 2021.

 

2022    48


Reconciliations of the statement of financial position and the statement of profit or loss

 

           Impact of correction of errors  
     Note     As previously
stated
01/01/21
    Adjustments     As restated
01/01/2021
 

Other intangible assets

     [3.1]       44,477         44,477  

Goodwill

     [3.2]       396,900         396,900  

Property, plant and equipment

     [3.3]       85,288         85,288  

Equity investments

     [3.4]       402         402  

Deferred tax assets

     [3.5]       29,702       2,193       31,895  

Other non-current assets

     [3.6]       663         663  
    

 

 

   

 

 

   

 

 

 
       557,432       2,193       559,625  
    

 

 

   

 

 

   

 

 

 

Inventories

     [3.7]       84,166         84,166  

Trade receivables

     [3.8]       63,070         63,070  

Current tax assets

     [3.9]       4,361         4,361  

Other current assets

     [3.10]       11,469         11,469  

Cash and cash equivalents

     [3.11]       26,273         26,273  
    

 

 

   

 

 

   

 

 

 

Total current assets

       189,340       —        189,340  
    

 

 

   

 

 

   

 

 

 

TOTAL ASSETS

       746,772       2,193       748,965  
    

 

 

   

 

 

   

 

 

 

Equity

        

Share capital

     [3.12]       9,868         9,868  

Share premium reserve

     [3.12]       14,425         14,425  

Other reserves

     [3.12]       310,762         310,762  

Retained earnings (accumulated deficit)

     [3.12]       565       (6,945     (6,380

Profit (loss) for the year

     [3.12]       (12,482       (12,482
    

 

 

   

 

 

   

 

 

 
       323,139       (6,945     316,194  
    

 

 

   

 

 

   

 

 

 

Total equity

       323,139       (6,945     316,194  
    

 

 

   

 

 

   

 

 

 

Non-current liabilities

        

Non-current financial liabilities

     [3.15]       287,222         287,222  

Employee benefits

     [3.14]       1,421         1,421  

Deferred tax liabilities

     [3.5]       12,986         12,986  

Provisions for risks and charges

     [3.13]       3,894       9,138       13,032  

Other non-current liabilities

     [3.16]       5,476         5,476  
    

 

 

   

 

 

   

 

 

 

Total non-current liabilities

       310,999       9,138       320,137  
    

 

 

   

 

 

   

 

 

 

Current liabilities

        

Current financial liabilities

     [3.15]       59,511         59,511  

Trade payables

     [3.17]       28,941         28,941  

Current tax liabilities

     [3.18]       491         491  

Other current liabilities

     [3.19]       23,692         23,692  
    

 

 

   

 

 

   

 

 

 

Total current liabilities

       112,635       —        112,635  
    

 

 

   

 

 

   

 

 

 

TOTAL EQUITY AND LIABILITIES

       746,772       2,193       748,965  
    

 

 

   

 

 

   

 

 

 

 

2022    49


Reconciliations of the statement of financial position and the statement of profit or loss

 

           Impact of correction of errors  

(€‘000)

                        
     Note     As previously
stated
31/12/21
    Adjustments     As restated
31/12/2021
 

ASSETS

        

Non-current assets

        

Other intangible assets

     [3.1]       53,595         53,595  

Goodwill

     [3.2]       398,305         398,305  

Property, plant and equipment

     [3.3]       81,773         81,773  

Equity investments

     [3.4]       2         2  

Deferred tax assets

     [3.5]       30,728       2,734       33,462  

Other non-current assets

     [3.6]       705         705  
    

 

 

   

 

 

   

 

 

 

Total non-current assets

       565,109       2,734       567,842  
    

 

 

   

 

 

   

 

 

 

Current assets

        

Inventories

     [3.7]       87,421         87,421  

Trade receivables

     [3.8]       66,891         66,891  

Current tax assets

     [3.9]       2,554         2,554  

Other current assets

     [3.10]       11,247         11,247  

Cash and cash equivalents

     [3.11]       21,503         21,503  
    

 

 

   

 

 

   

 

 

 

Total current assets

       189,617       —        189,617  
    

 

 

   

 

 

   

 

 

 

TOTAL ASSETS

       754,726       2,734       757,460  
    

 

 

   

 

 

   

 

 

 

EQUITY AND LIABILITIES

        

Equity

        

Share capital

     [3.12]       9,868         9,868  

Share premium reserve

     [3.12]       14,425         14,425  

Other reserves

     [3.12]       317,570         317,570  

Retained earnings (accumulated deficit)

     [3.12]       (11,917     (6,945     (18,862

Profit (loss) for the year

     [3.12]       (825     (1,713     (2,538
    

 

 

   

 

 

   

 

 

 

Total equity attributable to the owners of the parent

       329,121       (8,658     320,463  
    

 

 

   

 

 

   

 

 

 

Total equity

       329,121       (8,658     320,463  
    

 

 

   

 

 

   

 

 

 

Non-current liabilities

        

Non-current financial liabilities

     [3.15]       283,573         283,573  

Employee benefits

     [3.14]       1,442         1,442  

Deferred tax liabilities

     [3.5]       17,296         17,296  

Provisions for risks and charges

     [3.13]       3,922       11,392       15,314  

Other non-current liabilities

     [3.16]       5,250         5,250  
    

 

 

   

 

 

   

 

 

 

Total non-current liabilities

       311,483       11,392       322,875  
    

 

 

   

 

 

   

 

 

 

Current liabilities

        

Current financial liabilities

     [3.15]       61,536         61,536  

Trade payables

     [3.17]       32,343         32,343  

Current tax liabilities

     [3.18]       202         202  

Other current liabilities

     [3.19]       20,041         20,041  
    

 

 

   

 

 

   

 

 

 

Total current liabilities

       114,122       —        114,122  
    

 

 

   

 

 

   

 

 

 

TOTAL EQUITY AND LIABILITIES

       754,726       2,734       757,460  
    

 

 

   

 

 

   

 

 

 

 

2022    50


           Impact of correction of errors  

(€‘000)

                        
     Note     As previously
stated
31/12/21
    Adjustments     As restated
31/12/2021
 

Revenue

     [3.20]       212,798       (2,254     210,543  

Other revenues and income

     [3.20]       3,973         3,973  
    

 

 

   

 

 

   

 

 

 

Total revenue and income

       216,771       (2,254     214,517  
    

 

 

   

 

 

   

 

 

 

Raw materials, consumables, supplies and goods

     [3.21]       (53,530       (53,530

Services

     [3.22]       (69,910       (69,910

Change in w.i.p., semi-finished products and finished goods

     [3.23]       2,058         2,058  

Personnel expenses

     [3.24]       (60,773       (60,773

Amortisation and Depreciation

     [3.25]       (32,517       (32,517

Impairment losses on trade receivables

     [3.25]       (429       (429

Impairment losses on fixed assets

     [3.25]       (209       (209

Other operating costs

     [3.26]       (1,509       (1,509

Internal work capitalised

     [3.27]       16,250         16,250  
    

 

 

   

 

 

   

 

 

 

Operating costs

       (200,570     —        (200,570
    

 

 

   

 

 

   

 

 

 

Operating profit

       16,201       (2,254     13,947  
    

 

 

   

 

 

   

 

 

 

Financial income

     [3.28]       7,829         7,829  

Financial expense

     [3.28]       (20,785       (20,785
    

 

 

   

 

 

   

 

 

 

Net financial expense

       (12,956     —        (12,956
    

 

 

   

 

 

   

 

 

 

Pre-tax income (loss)

       3,245       (2,254     991  
    

 

 

   

 

 

   

 

 

 

Income tax benefit (expense)

     [3.29]       (4,070     541       (3,529
    

 

 

   

 

 

   

 

 

 

Profit (loss) for the year

       (825     (1,713     (2,539
    

 

 

   

 

 

   

 

 

 

of which attributable to the owners of the parent

       (825     (1,713     (2,539
    

 

 

   

 

 

   

 

 

 

 

           Impact of correction of errors  

(€‘000)

                        
     Note     As previously
stated
31/12/21
    Adjustments     As restated
31/12/2021
 

Profit (loss) for the year

       (825     (1,713     (2,539
    

 

 

   

 

 

   

 

 

 

Other comprehensive income (expense)

        

Items that will never be reclassified to profit or loss (A)

        

Remeasurements of the net defined benefit liability (asset)

     [3.14]       3       —        3  

Related tax

     [3.14]       (1     —        (1
    

 

 

   

 

 

   

 

 

 
       2       —        2  
    

 

 

   

 

 

   

 

 

 

Items that are or may be reclassified to profit or loss (B)

        

Exchange differences on translation of foreign operations

     [3.12]       1,842       —        1,842  
    

 

 

   

 

 

   

 

 

 
       1,842       —        1,842  
    

 

 

   

 

 

   

 

 

 

Other comprehensive income (expense), net of tax (A+B)

       1,844       —        1,844  
    

 

 

   

 

 

   

 

 

 

Comprehensive income (expense) for the year

       1,019       (1,713     (695
    

 

 

   

 

 

   

 

 

 

Comprehensive income (expense) attributable to:

       —       

Owners of the parent

       1,019       (1,713     (695
    

 

 

   

 

 

   

 

 

 

The effect originated by the restatement on the figures as at 31 December 2022 is a decrease of revenues for an amount equal to €2,925 thousand. The table reported below summarize the effects of the restatement on the financial statements as at 31 December 2022.

 

2022    51


Reconciliations of the statement of financial position and the statement of profit or loss

 

           Impact of correction of errors  

(€‘000)

                        
     Note     As previously
stated
31/12/22
    Adjustments     As restated
31/12/2022
 

ASSETS

        

Non-current assets

        

Other intangible assets

     [3.1]       58,234         58,234  

Goodwill

     [3.2]       384,216         384,216  

Property, plant and equipment

     [3.3]       79,837         79,837  

Equity investments

     [3.4]       2         2  

Deferred tax assets

     [3.5]       31,694       15       31,709  

Other non-current assets

     [3.6]       861         861  
    

 

 

   

 

 

   

 

 

 

Total non-current assets

       554,844       15       554,859  
    

 

 

   

 

 

   

 

 

 

Current assets

        

Inventories

     [3.7]       86,728         86,728  

Trade receivables

     [3.8]       70,161         70,161  

Current tax assets

     [3.9]       2,087         2,087  

Other current assets

     [3.10]       14,192         14,192  

Cash and cash equivalents

     [3.11]       25,920         25,920  
    

 

 

   

 

 

   

 

 

 

Total current assets

       199,088       —        199,088  
    

 

 

   

 

 

   

 

 

 

TOTAL ASSETS

       753,932       15       753,947  
    

 

 

   

 

 

   

 

 

 

EQUITY AND LIABILITIES

        

Equity

        

Share capital

     [3.12]       9,868         9,868  

Share premium reserve

     [3.12]       14,425         14,425  

Other reserves

     [3.12]       323,510         323,510  

Retained earnings (accumulated deficit)

     [3.12]       (13,308     (8,658     (21,966

Profit (loss) for the year

     [3.12]       (27,885     8,612       (19,274
    

 

 

   

 

 

   

 

 

 

Total equity attributable to the owners of the parent

       306,610       (47     306,564  
    

 

 

   

 

 

   

 

 

 

Total equity

       306,610       (47     306,564  
    

 

 

   

 

 

   

 

 

 

Non-current liabilities

        

Non-current financial liabilities

     [3.15]       10,165         10,165  

Employee benefits

     [3.14]       1,296         1,296  

Deferred tax liabilities

     [3.5]       19,275         19,275  

Provisions for risks and charges

     [3.13]       8,296       8,860       17,156  

Other non-current liabilities

     [3.16]       649         649  
    

 

 

   

 

 

   

 

 

 

Total non-current liabilities

       39,680       8,860       48,541  
    

 

 

   

 

 

   

 

 

 

Current liabilities

        

Current financial liabilities

     [3.15]       336,659         336,659  

Trade payables

     [3.17]       36,564         36,564  

Current tax liabilities

     [3.18]       877         877  

Other current liabilities

     [3.19]       33,542       (8,800     24,742  
    

 

 

   

 

 

   

 

 

 

Total current liabilities

       407,641       (8,800     398,842  
    

 

 

   

 

 

   

 

 

 

TOTAL EQUITY AND LIABILITIES

       753,932       14       753,946  
    

 

 

   

 

 

   

 

 

 

 

2022    52


           Impact of correction of errors  
(€‘000)                         
     Note     As previously
stated
31/12/22
    Adjustments     As restated
31/12/2022
 

Revenue

     [3.20]       248,594       (2,925     245,669  

Other revenues and income

     [3.20]       5,798         5,798  
    

 

 

   

 

 

   

 

 

 

Total revenue and income

       254,392       (2,925     251,467  
    

 

 

   

 

 

   

 

 

 

Raw materials, consumables, supplies and goods

     [3.21]       (56,391       (56,391

Services

     [3.22]       (81,645       (81,645

Change in w.i.p., semi-finished products and finished goods

     [3.23]       (887       (887

Personnel expenses

     [3.24]       (76,858       (76,858

Amortisation and Depreciation

     [3.25]       (35,408       (35,408

Impairment losses on trade receivables

     [3.25]       (502       (502

Impairment losses on fixed assets

     [3.25]       (16,152       (16,152

Other operating costs

     [3.26]       (16,113     14,256       (1,857

Internal work capitalised

     [3.27]       13,532         13,532  
    

 

 

   

 

 

   

 

 

 

Operating costs

       (270,424     14,256       (256,167
    

 

 

   

 

 

   

 

 

 

Operating profit

       (16,032     11,331       (4,700
    

 

 

   

 

 

   

 

 

 

Financial income

     [3.28]       14,561         14,561  

Financial expense

     [3.28]       (22,609       (22,609
    

 

 

   

 

 

   

 

 

 

Net financial expense

       (8,048     —        (8,048
    

 

 

   

 

 

   

 

 

 

Pre-tax income (loss)

       (24,080     11,331       (12,748
    

 

 

   

 

 

   

 

 

 

Income tax benefit (expense)

     [3.29]       (3,806     (2,720     (6,526
    

 

 

   

 

 

   

 

 

 

Profit (loss) for the year

       (27,886     8,612       (19,274
    

 

 

   

 

 

   

 

 

 

of which attributable to the owners of the parent

       (27,886     8,612       (19,274
    

 

 

   

 

 

   

 

 

 

 

2022    53


Reconciliations of the statement of cash flows

 

          Impact of correction of errors  
(€‘000)                        
    

Note

   As previously
stated
31/12/2022
    Adjustments     As restated
31/12/2022
 

Operating activities

         

Profit (loss) for the period

   [3.12]      (27,885     8,612       (19,273

Income tax (benefit)/expense

   [3.29]      3,806       2,720       6,526  

Net financial (income)/expense

   [3.28]      10,809       —        10,809  

Amortisation, depreciation and impairment losses

   [3.25]      50,649       —        50,649  

Accruals/(Release) to provisions

   [3.26]      4,374       (2,532     1,842  

Net (gains)/loss on disposals

   [3.20] [3.26]      (629     —        (629

FX on contingent consideration

   [3.28]      1,031       —        1,031  

Cash flows from operating activities before changes in working capital

        42,155       8,800       50,955  

Change in inventories

   [3.7]      693       —        693  

Change in trade receivables

   [3.8]      (3,270     —        (3,270

Change in trade payables

   [3.17]      4,220       —        4,220  

Change in other assets/liabilities

   [3.10] [3.16] [3.19]      9,116       (8,800     316  

Change in non-current assets

   [3.6]      (156     —        (156

Income taxes paid

        (2,019     —        (2,019
     

 

 

   

 

 

   

 

 

 

Cash flows from operating activities A)

        50,739       —        50,739  
     

 

 

   

 

 

   

 

 

 

Investing activities

         

Acquisitions of property, plant and equipment

   [3.3]      (25,234     —        (25,234

Disposal of property, plant and equipment

   [3.3]      1,418       —        1,418  

Acquisitions of intangible assets

   [3.1]      (12,229     —        (12,229

Disposal of intangible assets

   [3.1]      955       —        955  
     

 

 

   

 

 

   

 

 

 

Cash flows used in investing activities B)

        (35,090     —        (35,090
     

 

 

   

 

 

   

 

 

 

Financing activities

         

Third party funds

         

Net change in current financial liabilities

   [3.15]      8,916         8,916  

Gross change in non-current financial liabilities

   [3.15]      (0     —        (0

Decrease in lease liabilities

   [3.15]      (4,401     —        (4,401

Net interest income

   [3.28]      163       —        163  

Net interest paid

   [3.28]      (15,911     —        (15,911
     

 

 

   

 

 

   

 

 

 

Cash flows from (used in) financing activities C)

        (11,233     —        (11,233
     

 

 

   

 

 

   

 

 

 

Increase (decrease) in liquid funds (A ± B ± C)

        4,417       —        4,417  
     

 

 

   

 

 

   

 

 

 

Opening cash and cash equivalent

        21,503       —        21,503  

Closing cash and cash equivalent

        25,920       —        25,920  
     

 

 

   

 

 

   

 

 

 

Increase (decrease) in cash and cash equivalents

        4,417       —        4,417  
     

 

 

   

 

 

   

 

 

 

 

2022    54


            Impact of correction of errors  

(€000)

             
     Note      As previously 
stated
31/12/22
     Adjustments      As
restated

31/12/2022
 

Profit (loss) for the year

        (27,886      8,612        (19,274
     

 

 

    

 

 

    

 

 

 

Other comprehensive income (expense)

           

Items that will never be reclassified to profit or loss (A)

           

Remeasurements of the net defined benefit liability (asset)

     [3.14      71        —         71  

Related tax

     [3.14      (17      —         (17
     

 

 

    

 

 

    

 

 

 
        54        —         54  
     

 

 

    

 

 

    

 

 

 

Items that are or may be reclassified to profit or loss (B)

           

Exchange differences on translation of foreign operations

     [3.12      871        —         871  
     

 

 

    

 

 

    

 

 

 
        871        —         871  
     

 

 

    

 

 

    

 

 

 

Other comprehensive income (epense), net of tax (A+B)

        925        —         925  
     

 

 

    

 

 

    

 

 

 

Comprehensive income (expense) for the year

        (26,961      8,612        (18,349
     

 

 

    

 

 

    

 

 

 

Comprehensive income (expense) attributable to:

           

Owners of the parent

        (26,961      8,612        (18,349
     

 

 

    

 

 

    

 

 

 

In the statutory consolidated financial statement as at 31 December 2022 the payback was incorrectly accounted for as operating cost in the profit and loss as of 31 December 2022.

[4.2] Operating segments

The disclosure about operating segments was prepared in accordance with IFRS 8 Operating segments which provides for the presentation of information in line with the measures adopted by the chief operating decision maker to make operating decisions.

At operating level, the group has a matrix organisational structure split by product line, distribution channel and geographical segment providing a coherent strategic vision of the business. This structure can be seen in the way management monitors and directs the group’s activities. Specifically, senior management reviews the group’s results as a whole as it does not have identifiable operating segments. Therefore, the group’s operations are presented as a single segment for IFRS 8 reporting purposes.

 

2022    55


A breakdown of revenue earned in 2022 and 2021 by product line, distribution channel and geographical segment is shown below:

 

(€‘000)              

Revenue by PRODUCT LINE

   31/12/2022
restated
     31/12/2021
restated
 

Hip

     88,142        78,307  

Extremities

     98,537        83,966  

Knee

     49,234        39,700  

Fixation & Other

     9,756        8,570  
  

 

 

    

 

 

 

Total sales revenue

     245,669        210,543  
  

 

 

    

 

 

 

 

(€‘000)              

Revenue by DISTRIBUTION CHANNEL

   31/12/2022
restated
     31/12/2021
restated
 

Direct customers

     195,629        178,786  

Indirect channel

     50,040        31,757  
  

 

 

    

 

 

 

Total sales revenue

     245,669        210,543  
  

 

 

    

 

 

 

 

(€‘000)              

Revenue by GEOGRAPHICAL SEGMENT

   31/12/2022
restated
     31/12/2021
restated
 

Italy

     45,227        39,960  

Resto of Europe

     97,948        79,001  

APAC

     37,652        38,357  

United States

     43,111        35,283  

Rest of world

     21,731        17,942  
  

 

 

    

 

 

 

Total sales revenue

     245,669        210,543  
  

 

 

    

 

 

 

As required by IFRS 8, it is noted that the group does not have individual customers that generate revenue of 10% or more of its total revenue in 2022 and 2021.

The following table shows non-current assets other than financial assets and deferred tax assets by geographical segment at 31 December 2022 and 2021, allocated in line with the country where they are held. Unallocated non-current assets entirely consist of goodwill.

 

(€‘000)              
     31/12/2022
restated
     31/12/2021
restated
 

Italy

     444,336        442,738  

USA

     50,006        61,606  

Rest of Europe

     15,106        21,593  

APAC

     6,827        7,940  

Rest of the world

     6,873        502  
  

 

 

    

 

 

 

Total non-current assets

     523,148        534,379  
  

 

 

    

 

 

 

 

[4.3]

ERRORstruments - Fair value and risk management

 

  A.

Accounting classification and fair value

The next table shows the carrying amount and fair value of each financial asset and liability, including their fair value hierarchy level. Information about the fair value of financial assets and liabilities not measured at fair value is not provided as their carrying amount reasonably approximates their fair value.

Trade receivables and other assets and trade payables and other liabilities classified as held for sale are not included in the table. Their carrying amount reasonably approximates their fair value.

 

2022    56


(€‘000)

   Carrying Amount      Fair value  

31/12/2021 unaudited

  

Notes

   Fair value –
Hedging

instruments
     Mandatorily at
FVTPL - other
     FVOCI - debt
instruments
     FVOCI -
equity
instruments
     Financial Assets
measured at

amortised cost
     Other
liabilities
     Total      Level 1      Level 2      Level 3      Total  

Financial assets measured at fair value

                                   
        —                        —         —         —         —         —   

Financial assets not measured at fair value

                                   

Trade receivables and other assets

   [3.8] [3.10]                  78,138           78,138           78,138           78,138  

Cash and cash equivalents

   [3.11]                  21,503           21,503           21,503           21,503  
        —         —         —         —         99,642        —         99,642        —         99,641        —         99,641  

Financial liabilities measured at fair value

                                   

Liabilities for acquisitions - MT Ortho

   [3.15]                     185        185              185        185  

Liabilities for acquisitions - Techmah

   [3.15]                     13,434        13,434              13,434        13,434  
        —         —         —         —         —         13,619        13,619        —         —         13,619        13,619  

Financial liabilities not measured at fair value

                                   

Bank credit facilities

   [3.15]                     1,199        1,199           1,199           1,199  

Secured bank loans

   [3.15]                     47,000        47,000           47,000           47,000  

Undecured bank loans

   [3.15]                     1,024        1,024           1,024           1,024  

Secured bonds - listed bonds

   [3.15]                     272,556        272,556           272,556           272,556  

Lease liabilities - IFRS16

   [3.15]                     7,941        7,941           7,941           7,941  

Trade payables and other liabilities

   [3.18] [3.20]                     52,385        52,385           52,385           52,385  
          —       —       —       —       —       382,105      382,105             382,105             382,105  
     

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

TOTALE

        —         —         —         —         99,642        395,723        495,365        —         481,746        13,619        495,365  
     

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

(€‘000)

   Carrying Amount      Fair value  

31/12/2022 restated

  

Notes

   Fair value –
Hedging

instruments
     Mandatorily at
FVTPL - other
     FVOCI - debt
instruments
     FVOCI -
equity
instruments
     Financial Assets
measured at

amortised cost
     Other
liabilities
     Total      Level 1      Level 2      Level 3      Total  

Financial assets measured at fair value

                                   
          —                                          —       —       —       —       —   

Financial assets not measured at fair value

                                   

Trade receivables and other assets

   [3.8] [3.10]                  84,353           84,353           84,353           84,353  

Cash and cash equivalents

   [3.11]                  25,920           25,920           25,920           25,920  
        —         —         —         —         110,273        —         110,273        —         110,273        —         110,273  

Financial liabilities measured at fair value

                                   

Liabilities for acquisitions - MT Ortho

   [3.15]                     185        185              185        185  

Liabilities for acquisitions - Techmah

   [3.15]                     7,373        7,373              7,373        7,373  
        —         —         —         —         —         7,558        7,558        —         —         7,558        7,558  

Financial liabilities not measured at fair value

                                   

Bank credit facilities

   [3.15]                     383        383           383           383  

Secured bank loans

   [3.15]                     54,000        54,000           54,000           54,000  

Undecured bank loans

   [3.15]                     751        751           751           751  

Secured bonds - listed bonds

   [3.15]                     274,039        274,039           264,982           264,982  

Lease liabilities - IFRS16

   [3.15]                     7,817        7,817           7,817           7,817  

Trade payables and other liabilities

   [3.18] [3.20]                     70,105        70,105           70,105           70,105  
          —       —       —       —       —       407,095      407,095             398,038             398,038  
     

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

TOTALE

        —         —         —         —         110,273        414,653        524,926        —         508,311        7,558        515,869  
     

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

  B.

Fair value measurement

i. Measurement techniques and significant unobservable inputs

The following tables present the measurement techniques and significant unobservable inputs used to determine the fair value of level 2 and 3 financial instruments in the statement of financial position.

 

2022    57


Financial instruments measured at fair value

 

2021               
Type    Measurement technique   

Unobservable

significant inputs

   Relationship between
unobservable sig. inputs
and fair value measurement
Liabilities for TechMah acquisition   

Discounted cash flows:

 

This measurement technique considers the present value of the estimated payments, discounted using a discount rate that reflects the risk.

   – At 31 December 2021, these milestones have been estimated by independent experts as USD15.2 million.   

The estimated fair value would decrease if:

 

- achievement of each milestone does not happen in accordance with the agreed timeline

   These estimated cash flows are estimated by independent experts that define the net present value of the contract’s future cash outflows; these outflows are partly tied to the group’s business plan assuming the milestones will be achieved as agreed with TechMah’s former owners.   

– At 31 December 2021, independent experts have expected future cash outflows of USD9.3 million if the milestones are reached.

 

– Discount rate that reflects the risk (31 December 2021: 3.39%).

   - the discount rate reflecting the risk is higher
2022               
Type    Measurement technique   

Unobservable

significant inputs

  

Relationship between

unobservable sig. inputs

and fair value measurement

Liabilities for TechMah acquisition   

Discounted cash flows:

 

This measurement technique considers the present value of the estimated payments, discounted using a discount rate that reflects the risk.

   – At 31 December 2022, these milestones have been estimated by independent experts as USD7.4 million.   

The estimated fair value would decrease if:

 

- achievement of each milestone does not happen in accordance with the agreed timeline

   These estimated cash flows are estimated by independent experts that define the net present value of the contract’s future cash outflows; these outflows are partly tied to the group’s business plan assuming the milestones will be achieved as agreed with TechMah’s former owners.   

– At 31 December 2022,

independent experts have expected future cash outflows of USD5.6 million if the milestones are reached.

 

– Discount rate that reflects the risk (31 December 2022: 7.32%).

   - the discount rate reflecting the risk is higher

Financial instruments not measured at fair value

 

Type    Measurement technique
Secured bonds Lease liabilities Secured bank loans Unsecured bank loans   

Discounted cash flows:

 

This measurement technique considers the present value of estimated payments, discounted using a discount rate that reflects the risk.

 

2022    58


Reconciliation of level 3

 

(€‘000)

   Liabilities  

Balance at 31 December 2020

     21,265  

Gain (losses)

  

- Net change in fair value (unrealised)

     (680

- Foreing exchange (gain) losses

     1,264  

Payments

     (8,415

Balance at 31 December 2021 restated

     13,434  

Gain (losses)

  

- Net change in fair value (unrealised)

     (6,981

- Foreing exchange (gain) losses

     921  

Payments

  

Balance at 31 December 2022 restated

     7,374  

Sensitivity analysis

The reasonably possible changes at 31 December 2022 to one of the significant unobservable inputs would have the following effects on the fair value of the consideration:

 

€‘000                               
     Decrease     31 December 2022     Increase  

Equity value

     -10     -5     0     5     10

Techma liability

     7,362       7,369       7,373       7,383       7,389  

 

  C.

Financial risk management

The group is exposed to the following risks deriving from its use of financial instruments:

 

 

credit risk;

 

 

liquidity risk;

 

 

market risk.

Risk management system

Overall responsibility for the design and oversight of the group’s risk management system lies with the parent’s board of directors, which is in charge of developing and monitoring the group’s risk management policies.

The group’s risk management policies are designed to identify and analyse any risks it is exposed to, establish appropriate limits and controls and monitor the risks and compliance with such limits. The committee regularly revisits the policies and related systems to align them with market developments and the group’s business. The group aims to create a disciplined and constructive control environment through training programmes, standards and management procedures so that its employees are familiar with their roles and responsibilities.

The board of directors ensures compliance with the risk polices and management procedures and checks that the risk management system is appropriate to deal with risks that could affect the group.

The group’s financial instruments comprise cash and cash equivalents, loans, trade receivables and payables, current and non-current assets and liabilities as well as derivatives.

In its normal business operations, the group is exposed to:

 

   

market risk, mainly currency and interest rate risks;

 

   

commercial or counterparty credit risks, related to the risk of default on commercial or financial obligations by various counterparties as part of normal business operations or lending, investment and hedging transactions;

 

   

liquidity risk, related to the availability of financial resources and access to the credit market and to the need to meet the group’s financial needs in the short term.

 

2022    59


Financial risk management is carried out centrally and essentially ensures that there are enough financial resources to meet business development needs and that resources are suitably invested in profitable activities.

Market risk

Market risk can be broken down into the following components:

 

   

interest rate risk,

 

   

currency risk.

Interest rate risk

The group’s exposure to interest rate risk is chiefly related to cash and cash equivalents, bonds and bank loans and borrowings, especially the revolving credit facility that is managed centrally. At 31 December 2022, the group does not have any interest rate hedges. A 100bps increase in the interest rate applied would have led to an increase of roughly €3.2 million in financial expense.

Currency risk

As the group sells its products in various countries, it is exposed to currency risk. This risk mainly derives from sales in currencies other than the Euro, like the US dollar, British pound, Japanese yen and Australian dollar.

The group regularly assesses its exposure to market financial risks. It does not manage such risks by using derivatives.

 

2022    60


Its exposure in relation to foreign currency assets and liabilities is detailed in the following table (countervalue of the respective currencies in Euro):

 

€‘000                            
     Currency      Amount in
currency
     Exchange rate      Counter value in
Euro
 

Trade receivables

           
     AUD        2,493        2        1,588  
     BRL        16,391        6        2,907  
     CHF        479        1        487  
     CZK        32,315        24        1,340  
     DKK        1,219        7        164  
     GBP        2,570        1        2,898  
     HRK        7,526        8        999  
     JPY        527,636        141        3,751  
     KRW        3,980,038        1,344        2,961  
     NZD        971        2        578  
     PLN        14,923        5        3,188  
     SEK        2,914        11        262  
     TRY        3,483        20        174  
     USD        10,596        1        9,935  
     CAD        100        1        69  
     CNY        308        7        42  

Other assets

           
     USD        1,417        1        1,328  
     AUD        234        2        149  
     BRL        5,584        6        990  
     CHF        52        1        53  
     CNY        463        7        63  
     CZK        2,090        24        87  
     DKK        0        7        0  
     GBP        110        1        124  
     HRK        96        8        13  
     JPY        32,436        141        231  
     KRW        389,216        1,344        290  
     NZD        30        2        18  
     PLN        427        5        91  
     SEK        247        11        22  
     TRY        4,172        20        209  
     ZAR        1        18        0  
     CAD        133        1        92  

Cash and cash equivalents

           
     AUD        1,185        2        755  
     BRL        3,845        6        682  
     CHF        187        1        190  
     CZK        21,266        24        882  
     DKK        645        7        87  
     GBP        908        1        1,024  
     HRK        5,773        8        766  
     JPY        37,994        141        270  
     KRW        823,810        1,344        613  
     NZD        594        2        353  
     PLN        3,018        5        645  
     SEK        3,024        11        272  
     TRY        2,280        20        114  
     USD        5,360        1        5,025  
     ZAR        1,447        18        80  
     CAD        328        1        227  
     CNY        1,227        7        167  

 

2022    61


€‘000                            
     Currency      Amount in
currency
     Exchange rate      Counter value in
Euro
 

Trade payables

           
     AUD        206        2        131  
     CAD        85        1        59  
     CHF        457        1        465  
     CZK        911        24        38  
     DKK        1,428        7        192  
     GBP        606        1        683  
     JPY        77,918        141        554  
     KRW        62,011        1,344        46  
     NZD        252        2        150  
     PLN        2,520        5        538  
     SEK        2,289        11        206  
     TRY        1,133        20        57  
     USD        3,330        1        3,122  
     ZAR        77        18        4  
     HRK        68        8        9  
     BRL        28        6        5  
     CNY        62        7        8  

Financial liabilities

           
     AUD        498        2        318  
     CAD        1        1        0  
     CHF        359        1        364  
     CZK        6,357        24        264  
     GBP        212        1        240  
     JPY        56,134        141        399  
     KRW        159,876        1,344        119  
     NZD        163        2        97  
     TRY        0        20        0  
     USD        10,671        1        10,004  
     HRK        577        8        77  
     BRL        291        6        52  
     CNY        283        7        38  

Other liabilities

           
     AUD        1,049        2        668  
     CAD        3        1        2  
     CHF        804        1        817  
     CZK        4,928        24        204  
     DKK        238        7        32  
     GBP        882        1        995  
     JPY        154,243        141        1,097  
     KRW        110,305        1,344        82  
     NZD        211        2        125  
     SEK        1,111        11        100  
     TRY        4        20        0  
     USD        1,490        1        1,397  
     ZAR        66        18        4  
     HRK        261        8        35  
     BRL        617        6        110  

 

2022    62


Sensitivity analysis of currency risk

The financial assets and liabilities in currencies other than the functional currency of each group company at 31 December 2022 and 2021 were identified to perform the sensitivity analysis of currency risk. The group also considered foreign currency intragroup assets and liabilities to assess the potential effects on the profit or loss for the year.

Two scenarios were considered with a 5% appreciation or depreciation in the nominal exchange rate between the currency in which the caption is expressed and the Euro.

The next table shows the results of the sensitivity analysis:

 

€‘000

                           
     5% appreciation      5% depreciation  
     31 December      31 December  

Currency

   2022      2021      2022      2021  

USD

     1,961        2,232        (1,868      (2,126

JPY

     943        1,092        (898      (1,040

PLN

     613        537        (583      (512

KRW

     494        576        (470      (549

GBP

     447        415        (426      (395

BRL

     501        391        (477      (373

CHF

     71        124        (68      (118

AUD

     18        176        (18      (167

TRY

     74        151        (71      (144

SEK

     62        115        (59      (109

CZK

     92        100        (88      (95

DKK

     33        76        (31      (73

HRK

     82        58        (78      (55

Other

     115        74        (110      (70
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

     5,507        6,117        (5,245      (5,826
  

 

 

    

 

 

    

 

 

    

 

 

 

Credit risk

Credit risk is the risk that a customer or counterparty to a financial instrument may default on a contractual obligation generating a loss for the group. It mainly arises on trade receivables and debt instruments.

The group’s maximum exposure to this type of risk is the assets’ carrying amount.

Some of the markets on which the group operates have a higher level of risk, such as southern Italy, where the health system is deeply in debt, southern European countries, like Spain and Portugal, and eastern European countries, such as Croatia, the Czech Republic and Slovakia, where collection times are very long.

Most of the group’s receivables are due from public institutions, thus solely linked to the country risk. Moreover, payments from public administrations have improved notably in some cases in recent years thanks to measures taken to cut public entity debt with private companies.

Credit risk is also mitigated by the fact that the group is increasing its sales in countries with shorter average collection times. Therefore, the weight of markets with higher credit risk will be reduced.

At 31 December 2021 and 2022, the group does not have exposures with individual customers for more than 10% of its total trade receivables. Its top ten customers account for around 6% of total trade receivables at 31 December 2021 and 2022.

 

2022    63


The amount of financial assets for which recovery is doubtful is immaterial in terms of the total amount of trade receivables and is, in any case, covered by adequate accruals to the relevant allowances. The following table shows the group’s exposure to credit risk (amounts are inclusive of the loss allowance):

 

(€‘000)

                                         
     Not yet due      Overdue      Total  
            <30 days      30 - 90 days      90 - 180 days      Over 180
days
        

Gross trade receivables at 31 December 2021 restated

     41,111        6,422        5,362        4,622        11,454        68,971  

Loss allowance

     0        0        0        24        2,059        2,082  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Net trade receivables at 31 December 2021 restated

     41,114        6,422        5,362        4,598        9,395        66,891  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Gross trade receivables at 31 December 2022 restated

     47,203        7,324        6,108        4,519        7,394        72,548  

Loss allowance

     0        0        1        1        2,385        2,387  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Net trade receivables at 31 December 2022 restated

     47,203        7,324        6,107        4,518        5,009        70,161  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

The group monitors credit risk by grouping trade receivables by the credit worthiness of the customers, considering whether they belong to the private or public sector, their geographical location, relationship with the group and any previous financial difficulties.

Receivables are broken down by geographical segment as follows:

 

     Total Italy      Total EU      Rest of world      Total  

Trade receivables

     23,021        20,681        26,438        70,140  

From subsidiaries

     0        0        0        0  

From associates

     0        0        0        0  

From parents

     0        21        0        21  

From subsidiaries of parents

     0        0        0        0  
  

 

 

    

 

 

    

 

 

    

 

 

 

TOTAL

     23,021        20,702        26,438        70,161  
  

 

 

    

 

 

    

 

 

    

 

 

 

Liquidity risk

Liquidity risk derives from the ability to obtain financial resources at a sustainable cost to carry out the group’s normal business operations.

The group uses the usual tools to manage current trade receivables, as well as partially using the credit facilities available. Moreover:

 

   

the group has debt instruments and credit lines to deal with liquidity requirements;

 

   

there are no significant concentrations of liquidity risk with regard to financial assets.

The table below summaries the ageing of financial liabilities at 31 December 2022 on the basis of non-discounted contractual payments. The refinancing completed in the first quarter of 2023 guarantees enough liquid funds to the group to make the liquidity risk in the medium term immaterial.

 

     Within one year      After one year      After five years      Total  

Credit cards

     383        0        0        383  

Advances on exports

     0        0        0        0  

Current bank loans and borrowings

     54,298        0        0        54,298  

Non-current bank loans and borrowings

     386        363        2        751  

Bonds

     276,018        0        0        276,018  

Loans and borrowings with other financial backers

     2,310        5,248        0        7,558  

Lease liabilites as per IFRS 16

     3,265        3,997        555        7,817  
  

 

 

    

 

 

    

 

 

    

 

 

 

TOTAL

     336,659        9,607        557        346,824  
  

 

 

    

 

 

    

 

 

    

 

 

 

[4.4] Significant non-recurring transactions

None.

 

2022    64


[4.5] Guarantees

Reference should be made to section [3.15] of the notes to the Consolidated financial statements restated as at 31 December 2022.

[4.6] Related party transactions

The group carries out transactions with the ultimate parent recognised in line with the provisions of IAS 24. They are all financial in nature and are performed with full transparency and on an arm’s length basis. They do not include typical and/or unusual transactions.

Details of related party transactions carried out in 2022 and 2021 are as follows:

 

(€‘000)

                                                

2021 restated

 
     Payables      Receivables      Other non-
current
liabilities
     Other current
liabilities
     Sundry
recharges
     Services      Personnel
expenses
 

EMIL HOLDING II S.à.r.l.

     350        0           0        -1        350        0  

Senior Management

     0        0        4,812        82        0        741        -806  

Short-term

              82           275     

Post-empoyment

                    

Other long - term

                    

Share based benefits

           4,812              466        -806  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     350        0        4,812        82        -1        1,091        -806  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

(€‘000)

                                                

2022 restated

 
     Payables      Receivables      Other non-
current
liabilities
     Other current
liabilities
     Sundry
recharges
     Services      Personnel
expenses
 

EMIL HOLDING II S.à.r.l.

     350        21        —         —         -24        350        —   

Senior Management

     —         —         72        302        —         2,703        3,928  

Short-term

              302           586     

Post-empoyment

                    1,176     

Other long - term

                    

Share based benefits

           72              941        3,928  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     350        21        72        302        -24        3,054        3,928  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

No other significant related party transactions took place during the year.

The group operates in a market dominated by entities directly or indirectly controlled by the Italian government through state bodies, agencies, related parties and other organisations (entities related to government bodies). The parent does not carry out transactions with other entities related to government bodies, such as, for example, the sale and purchase of goods and materials, the supply or receipt of services, leasing of assets or use of public services.

Transactions with Emil Holding II S.à.r.l.

Financial transactions with the ultimate parent are part of the parent’s normal business operations and take place at conditions similar to those applied to transactions with unrelated parties.

 

2022    65


[4.7] Fees of directors, statutory auditors and key management personnel

The fees paid to directors and statutory auditors were as follows:

 

     2022      2021      Variation  

Statutory auditors’ fees

     57        57        0  

Directors’ fees

     2,704        741        1,963  
  

 

 

    

 

 

    

 

 

 

TOTAL

     2,760        798        1,962  
  

 

 

    

 

 

    

 

 

 

The fees of the independent auditors and entities belonging to its network for the statutory audit of the parent’s separate financial statements and the group’s consolidated financial statements restated as at 31 December 2022 and related activities amount to €237 thousand.

[4.8] Incentive plans

In accordance with IFRS 2, the parent identified cash-settled share-based payment and equity-settled share-based payment incentive plans for some managers.

Assumptions about the fair value of the share-based payment plans are based on the Monte Carlo method (by simulating the group’s gross operating profit and equity value).

In previous years, the parent had defined two types of plan:

 

   

Virtual share plan (“VSP”)

On 23 November 2016, the parent’s shareholders approved the 2016-2030 virtual share plan for one of its managers. This includes the free award of options to subscribe the parent’s ordinary shares. The manager has the right to receive a number of options each year calculated using a pre-set formula.

The plan vests on 31 December 2030 although this date may be brought forward in the case of i) an IPO, ii) a change of control, or iii) leaver events that lead to the beneficiary leaving the parent.

The manager’s right to exercise the options vests in line with their continued employment relationship with the events i), ii) and iii) being early exercise events.

This plan qualifies as a cash-settled plan under IFRS 2. Its fair value was calculated using market models and the market data at the reporting dates (such as interest rate curves, historical price curves of listed comparable companies’ shares, price volatility of listed comparable companies’ shares) as well as non-market conditions (the probability that the above events will take place). The parent updates the calculation each year. After the sole beneficiary of the VSP stepped down in the first half of 2022, the amount due under the VSP was defined and paid during the year.

 

   

MPP plan

In September 2016, the parent introduced an incentive plan for some group employees who signed agreements with Emil Holding I (Emil Holding II’s controlling shareholder) providing for i) the award of shares of Emil Holding II (the company that manages and coordinates the parent) to the plan beneficiaries, ii) the granting of call options by the beneficiaries to Emil Holding I whereby Emil Holding I can acquire the shares held by the beneficiaries if certain events occur, iii) the granting of put options by Emil Holding I to the beneficiaries whereby the latter can sell their shares in Emil Holding II at the same conditions set for the call option, generating an amount equal to the difference between the amount paid by the beneficiaries (on the subscription date or deferred) and the carrying amount of the shares at the option exercise date. The options can be exercised if one of the events occurs.

This plan qualifies as a cash-settled plan under IFRS 2. Its fair value was calculated using market models and the market data at the reporting dates (such as interest rate curve) as well as non-market conditions (the probability that the above leaver events will take place). The plan liability represents the plan’s future value less the cost incurred by each beneficiary as its initial investment to enter the plan. The parent updates the calculation each year.

These plans led to recognition of a non-current liability of €0 million at 31 December 2022 and costs of services and personnel expenses for the year of €346 thousand (€5.1 million and €340 thousand for 2021, respectively).

 

2022    66


   

The Bonus Payments

Starting from June 2022 the Controlling Entity and the Entity agreed with certain employees some compensation plans which provide that upon occurrence of certain events (the “Bonus Payment Trigger Events”) a payment of a certain amount based on the enterprise value of the Entity at the trigger event date (the “Trigger Event Enterprise Value”).

The Bonus Payment Trigger Events occur at the first of the following events:

 

   

the listing of Emil NewCo S.a.r.l. or any entity of the Lima Group of companies which holds, directly and indirectly, all or substantially all of the assets of the Lima Group, on a regulated stock exchange;

 

   

in case no listing pursuant to paragraph a) has taken place, (i) any sale or transfer by Emil Holding I to a third party purchaser (not related to any EQT Funds) of more than 50% of the ordinary shares held by Emil Holding I in Emil NewCo S.a.r.l. or (ii) any sale to a third party purchaser (not related to any EQT Funds) of more than 50% of the shares in any other entity which holds, directly or indirectly, all or substantially all of the business or assets of the Lima Group; or

 

   

an asset sale of all or substantially all of the assets of the Lima Group which results in the EQT Funds no longer holding any interest (except for unsubstantial assets) in the Lima Group.

Considering that the amount to be paid to the employees is based on the Trigger Event Enterprise Value of the Entity and is therefore based on the value of the Entity’s equity instrument, the Bonus Payment falls within the scope of the “IFRS 2 – Share Based Payments”.

In particular, the management accounted for the Bonus Payment as follows:

 

  (i)

the agreements in which the Entity has the obligation to settle the payment as cash-settled share-based payments (the “Cash-settled Bonus Payments”);

 

  (ii)

the agreements in which the obligation is settled by Emil Holding I as equity-settled share-based payments (the “Equity-settled Bonus Payments”).

In accordance with IFRS 2, the Equity-settled Bonus Payments are measured at the fair value of grant date. Instead, the Cash-settled Bonus Payments are measured at the fair value of grant date and then re-measured at each reporting date until settlement.

The fair value of the Bonus Payments is recognized as an expense during the vesting period.

In order to evaluate the fair value of the Bonus Payments, the management used a Monte Carlo valuation model.

 

   

The Grant Dates considered for the valuation are: June 6, 2022, June 18, 2022, June 28, 2022, and August 9, 2022, which are the grant dates of the major part of the agreements.

 

   

The management of the company has assumed that the exercise of the plan will occur following an Exit Event on June 30, 2024 with a probability of 100%.

 

   

The riskfree interest rate is retrieved from public Information Provider and range from a minimun of 1.3% and maximum of 1.8% over the grant dates.

 

   

The volatility was estimated based on historical series of Equity Value from comparable companies. An adjustment was then applied in order to obtain the volatility relative to Enterprise Value, considering the framework derived from the Merton model.

 

   

Expected dividends rate is 0% for all the Bonus Payments.

 

   

Employee exit rate is 0% for all the Bonus Payments.

The fair value of the Cash-settled Bonus Payments at grant date amounted to € 464.3 thousand.

The fair value of the Equity-settled Bonus Payments at grant date amounted to € 17,752.0 thousand.

As of 31 December 2022, this plan involves 11 employees and led to a recognition of personnel expenses of €4,523 thousand in 2022.

 

2022    67


[4.9] Information pursuant to article 1.125 of Law no. 124/2017

Pursuant to article 1 of Law no. 124 of 4 August 2017, in compliance with the transparency obligation, it is noted that the group received the following grants in 2022.

 

Granting body

   Grant received     

Reason

EUROPEAN COMMISSION      33      H2020 MSCA ITN 2017 mCBEEs - 764977: Advanced integrative solutions to corrosion problems beyond micro-scale: towards long-term durability of miniaturized Biomedical, Electronic and Energy systems
MINISTRY FOR ECONOMIC DEVELOPMENT      6      Project IAREPAM Artificial Intelligence for the Efficient Development of an Implant in Additive Manufacturing - subsidised loan
MINISTRY FOR ECONOMIC DEVELOPMENT      11      Project IAREPAM Artificial Intelligence for the Efficient Development of an Implant in Additive Manufacturing - advance on the 1st progress report
  

 

 

    
TOTAL      50     
  

 

 

    

The loan taken out to carry out the SICAT research and development project (commented on in note [3.15] Current and non-current financial liabilities in the notes to the consolidated financial statements restated as at 31 December 2022) bears interest at a subsidised rate of 0.80%.

The loan taken out to carry out the IAREPAM research and development project (commented on in note [3.15] Current and non-current financial liabilities in the notes to the consolidated financial statements restated as at 31 December 2022) bears interest at a subsidised rate of 0.13%.

For the purposes of the above disclosure requirements, in relation to any other relevant grants received, reference should also be made to the national register which is available for public consultation.

[4.10] Going concern

Though some parts of the world still felt the effects of the Covid-19 pandemic in early 2022, the current global situation means this is not a tangible or imminent significant factor in the group’s ability to continue as a going concern.

Due to the completion of the refinancing of the group described earlier and the economic and financial forecasts for the current year, supported by the group’s performance in early 2023, the directors believe that going concern is comfortably ensured.

[4.11] Events after the reporting date

As described in more detail in the paragraph [3.15] Current and non-current financial liabilities, the group completed the restructuring of its credit facilities and bonds at the beginning of 2023, deferring maturity to early 2028. This was partly financed by a capital injection by the shareholder.

On 16 March 2023, the parent Limacorporate S.p.A. signed a mutually-agreed assessment settlement procedure with the tax authorities following the tax assessment carried out on 2016.

In summer 2023 the management of Limacorporate took the strategic decision to stop the Smart Space project (referred to TechMah CGU), all digital activities and resources have been refocused on other projects. The event has been considered as non-adjusting event under IAS 10 as the decision has been fully taken in 2023.

On 18th September 2023 the company was served a Complaint filed by the founding shareholders of TechMah Medical (“TechMah Founders”) versus Lima USA Inc. and Limacorporate S.p.A. for alleged breach contract based on the milestones set out in the Investor and Founders Agreement entered into by TechMah Medical LLC, TechMah Founders, Lima USA Inc., and Limacorporate S.p.A. on 8th October 2021.

The Complaint contains high level allegations that Lima USA, Inc. and Limacorporate S.p.A. breached the Investor and Founders Agreement by not using their “reasonable best efforts” to achieve some Regulatory Milestones and by failing to pay out certain Commercial Milestones the Founders assume have been met. The Founders have claimed damages in a range of USD 5.5 – 11.5 million.

 

2022    68


On 15th November 2023 the company filed a Motion to dismiss providing evidence that Lima did not breach the Investor and Founders Agreement Agreement and has no liability to Plaintiffs.

Enovis Corporation, an innovation-driven, medical technology growth company listed in NYSE, announced on September 25, 2023 a definitive agreement to acquire LimaCorporate S.p.A..

On 03 January 2024 Enovis Corporation (NYSE: ENOV) announced the completion of the acquisition of the shares of Limacorporate S.p.A. as anticipated on 25 September 2023. On the same date, Limacorporate S.p.A. fully reimbursed its bond and revolving credit facility. Such reimbursement was fully funded by an intercompany loan granted by Enovis Corporation.

On 09 January 2024 Limacorporate S.p.A. transferred the shares of Lima USA to Enovis Corporation

31 January 2024

 

LOGO

 

2022    69


LOGO

KPMG S.p.A.

Revisione e organizzazione contabile

Piazza Salvemini, 20

35131 PADOVA PD

Telefono +39 049 8249101

Email it-fmauditaly@kpmg.it

PEC kpmgspa@pec.kpmg.it

Independent Auditors’ Report

To the board of directors of

Limacorporate S.p.A.

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the consolidated financial statements of Limacorporate S.p.A. and its subsidiaries (the Company), which comprise the consolidated statements of financial position as of December 31, 2022 and 2021, and January 1, 2021, and the related consolidated statements of comprehensive income, comprehensive income, changes in equity, and cash flows for the years ended December 31, 2022 and 2021, and the related notes to the consolidated financial statements.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and January 1, 2021, and its financial performance and its cash flows for the years ended December 31, 2022 and 2021 in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB).

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditors’ Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are required to be independent of the Company and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Emphasis of Matter

As described in Note 4.1 “Correction of errors” to the consolidated financial statements, the Company has restated the 2022 and 2021 financial statements for a correction of an error related to the payback mechanism accounted in compliance with IFRS 15, Revenue from Contracts with Customers. Our opinion is not modified in respect of this matter.

 

LOGO


LOGO

Limacorporate S.p.A.

Independent Auditors’ Report

December 31, 2022 and 2021

 

Responsibilities of Management for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with IFRS as issued by the IASB, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise significant doubt about the Company’s ability to continue as a going concern for one year after the date that the consolidated financial statements are authorized for issuance.

Auditors’ Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors’ report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.

In performing an audit in accordance with GAAS, we:

 

   

Exercise professional judgment and maintain professional skepticism throughout the audit.

 

   

Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.

 

   

Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control. Accordingly, no such opinion is expressed.

 

   

Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.

 

   

Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise significant doubt about the Company’s ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

 

LOGO

KPMG S.p.A.

Padua, Italy

February 1, 2024

 

2

EX-99.2

Exhibit 99.2

 

LOGO

Condensed consolidated interim financial statements as of and for the nine-months ended 30 September 2023

 

LOGO


Contents

 

Condensed consolidated statement of financial position

     3  

Condensed consolidated income statement

     4  

Condensed consolidated statement of comprehensive income

     5  

Condensed consolidated statement of changes in equity

     6  

Condensed consolidated statement of cash flows

     7  

Notes to the condensed consolidated interim financial statements

     8  

 

2


Condensed consolidated statements of financial position

 

(€‘000)

 

ASSETS

   Note   30/09/2023     31/12/2022
Restated
 

Non-current assets

  

Other intangible assets

   [3.1]     20,625       58,234  

Goodwill

   [3.2]     384,268       384,216  

Property, plant and equipment

   [3.3]     77,173       79,837  

Equity investments

   [3.4]     2       2  

Deferred tax assets

   [3.5]     33,322       31,709  

Other non-current financial assets

   [3.6]     940       —   

Other non-current assets

   [3.7]     958       861  
    

 

 

   

 

 

 

Total non-current assets

       517,289       554,859  
    

 

 

   

 

 

 

Current assets

      

Inventories

   [3.8]     91,033       86,728  

Trade receivables

   [3.9]     72,829       70,161  

Current tax assets

   [3.10]     1,386       2,087  

Other current assets

   [3.11]     13,929       14,192  

Cash and cash equivalents

   [3.12]     27,127       25,920  
    

 

 

   

 

 

 

Total current assets

       206,304       199,088  
    

 

 

   

 

 

 

TOTAL ASSETS

       723,593       753,947  
    

 

 

   

 

 

 

LIABILITIES

      

Equity

      

Share capital

   [3.13]     9,868       9,868  

Share premium reserve

   [3.13]     14,425       14,425  

Other reserves

   [3.13]     380,751       323,510  

Retained earnings (losses carried forward)

   [3.13]     (41,236     (21,966

Profit (loss) attributable to the owners of the parent

   [3.13]     (47,784     (19,273
    

 

 

   

 

 

 

Total equity attributable to the owners of the parent

       316,024       306,564  
    

 

 

   

 

 

 

Total equity

       316,024       306,564  
    

 

 

   

 

 

 

Non-current liabilities

      

Non current financial liabilities

   [3.16]     285,597       10,165  

Employee benefits

   [3.15]     1,258       1,296  

Deferred tax liabilities

   [3.5]     9,273       19,275  

Provisions for risks and charges

   [3.14]     29,473       17,156  

Other non-current liabilities

   [3.18]     870       649  
    

 

 

   

 

 

 

Total non-current liabilities

       326,471       48,541  
    

 

 

   

 

 

 

Current liabilities

      

Current financial liabilities

   [3.16]     20,102       336,659  

Trade payables

   [3.19]     33,405       36,564  

Current tax liabilities

   [3.20]     1,917       877  

Other current liabilities

   [3.21]     25,673       24,742  
    

 

 

   

 

 

 

Total current liabilities

       81,097       398,842  
    

 

 

   

 

 

 

TOTAL EQUITY AND LIABILITIES

       723,593       753,947  
    

 

 

   

 

 

 

The notes commenting on the individual items are an integral part of these condensed consolidated interim financial statements.

 

3


Condensed consolidated income statements

 

(€‘000)

 
     Note   30/09/2023     30/09/2022
Restated
 

Revenue

   [3.22]     200,736       178,794  

Other revenues and income

   [3.22]     4,214       3,472  
    

 

 

   

 

 

 

Total revenues and income

       204,950       182,266  
    

 

 

   

 

 

 

Raw materials, consumables, supplies and goods

   [3.24]     (50,902     (42,250

Services

   [3.25]     (63,036     (60,200

Change in w.i.p., semi-finished products and finished goods

   [3.26]     3,890       2,326  

Personnel expenses

   [3.27]     (67,412     (56,313

Amortisation and Depreciation

   [3.28]     (22,972     (26,131

Impairment losses on trade receivables

   [3.28]     (944     (101

Impairment losses on fixed assets

   [3.28]     (38,082     (853

Other operating costs

   [3.29]     (10,565     (1,195

Internal work capitalised

   [3.23]     9,156       10,181  
    

 

 

   

 

 

 

Operating costs

       (240,868     (174,534
    

 

 

   

 

 

 

Operating profit (loss)

       (35,918     7,732  
    

 

 

   

 

 

 

Financial income

   [3.30]     11,574       19,789  

Financial expense

   [3.30]     (32,605     (17,959
    

 

 

   

 

 

 

Net financial income (expense)

       (21,030     1,830  
    

 

 

   

 

 

 

Pre-tax income (loss)

       (56,949     9,562  
    

 

 

   

 

 

 

Income tax benefit/(expense)

   [3.31]     9,164       (266
    

 

 

   

 

 

 

Profit (loss) for the year

       (47,784     9,296  
    

 

 

   

 

 

 

of which attributable to the owners of the parent

       (47,784     9,296  
    

 

 

   

 

 

 

The notes commenting on the individual items are an integral part of these condensed consolidated interim financial statements.

 

4


Condensed consolidated statements of comprehensive income

Statement of comprehensive income

 

(€‘000)

 
     Note     30/09/2023     30/09/2022
Restated
 

Profit (loss) for the year

       (47,784     9,296  
    

 

 

   

 

 

 

Other comprehensive income (expense)

      

Items that will never be reclassified to profit or loss (A)

      

Remeasurements of the net defined benefit liability (asset)

     [3.15]       —        —   

Related tax

     [3.15]       —        —   
    

 

 

   

 

 

 
       —        —   
    

 

 

   

 

 

 

Items that are or may be reclassified to profit or loss (B)

      

Exchange differences on translation of foreign operations

     [3.13]       628       457  
    

 

 

   

 

 

 
       628       457  
    

 

 

   

 

 

 

Other comprehensive income (epense), net of tax (A+B)

       628       457  
    

 

 

   

 

 

 

Comprehensive income (expense) for the year

       (47,156     9,753  
    

 

 

   

 

 

 

Comprehensive income (expense) attributable to:

      

Owners of the parent

       (47,156     9,753  
    

 

 

   

 

 

 

The notes commenting on the individual items are an integral part of these condensed consolidated interim financial statements.

 

5


Condensed consolidated statements of changes in equity

 

(€‘000)

 
    Note     Share
capital
    Share
premium
reserve
    Legal
reserve
    Merger
reserve
    FTA
reserve
    Capital
contribution
    Translation
reserve
    Reserve for
defined
benefit

plans
(IAS 19)
    Other
reserves
    Retained
earnings
including

Profit (loss)
for the year
    Total
equity
attributable

to the owners
of the parent
    Total
equity
 

At 1 January 2022

      9,868       14,425       2,101       288,261       (3,840     28,051       1,508       (23     1,511       (12,742     329,121       329,121  
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

At 1 January 2022 restated

      9,868       14,425       2,101       288,261       —        28,051       1,508       (23     (2,329     (21,401     320,462       320,462  
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Statement of comprehensive income

                         

Profit (loss) for the year

    [3.13]       —        —        —        —        —        —        —        —        —        9,296       9,296       9,296  

Other comprehensive income

    [3.13]       —        —        —        —        —        —        457       —        —        —        457       457  

Comprehensive income

      —        —        —        —        —        —        457       —        —        9,296       9,753       9,753  

Owner transactions

                         

Allocation of the loss for the previous year

    [3.13]       —        —        —        —        —        —        —        —        565       (565     —        —   

Other owner transactions

    [3.13]       —        —        —        —        —        —        —        —          —        —        —   

Total owner transactions

      —        —        —        —        —        —        —        —        565       (565     —        —   

Other changes

    [3.13]       —        —        —        —        —        —        —        —        1,989       —        1,989       1,989  
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

At 30 September 2022

      9,868       14,425       2,101       288,261       —        28,051       1,965       (23     225       (12,670     332,204       332,204  
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 
      —        —        0       —        3,840       (0     0       (0     (3,840     (9,943     (9,944     (9,944
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

At 1 January 2023

      9,868       14,425       2,101       288,261       (3,840     28,051       2,379       31       6,526       (41,193     306,610       306,610  
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Payback

              3,840             (3,840     (46     (46     (46
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

At 1 January 2023 restated

      9,868       14,425       2,101       288,261       —        28,051       2,379       31       2,686       (41,239     306,564       306,564  
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Statement of comprehensive income

                         

Profit (loss) for the year

    [3.13]       —        —        —        —        —        —        —        —        —        (47,784     (47,784     (47,784

Other comprehensive income

    [3.13]       —        —        —        —        —        —        628       —        —        —        628       628  

Comprehensive income

      —        —        —        —        —        —        628       —        —        (47,784     (47,156     (47,156

Owner transactions

                         

Allocation of the loss for the previous year

    [3.13]       —        —        —        —        —        —        —        —        —        —        —        —   

Other owner transactions

    [3.13]       —        —        —        —        —        46,296       —        —          —        46,296       46,296  

Total owner transactions

      —        —        —        —        —        46,296       —        —        —        —        46,296       46,296  

Other changes

    [3.13]       —        —        —        —        —        —        —        0       10,317       3       10,321       10,321  
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

At 30 September 2023

      9,868       14,425       2,101       288,261       —        74,347       3,007       31       13,003       (89,020     316,024       316,024  
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

The notes commenting on the individual items are an integral part of these condensed consolidated interim financial statements.

 

6


Condensed consolidated statements of cash flows

 

(€‘000)

 
     30/09/2023     30/09/2022
Restated
 

Operating activities

    

Profit (loss) for the period

     (47,784     9,296  

Income tax (benefit)/expense

     (9,164     266  

Net financial (income)/expense

     21,030       (589

Amortisation, depreciation and impairment losses

     59,295       26,340  

Accruals/(Release) to provisions

     12,317       2,760  

Net (gains)/loss on disposals

     (685     (469

FX on contingent consideration

     1,243       2,395  

Equity-settled share based payment transaction

     9,285    

Cash flows from operating activities before changes in working capital

     45,537       39,999  

Change in inventories

     (4,305     (2,726

Change in trade receivables

     (2,668     (2,679

Change in trade payables

     (3,158     808  

Change in other current assets/liabilities

     2,960       (341

Change in non-current assets

     (97     (207

Income taxes paid

     (2,489     (678
  

 

 

   

 

 

 

Cash flows from operating activities A)

     35,780       34,177  
  

 

 

   

 

 

 

Investing activities

    

Acquisitions of property, plant and equipment

     (18,142     (17,359

Disposal of property, plant and equipment

     687       582  

Acquisitions of intangible assets

     (2,947     (8,202

Disposal of intangible assets

     —        463  
  

 

 

   

 

 

 

Cash flows used in investing activities B)

     (20,402     (24,516
  

 

 

   

 

 

 

Financing activities

    

Third party funds

    

Bonds repayment

     (274,039  

Bank loans repayment

     (47,000  

Bonds issuance

     279,613    

Net change in current financial liabilities

     —     

Net change in non-current financial liabilities

     —     

Payment of lease liability

     (3,363     (3,480

Gross interest received

     243       107  

Gross interest paid

     (20,921     (11,054

Capital injection

     46,296       —   

Other financial liabilities

     5,000       9,518  
  

 

 

   

 

 

 

Cash flows used in financing activities C)

     (14,171     (4,909
  

 

 

   

 

 

 

Increase (decrease) in cash and cash equivalents (A ± B ± C)

     1,207       4,751  
  

 

 

   

 

 

 

Opening cash and cash equivalent

     25,920       21,503  

Closing cash and cash equivalent

     27,127       26,254  
  

 

 

   

 

 

 

Increase (decrease) in cash and cash equivalents

     1,207       4,751  
  

 

 

   

 

 

 

 

7


Notes to the condensed consolidated interim financial statements

[2.1] General information

The Limacorporate Group (the “group”) creates, designs and sells joint implants and orthopaedic solutions in the medical sector.

The parent, Limacorporate S.p.A. (“Limacorporate” or the “parent”), was set up and is domiciled in Italy. Its registered office is at Via Nazionale 52, San Daniele del Friuli (Udine) and its company registration number is 173824.

The group carries out most of its business at its registered office while some activities are also performed by the subsidiaries.

The condensed consolidated interim financial statements as of and for the nine-months ended 30 September 2023 include the financial statements of the parent and the subsidiaries (together the “group”).

The parent is managed and coordinated by Emil Holding II S.à.r.l., whose details are provided below:

 

   

Registered office: 26A, Boulevard Royal, L-2449 Luxembourg.

 

   

Legal form: limited liability company.

 

   

Description of its business activities and main operations: holding company

 

   

Parent’s name: Emil NewCo S.à.r.l.

 

   

Name of the ultimate indirect parent: EQT Luxembourg Management S.à r.l.

In early July 2023 the management of Limacorporate announced the strategic decision, substantially taken over the weeks before the reporting date, to stop the Smart Space project (referred to TechMah CGU), all digital activities and resources have been refocused on other projects.

On 18th September 2023 the company was served a Complaint filed by the founding shareholders of TechMah Medical (“TechMah Founders”) versus Lima USA Inc. and Limacorporate S.p.A. for alleged breach contract based on the milestones set out in the Investor and Founders Agreement entered into by TechMah Medical LLC, TechMah Founders, Lima USA Inc., and Limacorporate S.p.A. on 8th October 2021.

The Complaint contains high level allegations that Lima USA, Inc. and Limacorporate S.p.A. breached the Investor and Founders Agreement by not using their “reasonable best efforts” to achieve some Regulatory Milestones and by failing to pay out certain Commercial Milestones the Founders assume have been met. The Founders have claimed an amount in a range of USD 5.5 – 11.5 million.

The company has filed a Defendants’ Answer To Verified Amended Complaint and Defendants Counterclaims which contains a request for compensatory damages in an amount to be determined at trial, but not less than $ 50 million.

[2.2] Format and content of the condensed consolidated interim financial statements

The condensed consolidated income statement and consolidated statement of comprehensive income for the nine-month period ended 30 September 2023 and the nine-month period ended 30 September 2022 have been prepared in accordance with IAS 34 issued by International Accounting Standards Board (IASB). They do not include all the information that would be required for the annual consolidated financial statements and should be read in conjunction with the consolidated financial statements for the year ended as of 31 December 2022 and 31 December 2021 which was prepared in accordance with the International Financial Reporting Standards (“IFRS”) issued by the International Accounting Standards Board (“IASB”).

The term “IFRS” is also used to refer to all revised international accounting standards (“IAS”), all interpretations of the International Financial Reporting Interpretations Committee (“IFRIC”), formerly known as the Standing Interpretations Committee (“SIC”).

 

8


These condensed consolidated interim financial statements comprise the statements of financial position, profit or loss, statement of changes in equity, statement of cash flows and these notes. They comply with the provisions of IAS 1 Presentation of financial statements and the general principle of historical cost, except for those items that, pursuant to the IFRS, are measured at fair value. The statement of financial position has been prepared by separating assets and liabilities into current and non-current, whereas costs are classified in the income statements on the basis of their nature. The statement of cash flows has been prepared using the indirect method.

The notes to the condensed consolidated interim financial statements include the information generally required by ruling legislation and the IFRS, suitably presented with reference to the financial statements schedules used.

The condensed consolidated interim financial statements have been prepared on a going concern basis, as the related assumptions are deemed to be met.

All figures are in Euros, unless indicated otherwise. The Euro is the parent’s functional and presentation currency. For each financial statements caption, the corresponding amount of the previous year is provided for comparative purposes.

Correction of error

As already reported in the consolidated financial statements as of 31 December 2022 prepared in accordance with the IFRS issued by IASB, the Group restated the Group’s equity and profit for the year previously determined under the IFRS endorsed by the European Union. Accordingly, the Group also restated the comparative information of this condensed consolidated interim financial statements as of and for the nine-months ended 30 September 2023.

In the consolidated financial statements as of 31 December 2022 prepared the Group corrected the payback treatment in compliance with IFRS 15 considering it as a variable consideration. The company incorrectly accounted for the payback treatment as a provision in previously issued financial statements. The effect of the correction of error as of 1 January 2021 is a lower Group’s net equity of €6.9 million. For the correction reflected in the opening equity please refer to the previous mentioned consolidated financial statements as of 31 December 2022. Instead, as provide for IAS 8, in the table below are reflected the effects affecting the profit and loss of the consolidated interim financial statements as of and for the nine- months ended 30 September 2022 that led to a decrease of the net result of the period of €1.3 million.

 

9


Reconciliations of the statement of profit or loss

 

(€‘000)

 
     Note     As previously
reported
30/09/2022
    Error correction     As restated
30/09/2022
 

Revenue

     [3.22]       180,485       (1,691     178,794  

Other revenues and income

     [3.22]       3,472         3,472  
    

 

 

   

 

 

   

 

 

 

Total revenue and income

       183,957       (1,691     182,266  
    

 

 

   

 

 

   

 

 

 

Raw materials, consumables, supplies and goods

     [3.24]       (42,250       (42,250

Services

     [3.25]       (60,200       (60,200

Change in w.i.p., semi-finished products and finished goods

     [3.26]       2,326         2,326  

Personnel expenses

     [3.27]       (56,313       (56,313

Amortisation and Depreciation

     [3.28]       (26,131       (26,131

Impairment losses on trade receivables

     [3.28]       (101       (101

Impairment losses on fixed assets

     [3.28]       (853       (853

Other operating costs

     [3.29]       (1,195       (1,195

Internal work capitalised

     [3.23]       10,181         10,181  
    

 

 

   

 

 

   

 

 

 

Operating costs

       (174,534     —        (174,534
    

 

 

   

 

 

   

 

 

 

Operating profit

       9,422       (1,691     7,732  
    

 

 

   

 

 

   

 

 

 

Financial income

     [3.30]       19,789         19,789  

Financial expense

     [3.30]       (17,959       (17,959
    

 

 

   

 

 

   

 

 

 

Net financial expense

       1,830       —        1,830  
    

 

 

   

 

 

   

 

 

 

Pre-tax income (loss)

       11,252       (1,691     9,562  
    

 

 

   

 

 

   

 

 

 

Income tax benefit (expense)

     [3.31]       (672     406       (266
    

 

 

   

 

 

   

 

 

 

Profit (loss) for the year

       10,581       (1,285     9,296  
    

 

 

   

 

 

   

 

 

 

of which attributable to the owners of the parent

       10,581       (1,285     9,296  
    

 

 

   

 

 

   

 

 

 

 

(€‘000)

 
     Note     As previously
reported
30/09/2022
     Error correction     As restated
30/09/2022
 

Profit (loss) for the year

       10,581        (1,285     9,296  
    

 

 

    

 

 

   

 

 

 

Other comprehensive income (expense)

         

Items that will never be reclassified to profit or loss (A)

       —         —        —   

Remeasurements of the net defined benefit liability (asset)

     [3.15]       —         —        —   

Related tax

     [3.15]       —         —        —   
    

 

 

    

 

 

   

 

 

 
       —         —        —   
    

 

 

    

 

 

   

 

 

 

Items that are or may be reclassified to profit or loss (B)

         

Exchange differences on translation of foreign operations

     [3.13]       797        —        797  
    

 

 

    

 

 

   

 

 

 
       797        —        797  
    

 

 

    

 

 

   

 

 

 

Other comprehensive income (expense), net of tax (A+B)

       797        —        797  
    

 

 

    

 

 

   

 

 

 

Comprehensive income (expense) for the year

       11,378        (1,285     10,093  
    

 

 

    

 

 

   

 

 

 

Comprehensive income (expense) attributable to:

       —        

Owners of the parent

       11,378        (1,285     10,093  
    

 

 

    

 

 

   

 

 

 

 

10


[2.3] Consolidation scope

The condensed consolidated interim financial statements of the Limacorporate Group include the financial statements of the parent and the Italian and foreign subsidiaries as at 30 September 2023 and detailed in the following table:

 

Description

  

Location

  

Currency

  

%

LIMA AUSTRIA GmbH    Seestadtstrasse 27 Top 6-7, 1220 Wien (Osterreich)    (EUR)    100%
LIMA BELGIUM SRL    Chaussée de Wavre 504, boîte 5A - 1390 Grez Doiceau (Belgium)    (EUR)    100%
LIMA CZ s.r.o.    Do Zahràdek I., 157/5 - 155 21 Praha 5 - Třebonice - (Czech Republic)    (CZK)    100%
LIMA DENMARK ApS    Lyngebaekgards Alle 2, 2990 Niva (Denmark)    (DKK)    100%
LIMA DEUTSCHLAND GmbH    Gasstraße 18 | Haus 1 - 22761 Hamburg - Germany    (EUR)    100%
LIMA DO BRASIL LTDA    Al. Campinas, 728 – 2° andar salas 201, 202, 203 e 204.- Jardim Paulista - Sao Paulo - SP - CEP:01404-001 (Brasil)    (BRL)    100%
LIMA FRANCE Sas    1, Allée des Alisiers - Immeuble “Le Galilée” - 69500 Bron - (France)    (EUR)    100%
LIMA IMPLANTES PORTUGAL S.U. LDA    Rua Pêro Vaz de Caminha 8 E 2660-441 Stº António Cavaleiros - (Portugal)    (EUR)    100%
LIMA IMPLANTES Slu    Francisco Sancha, 4 3ª planta | 28034 Madrid | España    (EUR)    100%
LIMA JAPAN K.K.    Tokyo Front Terrace 13F 2-3-14 Higashi Shinagawa,Shinagawa, Tokyo, 140-0002 , (Japan)    (JPY)    100%
LIMA KOREA Co., Ltd   

2Fl., EunSung Bldg., 741 Yeongdong-daero, Gangnam Gu,

Seoul, 06071, Korea

   (KRW)    100%
LIMA NETHERLANDS B.V.    Bergweg 153A, 3707AC Zeist - (Netherlands)    (EUR)    100%
LIMA O.I. d.o.o. - ORTOPEDIJA I IMPLANTATI    Ante Kovačića, 3 - 10000 Zagreb - (Croatia)    (EUR)    100%
LIMA ORTHOPAEDICS AUSTRALIA Pty Ltd    Unit 1, 40 Ricketts Road - Mt Waverley, 3149 Victoria - (Australia)    (AUD)    100%
LIMA ORTHOPAEDICS NEW ZEALAND Pty Ltd    20 Crummer Rd Grey Lynn 1021 Auckland 1021 - New Zealand    (NZD)    100%
LIMA ORTHOPAEDICS SOUTH AFRICA (PTY) LTD   

Northlands Deco Park, Stand 326, 10 Newmarket Street, Design Boulevard,

Northriding, 2186 (South Africa)

   (ZAR)    100%
LIMA ORTHOPAEDICS UK Ltd    4 Office Village Forder Way Cygnet Park Hampton Peterborough Peterborough PE7 8GX (United Kingdom)    (GBP)    100%
LIMA POLSKA SP. z.o.o.    ul. Ul Lopuszanska 95 - 02-457 Warsaw (Poland)    (PLN)    100%
LIMA SK S.r.o.    Cesta na Stadiòn 7 - 97404 Banska Banska Bystrica - (Slovakia)    (EUR)    100%
LIMA SWEDEN AB    Box 180 - SE-184 22 Akersberga - (Sweden)    (SEK)    100%
LIMA SWITZERLAND SA    Birkenstrasse, 49 - 6343 Rotkreuz - Zug - (Switzerland)    (CHF)    100%
TASFIYE HALINDE LIMA TURKEY ORTOPEDI AS    Serifali Mah. Hendem Cad.No: 54 Canan Residence OFIS A-2,34775 - UMRANIYE - Istanbul - (Turkiye)    (TRY)    100%
LIMA USA Inc.    2001 NE Green Oaks Blvd, Suite 100 - Arlington, TX 76006 - (United States)    (USD)    100%
LIMA SM S.p.A. in liquidazione    Strada Borrana, 38 - Serravalle 47899 - (Repubblica di San Marino)    (EUR)    100%
LIMA (BEIJING) MEDICAL DEVICES CO., LTD.    Room 616, 6/F, Building 1, No.1, Lize Zhong 2 Road, Chaoyang District, Beijing, China    (CNY)    100%
LIMA ORTHOPAEDICS CANADA INC.    3715 Laird Road Suite Unit 9, Mississauga, ON, Canada    (CAD)    100%

Subsidiaries are those companies over which the group has control, as defined by IFRS 10 Consolidated financial statements. Control exists when the group has the power to, directly or indirectly, govern the financial and operating policies of an entity to obtain benefits from its activities. The financial statements of subsidiaries are included in the consolidated financial statements starting from when control is assumed and until such control ceases to exist.

Subsidiaries are included in the consolidation scope from when the group acquires control, as defined above, and are excluded from when the group no longer has control.

On 1 January 2023, the subsidiary TechMah Medical LLC was merged by incorporation into the subsidiary Lima USA Inc.

The interim reporting date of all the consolidated companies is 30 September.

The basis of consolidation is set out below:

 

   

The line-by-line method, showing the portions of equity and profit or loss for the year attributable to non-controlling interests and recognising assets, liabilities, revenue and costs regardless of the percentage held in the subsidiaries.

 

   

Eliminating items deriving from intragroup transactions involving consolidated companies, including any unrealised gains and losses arising from intragroup transactions and recognising the resulting deferred tax effects.

 

   

Eliminating intragroup dividends and reallocating them to opening equity reserves.

 

11


   

Eliminating the carrying amount of investments in consolidated companies and the relevant portion of equity, allocating the resulting positive and negative differences to the relevant captions (assets, liabilities and equity), as defined at the time of acquisition of the investment and considering any subsequent variations. After control is acquired, any acquisitions of non-controlling interests or sales of shares to non-controlling interests that do not entail loss of control are recognised as owner transactions and the relevant effects are taken directly to equity. Any differences between the change in equity attributable to non-controlling interests and cash and cash equivalents exchanged are recognised under changes in equity attributable to the owners of the parent.

 

   

The financial statements of foreign operations are translated into Euros using the annual average rate for income statement items and the closing rate for statement of financial position items. The difference between the two rates along with the translation differences deriving from changes in opening and closing exchange rates are recognised as changes in equity.

The following rates were applied in translating the financial statements of foreign operations:

 

Currency

   Average rate
2023
     Closing rate:
30/09/2023
     Average rate
2022
     Closing rate:
30/09/2022
 

AUD - Australian Dollar

     1.6205        1.6339        1.5044        1.5076  

BRL - Brazilian Real

     5.4245        5.3065        5.4631        5.2584  

CAD - Canadian Dollar

     1.4576        1.4227        1.3643        1.3401  

CHF - Swiss Franc

     0.9774        0.9669        1.0118        0.9561  

CNY - Yuan Renminbi

     7.6235        7.7352        7.0193        6.9368  

CZK - Czech Koruna

     23.8359        24.3390        24.6248        24.5490  

DKK - Danish Krone

     7.4486        7.4571        7.4399        7.4365  

GBP - Pound Sterling

     0.8707        0.8646        0.8472        0.8830  

HRK - Croatian Kuna

     n.a        n.a        7.5335        7.5240  

JPY - Yen

     149.6515        158.1000        135.9679        141.0100  

KRW - Won

     1,410.2500        1,425.2600        1,348.7900        1,400.6900  

NZD - New Zealand Dollar

     1.7547        1.7575        1.6468        1.7177  

PLN - Zloty

     4.5820        4.6283        4.6724        4.8483  

SEK - Swedish Krona

     11.4789        11.5325        10.5274        10.8993  

TRY - Turkish Lira

     24.1485        29.0514        16.8796        18.0841  

USD - US Dollar

     1.0833        1.0594        1.0638        0.9748  

ZAR - Rand

     19.8865        19.9813        16.9517        17.5353  

[2.4] Basis of presentation

[2.4.1] Business combinations and goodwill

Business combinations are recognised using the acquisition method under IFRS 3. To this end, the acquired identifiable assets and the assumed liabilities are recognised at their respective acquisition-date fair value. The consideration transferred in a business combination is the aggregate of the fair value, at the date of exchange, of assets acquired, assumed liabilities and equity instruments issued by the acquirer, in exchange for control of the acquiree.

Goodwill is the positive difference between the consideration transferred, increased by both the fair value at the acquisition date of any non-controlling interests already held in the acquiree and the amount of non-controlling interests held in the acquiree by third parties (measured at fair value or based on the present value of the acquiree’s identifiable net assets), and the fair value of such assets and liabilities.

At the acquisition date, goodwill is allocated to the single cash-generating unit that is expected to benefit from the synergies of the business combination.

If the difference between the consideration transferred (increased by the above components) and the fair value of the net assets acquired is negative, this is recognised as a gain from a bargain purchase in the income statement in the year of acquisition.

Any goodwill related to non-controlling interests is included in the carrying amount of the relevant equity investments.

 

12


After initial recognition, goodwill is not amortised and is recognised net of any cumulative impairment losses, calculated using the methods set out in section [2.4.6] Impairment losses on assets.

As set out in section [3.2] Goodwill of this report, the market multiples method is used to determine the fair value of goodwill, using listed comparable companies (these multiples are compared with the implicit multiple calculated using the group’s actual figures), except for CGU TechMah for which the value in use is defined using estimated future cashflows by applying a discount rate.

IFRS 3 is not applied retrospectively to business combinations that took place prior to 1 January 2018, i.e., the date of the parent’s transition to the IFRS. Accordingly, the amount of goodwill determined under the previous reporting standards, i.e., the carrying amount at such date, is maintained for such business combinations, subject to the recognition of any impairment losses.

[2.4.2] Intangible assets

An intangible asset is an identifiable asset without physical substance, controlled by the group and that generates future economic benefits, in addition to goodwill when acquired against consideration.

Identifiability is defined with reference to the possibility of distinguishing the intangible asset acquired from goodwill. An intangible asset is identifiable when it: (i) arises from a legal or contractual right or (ii) is separable, i.e., can be sold, transferred, licensed, rented, or exchanged, either individually or together with a related contract. An entity controls an asset if it has the power to obtain the future economic benefits flowing from the underlying resource and to restrict the access of others to such benefits.

Intangible assets are stated at cost, which is determined in same manner as for property, plant and equipment.

Intangible assets with finite useful lives are amortised over their estimated useful lives starting from when they are available for use.

The amortisation rates adopted in 2022 and 2023 are shown in the following table by asset category:

 

Description

  

2023 - 2022 (*)

Start-up and capital costs

   3 - 4 - 5 years

Development expenditure

   5 - 10 years

Patents and intellectual property rights

   10 - 20 years

Licences, trademarks and simiilar rights

   3 - 4 - 5 years

Other

   Contract term/Maximum 6 years

 

*

There were no changes to the amortisation rates

Development expenditure

Development expenditure is expensed when incurred.

Development expenditure incurred for a specific project is only capitalised when the group can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use and for sale, its intention to complete such asset and use or sell it, how the intangible asset will generate probable future economic benefits, the availability of adequate technical, financial and other resources to complete the development and its ability to measure reliably the expenditure attributable to the intangible asset during its development.

Subsequent to initial recognition, development expenditure is measured at cost less any accumulated amortisation and any accumulated impairment losses. Amortisation of the asset starts from when the development phase has been completed and the asset is available for use. The asset is amortised over the period for which the underlying project is expected to generate revenue for the group.

Patents and intellectual property rights

Patents and intellectual property rights refer to costs for patents owned by Limacorporate S.p.A.

 

13


Licences, trademarks and similar rights

This caption refers to costs to file and register trademarks and costs incurred to acquire commercial licences. The acquisition costs are amortised over a period equal to the useful life of the acquired right.

Other intangible assets

This caption refers to leasehold improvements carried out in prior years. The capitalised costs are amortised on the basis of the residual term of the relevant lease contract.

[2.4.3] Property, plant and equipment

Property, plant and equipment are recognised at acquisition or production cost including directly attributable costs incurred to ready the asset for its intended use. Such cost includes costs to replace parts of equipment and plant when they are incurred if they meet the recognition requirements.

Assets acquired under business combinations before 1 January 2018 (the date of the parent’s e to the IFRS) are recognised at their pre-existing carrying amount, determined within such business combinations in accordance with the previous reporting standards, i.e., at deemed cost.

The carrying amount (cost less accumulated depreciation and cumulative impairment losses) of the replaced parts of equipment and plant is taken to profit or loss at the time of replacement.

Maintenance and repair costs, which do not add to the value of the assets and/or prolong their residual useful lives, are expensed when incurred. Otherwise they are capitalised.

Property, plant and equipment are stated net of any accumulated depreciation and any cumulative impairment losses determined using the methods set out below. Depreciation is calculated on a straight-line basis over the estimated useful life of the asset for the group.

The depreciation rates used are shown in the following table by asset category:

 

     2023   2022

Buildings

   3%   3%

Light constructions

   10%   10%

Generic and specific plant

   10% - 15.5%   10% - 15.5%

Machinery

   15.5%   16%

Sundry and small equipment

   25%   25%

Production equipment

   10%   10%

Office furniture and machines

   12%   12%

Electronic office machines

   20%   20%

Transport vehicles

   20%   20%

Cars

   25%   25%

Right-of-use assets

   Lease term   Lease term

The residual value of the assets, the useful life and the depreciation method applied are reviewed at each periods end and adjusted prospectively if necessary.

If significant parts of an item of property, plant and equipment have different useful lives, such parts are recognised separately. Land, free of construction or annexed to buildings, is recognised separately and is not depreciated since it has an unlimited useful life.

The carrying amount of an item of property, plant and equipment and every significant part initially recognised is eliminated on disposal or when no future economic benefits are expected from its use or disposal. The gain or loss arising from the derecognition of the item (calculated as the difference between the carrying amount of the asset and the net disposal proceeds) is included in profit or loss when the item is derecognised.

 

14


[2.4.4] Leases

If a contract contains a lease, at the commencement date, the lessee shall recognise an asset representing its right to use the underlying leased asset and a lease liability representing its obligation to make lease payments. The lessee shall recognise interest on the lease liability and depreciation of the right-of-use asset separately. At inception of a contract, the entity shall assess whether the contract is, or contains, a lease. The contract is, or contains, a lease if it conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

[2.4.5] Equity investments

Investments in associates are measured using the equity method, recognising the group’s share of the profits or losses for the period in the income statement, with the exception of the effects related to other changes in the equity of the investee, other than owner transactions, that are directly recognised in other comprehensive income.

In the event of losses exceeding the carrying amount of the equity investment, the excess is recognised in a specific provision to the extent the parent is obliged to fulfil legal or constructive obligations to the investee or to cover its losses.

Investments in other companies are measured at fair value and the fair value gains and losses are taken to equity. If fair value cannot be reliably determined, they are measured at cost, adjusted for any impairment losses.

[2.4.6] Impairment losses

At the reporting date, the carrying amount of property, plant and equipment, intangible assets, financial assets and equity investments is tested for indicators of impairment. Should such indicators exist, the group estimates the recoverable amount of the asset to check the recoverability of the carrying amount and determine any impairment loss to be recognised. Intangible assets with indefinite useful lives or not yet available for use are tested for impairment at least annually, irrespective of whether any indication of impairment exists, or more frequently if an indication of impairment exists.

In order to identify impairment losses, assets are grouped into the smallest identifiable group of assets that generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets (the cash-generating unit, CGU). Reference should be made to section [3.2] Goodwill for details of the group’s CGU. The recoverable amount of an asset or a CGU is the higher of its value in use and its fair value less costs to sell.

The market multiples method is used to determine the value in use using listed comparable companies. These multiples are compared with the implicit multiple calculated using the group’s actual figures. When the carrying amount of an asset or a CGU exceeds its recoverable amount, the group recognises an impairment loss in profit or loss. Impairment losses on the CGU are allocated first to reduce the carrying amount of any goodwill allocated to it and then to the other assets of the CGU pro rata on the basis of their carrying amounts. Impairment losses on goodwill cannot be reversed. Impairment losses on other assets are reversed to the carrying amount that would have been determined (net of amortisation and depreciation) had no impairment losses been recognised in prior periods.

[2.4.7] Financial instruments

The financial instruments held by the group are described below.

Financial assets

Financial assets include equity investments, loans and borrowings, as well as derivatives with a positive fair value, trade receivables and other assets, in addition to cash and cash equivalents.

Specifically, cash and cash equivalents include cash, bank deposits and highly marketable securities that are readily convertible to cash and are subject to an immaterial risk of changes in value.

Financial assets represented by debt instruments are classified in the consolidated financial statements and measured using the business model adopted by the group for managing financial assets and based on the cash flows related to each financial asset. Financial assets also include equity investments not held for trading. Such assets are strategic investments, and the group has opted to recognise fair value gains or losses thereon through profit or loss (fair value through profit or loss, FVTPL).

Financial assets are tested for impairment using a model based on expected credit losses.

 

15


Financial liabilities

Financial liabilities include loans and borrowings, as well as derivatives with a negative fair value, trade payables and other liabilities.

Financial liabilities are classified and measured at amortised cost, with the exception of those initially measured at fair value, e.g., financial liabilities related to considerations for business combinations and derivatives and financial liabilities for options on non-controlling interests.

Derecognition of financial assets and liabilities

A financial asset or liability (or, where applicable, part of a financial asset/liability or part of a group of similar financial assets/liabilities) is derecognised when the group unconditionally transfers the contractual rights to receive the cash flows of the financial asset or the obligation to make payments or fulfil other obligations related to the liability.

Derivatives and hedging transactions

To cover-interest-rate risks, interest-rate swap contracts are generally used. All derivatives are measured at fair value. If an economic hedge does not qualify for hedge accounting, then any derivative used is measured at fair value with all changes in fair value recognised in profit or loss. These changes will not be offset by gains or losses on the hedged item when the hedged item is not also measured at FVTPL.

[2.4.8] Inventories

Raw materials and packaging are measured at the lower of purchase cost and estimated replacement value based on market trends. The cost is calculated using the weighted average cost for the period.

Semi-finished products and finished goods are measured at purchase or production cost, considering their stage of completion, or their realisable value based on market trends, if lower. The production cost includes the reasonably attributable portion of direct and indirect manufacturing costs.

The resulting amount is written down through the allowance for inventory write-down to account for items whose expected realisable value is lower than their cost.

[2.4.9] Trade receivables and other assets and trade payables and other liabilities

Trade receivables and other assets that derive from the supply of credit facilities, goods or services to third parties are classified under current assets, except when they are due after one year of the reporting date with reference to loans and receivables. If they have a set due date, current and non-current loans and receivables, other current and non-current assets and trade receivables, with the exception of derivatives, are measured at amortised cost calculated using the effective interest method. If they do not have a set due date, financial assets are measured at cost. Loans and receivables due after one year that are non-interest bearing or accruing interest lower than market rates are discounted using market rates.

The above financial assets are measured using the expected credit loss impairment model introduced by IFRS 9.

Trade payables and other liabilities that arise from the acquisition of credit facilities, goods or services from a third part supplier are classified under current liabilities, except when they are due after one year of the reporting date with reference to loans and borrowings.

On initial recognition, current and non-current loans and borrowings, other current and non-current liabilities and trade payables are stated at fair value, which normally coincides with the transaction price including transaction costs. Subsequently, with the exception of derivatives, all financial liabilities are measured at amortised cost calculated using the effective interest method. Hedged financial liabilities are measured in accordance with hedge accounting.

 

16


[2.4.10] Employee benefits

The liability related to short-term employee benefits paid during the employment relationship is recognised on an accruals basis at the amount accrued at the reporting date.

The liability related to employee benefits paid upon or after termination of the employment relationship via defined benefit plans, is recognised at the amount accrued at the reporting date.

The liability related to employee benefits paid upon or after termination of the employment relationship via defined benefit plans, net of any plan assets and advances granted, is calculated using actuarial assumptions and recognised on an accruals basis in line with the service needed to obtain the benefits. Such liability is calculated by independent actuaries. The gain or loss deriving from the actuarial calculation is fully recognised in the statement of comprehensive income.

Defined benefit plan liabilities are measured using the actuarial assumptions set out in section [3.15] Employee benefits.

[2.4.11] Provisions for risks and charges

The provisions for risks and charges are recognised when the group has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation.

The amount recognised as a provision is the best estimate of the expenditure required to settle the present obligation or transfer it to third parties at the reporting date. Where the effect of the discounting is material, the provisions are calculated by discounting the estimated future cash flows at a rate that reflects current market assessments of the time value of money. When discounting is used, the carrying amount of the provision increases to reflect the passage of time and this increase is recognised as borrowing cost.

[2.4.12] Share-based payments

The grant-date fair value of equity-settled share-based payment arrangements granted to employees is generally recognised as an expense, with a corresponding increase in equity, over the vesting period of the awards. The amount recognised as an expense is adjusted to reflect the number of awards for which the related service and non-market performance conditions are expected to be met, such that the amount ultimately recognised is based on the number of awards that meet the related service and non-market performance conditions at the vesting date. For share-based payment awards with non-vesting conditions, the grant-date fair value of the share-based payment is measured to reflect such conditions. With regard to non-vesting conditions, any differences between expected and actual outcomes do not have an impact on the consolidated financial statements.

The fair value of the amount payable to employees in respect of cash-settled share-based payments is recognised as an expense with a corresponding increase in liabilities, over the period during which the employees become unconditionally entitled to payment. The liability is remeasured at each reporting date and at the settlement date based on the fair value of the share-based payments. Any fair value gains or losses are recognised in profit or loss.

The parent has agreements with some managers for the award of options and/or shares (see section [4.7] Management Incentive plans).

[2.4.13] Revenue and expense

Based on the five-step model introduced by IFRS 15, the group recognises revenue after identifying the contract(s) with a customer and the performance obligations in the contract (transfer of goods and/or services), determining the transaction price to which it expects to be entitled in exchange for fulfilling performance obligations (at a point in time or over time). Revenue is measured on the basis of the transaction price excluding amounts collected on behalf of third parties. Based on the group’s internal analysis of contracts with customers, the group has not identified any performance obligations that are satisfied over time and, therefore, the group recognises revenue upon the transfer of control of the promised goods or services to the customer. Revenue is measured to the extent that it is probable that the economic benefits will flow to the group and the amount can be measured reliably.

 

17


Revenue is adjusted for any discounts and volume rebates allowed by the group in contracts with customers and for the payback (variable considerations) see [3.22] Revenue and other revenue and income and [3.14] Provisions for risks and charges for payback system.

Expense is recognised when the goods and services are sold or consumed during the period or by systematic allocation, or when it is not possible to identify their future use.

Expense items are classified by nature in accordance with the applicable IFRS.

[2.4.14] Government grants

Grants are recognized when there is reasonable assurance that the grant will be received.

Grants related to income are taken to profit or loss in the period in which the relevant expense is recognised.

Grants related to assets received for projects and development activities are recognised under liabilities and subsequently recognised under operating revenue in line with the amortisation and depreciation of the relevant assets.

Grants due for investments in research and development are recognised in line with the progress of the research, calculated on the basis of the progress reports issued to the relevant bodies and the stage of completion reported by those in charge of the research, if all requirements for their disbursement are met.

[2.4.15] Financial income and expense

Financial income and expense are recognised on the basis of interest accrued on the net amount of the relevant financial assets and liabilities, using the effective interest method.

[2.4.16] Dividends

Dividends are recognised when the shareholder’s right to receive payment is established.

[2.4.17] Income taxes

Income taxes recognised in profit or loss are the sum of current and deferred taxes.

Income taxes for the period are determined on the basis of ruling legislation. They are recognised in profit or loss, except for those related to items recognised directly in equity, for which the tax effect is accounted for directly in equity.

Income tax payables are recognised under current tax liabilities, net of advances paid. Any tax credits are recognised under current tax assets.

Deferred tax assets and liabilities are calculated on the temporary differences between the carrying amounts of assets and liabilities (resulting from the application of the accounting policies set out in note 2.4 “Basis of presentation”) and their tax bases (deriving from the application of the tax legislation ruling in the country of the subsidiaries). Current and deferred tax assets and liabilities are offset when the group has the legally enforceable right to offset.

Deferred taxes are calculated using the tax rates expected to be enacted in the periods in which the temporary differences will be recovered or settled. Deferred tax assets and liabilities are not discounted.

Deferred tax assets are recognised on temporary differences and to the extent that it is probable the group will have future taxable profits that will allow their recovery.

[2.4.18] Fair value

IFRS 13 is a common framework for fair value measurement and relevant disclosure when this measurement is required or allowed by other IFRS. Specifically, the standard sets out the definition of fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

 

18


IFRS 13 establishes a hierarchy that categorises the inputs used in the valuation techniques adopted to measure fair value into different levels, as follows:

 

   

level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity has the ability to access at the measurement date;

 

   

level 2: inputs other than quoted prices included in Level 1 that are observable for the assets or liabilities, either directly or indirectly;

 

   

level 3: inputs for the assets or liabilities that are not based on observable market data (unobservable inputs).

In some cases, the inputs used to measure the fair value of an asset or a liability might be categorised within different levels of the fair value hierarchy. In those cases, the fair value measurement is categorised in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement.

The group recognises transfers among the different levels of the fair value hierarchy at the end of the periods in which the transfer took place.

Reference should be made to the notes to the individual financial statements’ items for the definition of the fair value hierarchy level used to classify the individual instruments measured at fair value or whose fair value is disclosed.

The fair value of derivatives is calculated by discounting estimated cash flows using the market interest rates at the reporting date and the credit default swaps issued by the counterparty and group companies, to include the non-performance risk explicitly provided for under IFRS 13.

Where market prices are not available, the fair value of non-derivative medium/long-term financial instruments is calculated by discounting estimated cash flows using the market interest rates at the reporting date and considering counterparty risk for financial assets and credit risk for financial liabilities.

[2.4.19] Use of estimates

In preparing the condensed consolidated interim financial statements, the directors were required to apply accounting policies that are, at times, based on judgements or past experience or assumptions deemed reasonable and realistic at the time, depending on the relevant circumstances. The application of such estimates and assumptions impacts the carrying amounts recognised in the statement of financial position, income statement, statement of comprehensive income and statement of cash flows, in addition to the disclosure provided. The end results of the assessments in which such estimates and assumptions were used may differ from those recognised in the consolidated financial statements due to the inherent uncertainty of the assumptions and the conditions underlying the estimates.

Actual results may differ from those estimated. Estimates and assumptions are reviewed on an ongoing basis. The effect of a change in accounting estimates is recognised in profit or loss in the period of the change, if the change affects that period only, or the period of the change and future periods, if the change affects both.

Estimates mainly refer to the following captions:

 

   

impairment losses on non-current assets and goodwill;

 

   

loss allowance;

 

   

allowance for inventory write-down;

 

   

recoverability of deferred tax assets;

 

   

estimate of the provisions for risks and contingent liabilities;

 

   

financial liabilities;

 

   

employee incentive plans.

 

19


Impairment losses on non-current assets and goodwill

Non-current assets include property, plant and equipment, intangible assets including goodwill and other financial assets.

Management periodically revises the carrying amount of non-current assets held and used and assets held for sale when events and circumstances require such revision. This is performed using the estimates of cash flows the group expects to derive from using or selling the asset and suitable discount rates for calculating the present value.

When the carrying amount of a non-current asset has been impaired, the group recognises an impairment loss equal to the excess between the carrying amount and the amount to be recovered through use or sale of the asset, determined using the parent’s or group’s most recent plans. Reference should be made to note [3.28] Impairment losses.

Loss allowance

The loss allowance is management’s best estimate of the potential credit losses on trade receivables from end customers. Reference should be made to note [3.9] Trade receivables and other assets and [3.19] trade payables and other liabilities for a description of the criteria used in estimating the allowance.

Allowance for inventory write-down

Inventories of slow-moving raw materials and finished goods are periodically analysed on the basis of historical data and the possibility of selling them at prices lower than normal market transactions. If, as a result, the carrying amount of inventories needs to be written down, the group recognises a specific allowance for inventory write-down.

Recoverability of deferred tax assets

The group pays taxes in numerous countries and some estimates are required to calculate the taxes in each jurisdiction. It recognises deferred tax assets to the extent that it is probable that future taxable profits will be available and over a period of time compatible with the time horizon implicit in the management estimates.

Estimate of the provisions for risks and contingent liabilities

The group could be subject to legal and tax disputes regarding a vast range of issues that are subject to the jurisdiction of various countries. Disputes and litigation against the group are subject to a different degree of uncertainty, including the facts and circumstances inherent to each dispute, the jurisdiction and different applicable laws. In the ordinary course of business, management consults its legal consultants and legal and tax experts. The group recognises a liability for such disputes when it is deemed probable that they will result in an outflow of resources and when the amount of the resulting losses can be reasonably estimated. If an outflow of resources is possible but the amount cannot be determined, such fact is disclosed in the notes to the consolidated financial statements.

Employee incentive plans and financial liabilities

Reference is made to section [4.7] for a description of the calculation of the fair value of share-based payments as part of group management incentive plans.

Section [3.16] provides details of the calculation of fair value of the group’s financial liabilities.

[2.4.20] Translation of foreign currency items

The financial statements of each consolidated company are prepared using the functional currency related to the economy where each company operates. Transactions in currencies other than the functional currency are recognised at the exchange rate at the date of the transaction. Foreign currency monetary assets and liabilities are subsequently translated at the closing rate and any exchange differences are taken to profit or loss. Foreign currency non-monetary assets and liabilities recognised at historical cost are translated using the exchange rate at the date of the transaction.

For consolidation purposes, the foreign currency financial statements prepared for consolidation purposes of the consolidated companies are translated using the closing rates for asset and liability captions, including goodwill and consolidation adjustments, and the average rate for the period (if similar to the respective transaction-date rates) or the period under consolidation, if lower, for income statement captions. The relevant exchange differences are taken directly to the statement of comprehensive income and reclassified to profit or loss when control over the investee is lost and, thus, it is deconsolidated.

 

20


[2.4.21] Operating segments

An operating segment is a component of an entity:

 

   

that engages in business activities from which it may earn revenue and incur expenses (including revenue and expenses relating to transactions with other components of the same entity);

 

   

whose operating results are regularly reviewed by the entity’s chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance; and

 

   

for which discrete financial information is available.

Note [4.1] provides information about the single operating segment identified.

[2.4.22.1] New standards and interpretations applicable from 1 January 2023

The amendments to the IFRS adopted during the period included:

 

Document Title

  

Issued Date

  

Effective Date

IFRS 17, ‘Insurance contracts’    December 2021    Annual periods beginning on or after 1 January 2023.
Narrow scope amendments to IAS 1, Practice statement 2 and IAS 8    February 2021    Annual periods beginning on or after 1 January 2023
Amendment to IAS 12 – deferred tax related to assets and liabilities arising from a single transaction    May 2021    Annual periods beginning on or after 1 January 2023
Amendment to IAS 12 - International tax reform - pillar two model rules    May 2021    23 May 2023

There are not any material impact from the application of these amendments.

[2.4.22.2] Other Standards

 

Document Title

  

Issue date by

IASB

  

Effective date of

IASB document

Amendments      
Sale or Contribution of Assets between an Investor and its Associate or Joint Venture (Amendments to IFRS 10 and IAS 28)    September 2014    Deferred until the completion of the IASB project on the equity method
Amendment to IAS 1 – Non-current liabilities with covenants    October 2022    1 January 2024
Amendment to IFRS 16 – Leases on sale and leaseback    September 2022    1 January 2024

 

21


The group will adopt such new standards and amendments, on the basis of the relevant application date, and will assess the potential impacts on the consolidated financial statements. There are not any material impact from the application of these amendments.

[3] Notes to the condensed consolidated interim financial statements

Below are comments on the statement of financial position captions as at 30 September 2023. For details on statement of financial position captions deriving from related party transactions, reference should be made to note [4.5] Related party transactions.

[3.1] Other intangible assets

The carrying amount of other intangible assets at each period is as follows:

 

   

€20,625 thousand at 30 September 2023;

 

   

€58,234 thousand at 31 December 2022;

Changes in other intangible assets between 30 September 2023 and 31 December 2022 and a breakdown of historical cost, accumulated amortisation and any cumulative impairment losses are summarised in the following tables.

 

(€‘000)

 

Description

   31/12/2022
Restated
     Exchange
Difference
    Increases      Reclassifications     Decreases     Amortization     30/09/2023  

Development expenditure

     37,118        (548     1,837        —        (35,492     (508     2,407  

Industrial patents and intellectual property rights

     2,208        (0     198        —        (0     (273     2,133  

Concessions, licences, trademarks and similar rights

     5,900        38       856        26       (150     (2,434     4,236  

Assets under development and payments on account

     12,507        (400     747        (26     (1,272     —        11,556  

Other

     500        (9     13        —        (112     (99     293  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

TOTAL

     58,234        (919     3,651        —        (37,026     (3,314     20,625  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

 

(€‘000)

 
     30/09/2023  

Description

   Historical Cost      Accumulated
Amortization
     Carrying
amount
 

Development expenditure

     3,548        1,141        2,407  

Industrial patents and intellectual property rights

     3,739        1,606        2,133  

Concessions, licences, trademarks and similar rights

     20,265        16,030        4,236  

Assets under development and payments on account

     11,556        —         11,556  

Other

     1,615        1,323        293  
  

 

 

    

 

 

    

 

 

 

TOTAL

     40,724        20,099        20,625  
  

 

 

    

 

 

    

 

 

 

Intangible assets with an indefinite useful life only comprise goodwill, while the other assets (development expenditure, industrial patents and intellectual property, concessions, licences, trademarks and similar rights, other intangible assets and assets under development and payments on account) all have a finite life. More information on each item is provided below.

Capitalized development expenditure amounts to €2,407 thousand at 30 September 2023 compared to €37,118 thousand at 31 December 2022. The significant decrease is mainly due to the write-off, made in the first nine months of 2023, of developments costs related to TechMah business, as consequence of the interruption of the project and the subscription of a new partnership with a software supplier on shoulder preoperative planning.

The decision to interrupt the project was formalized by an internal communication issued on 7 July 2023 by the new CEO, who was appointed on 12 September 2022, after investing several months in reviewing the pre-existing technologies strategy and consequently re-defining the strategy for 2023 and further years. See also [4.8] Events after the reporting date.

 

22


Industrial patents and intellectual property rights, amounting to € 2,133 thousand and €2,208 thousand at 30 September 2023 and 31 December 2022, respectively, are comprised of costs incurred by Limacorporate S.p.A. to acquire patents in half of 2023 and previous period.

Concessions, licences, trademarks and similar rights amounting to €4,236 thousand and €5,900 thousand at 30 September 2023 and 31 December 2022, respectively. The amount is mainly referred to the parent cost to register Lima products on the European, US, Chinese, Korean and Japanese markets.

Assets under development and payments on accounts, amounting to €11,556 thousand and €12,507 thousand at 30 September2023 and 31 December 2022, respectively.

[3.2] Goodwill

Goodwill amounts to €384,268 thousand and €384,216 thousand at 30 September 2023 and 31 December 2022, respectively.

Pursuant to IAS 36, goodwill is not subject to amortisation, but is tested for impairment at least annually or more frequently if events or circumstances indicate that it might be impaired. With regard to testing goodwill for impairment, the group identified a two operating CGUs for its operations, one for the Group except TechMah (“Group CGU”) and one related to TechMah.It considered the sources of information set out by IAS 36 such as the fact that management monitors the group’s performance and takes strategic decisions about its product offering and investments at group level.

The goodwill recognised in Limacorporate condensed consolidated interim financial statements in relation to the above- mentioned merger, together with other items of goodwill, was tested for impairment as at 31 December 2022. Specifically, the recoverable amount of the group’s assets was calculated by estimating their fair value and comparing it with the carrying amount of consolidated net invested capital at 31 December 2022 in order to examine whether recognised amounts had to be impaired.

At 30 September 2023 management evaluated that there are no indicators of triggering events which required to update the impairment test of Group CGU performed at 31 December 2022. In the context of the acquisition of Limacorporate Group by Enovis, the enterprise value shows the full recoverability of goodwill (25 September 2023 public information are available on Enovis Corporation website: “€800 million transaction includes a cash payment of €700 million at closing, and €100 million in shares of Enovis common stock expected to be issued within 18 months after closing…”).

Given the decision taken in early July by the management to interrupt the Smart Space project, an impairment test of TechMah CGU has been performed and led to the full write-off of the capitalized cost of Techmah CGU at 30 September 2023. See also [3.1] Other intangible assets.

[3.3] Property, plant and equipment

The carrying amount of property, plant and equipment and other assets at each period end is as follows:

 

   

€77,173 thousand at 30 September 2023;

 

   

€79,837 thousand at 31 December 2022.

 

23


Changes in property, plant and equipment assets between 30 September 2023 and 31 December 2022 and a breakdown of historical cost, accumulated amortisation and any cumulative impairment losses are summarised in the following tables:

 

(€‘000)

 

Description

   31/12/2022
Restated
     Exchange
Difference
    Increases      Reclassifications     Decreases     Other
changes
    Depreciation     30/09/2023  

Land and buildings

     15,496        —        119        —        —        —        (514     15,102  

Leased land and buildings

     6,755        (46     1,035        —        —        (143     (2,775     4,825  

Plant and equipment

     16,416        5       1,270        118       —        —        (3,062     14,746  

Leased plant and equipment

     79        0       —         —        —        —        (12     67  

Industrial and commercial equipment

     34,674        (222     10,340        45       (657     —        (11,715     32,465  

Leased industrial and commercial equipment

     19        (0     45        —        —        —        (15     49  

Other assets

     1,787        (17     475        —        (31     —        (484     1,730  

Other leased assets

     2,299        (23     1,116        —        0       (14     (1,081     2,298  

Assets under construction and payments on account

     2,311        (0     3,743        (163     —        —        —        5,891  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

TOTAL

     79,837        (304     18,142        —        (687     (157     (19,659     77,173  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

(€‘000)

 

Description

   30/09/2023  
   Historical
Cost
     Accumulated
Depreciation
     Accumulated
Impairment

Losses
     Carrying
amount
 

Land and buildings

     23,990        8,888        —         15,102  

Leased land and buildings

     17,458        12,632        —         4,825  

Plant and equipment

     60,532        45,786        —         14,746  

Leased plant and equipment

     202        134        —         67  

Industrial and commercial equipment

     144,966        112,067        434        32,465  

Leased industrial and commercial equipment

     74        25        —         49  

Other assets

     8,290        6,560        —         1,730  

Other leased assets

     5,330        3,032        —         2,298  

Assets under construction and payments on account

     5,891        —         —         5,891  
  

 

 

    

 

 

    

 

 

    

 

 

 

TOTAL

     266,732        189,124        434        77,173  
  

 

 

    

 

 

    

 

 

    

 

 

 

Land and building, amounting to €15,102 thousand at 30 September 2023 and €15,496 thousand at 31 December 2022. The decrease occurred during the first nine months of 2023 is mainly due to the amortization effect.

Plant and equipment, amounting to €14,746 thousand at 30 September 2023 and €16,416 thousand at 31 December 2022. The decrease in plant and equipment during the first nine months of 2023 mainly refers to the amortization effect. The investments of €1,270 thousand refer to the acquisition of production machines.

Industrial and commercial equipment amounting to €32,465 thousand and €34,674 thousand at 30 September 2023 and 31 December 2022, respectively and is chiefly comprised of equipment capitalised during the current and previous years. The decrease of €657 thousand is mainly due to write-off of obsoleted instrument sets.

Other assets amounting to €1,730 thousand and €1,787 thousand at 30 September 2023 and 31 December 2022, respectively. This category includes office furniture and machines, electronic office machines, transport vehicles and cars. Investments, during the first nine months of 2023 amounting to €475 thousand refer to purchases of electronic office machines and furniture.

Asset under construction amounting to €5,891 thousand and €2,311 thousand at 30 September 2023 and 31 December 2022, respectively. The increase in assets under construction and payments on account during 2023 is mainly due to costs incurred to expand the Villanova production facility and for the purchase of production equipment and machinery.

Some plant and equipment are subject to a special lien at the reporting dates. Additional information is provided in note [3.16] Current and non-current financial liabilities.

 

24


Changes in right-of-use assets deriving from the application of IFRS 16 are set out in the following tables, where such changes are shown for each asset category along with details on the historical cost and accumulated depreciation:

 

(€‘000)

 

Description

   31/12/2022
Restated
     Exchange
Difference
    Increases      Decreases      Other
changes
    Depreciation     30/09/2023  

Right-of-use assets

                 

Leased land and buildings

     6,755        (46     1,035        —         (143     (2,775     4,825  

Leased plant and equipment

     79        0       —         —         —        (12     67  

Leased industrial and commercial equipment

     19        (0     45        —         —        (15     49  

Other leased assets

     2,299        (23     1,116        0        (14     (1,081     2,298  
  

 

 

    

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

TOTAL

     9,153        (69     2,195        0        (157     (3,883     7,239  
  

 

 

    

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Lease liabilities deriving from the application of IFRS 16 are included under current and non-current financial liabilities (analysed in note [3.16] Current and non-current financial liabilities). Changes in current and non-current lease liabilities between 30 September 2023 and 31 December 2022 are set out below:

 

(€‘000)

 

Description

   31/12/2022
Restated
     Exchange
Difference
    Increases      Decreases     Other
changes
    Reclassifications     30/09/2023  

Lease liabilities as per IFRS 16 - non-current portion

     4,552        (6     2,194        (605     (157     (1,474     4,504  

Lease liabilities as per IFRS 16 - current portion

     3,265        (63     1        (2,758     —        1,474       1,920  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

TOTAL

     7,817        (68     2,195        (3,363     (157     —        6,424  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

The decrease in lease liabilities of current portion of €2,758 thousand refers to the payments of the period.

The increase of €2,194 thousand refers for about €700 thousand to new offices in Germany and for about €1,494 to other assets.

[3.4] Equity investments

Equity investments amount to €2 thousand as at 30 September 2023 and no changes in the caption occurred compared to 31 December 2022.

The following information is provided on direct and indirect equity investments in subsidiaries, associates and other companies.

Subsidiaries

On 1 January 2023, the subsidiary TechMah Medical LLC was merged by incorporation into the subsidiary Lima USA Inc.

Other companies

Equity investments in other companies amount to €2 thousand and refer to CAAF Interregionale dipendenti S.r.l., Consorzio Friuli Energia, Terra degli Elimi and CE.R.ME.T..at 30 September 2023.

[3.5] Deferred tax assets and liabilities

Deferred tax assets and liabilities are only offset when there is a legal provision within the same tax jurisdiction. The group recognised deferred tax assets and liabilities on the temporary differences between carrying amounts and tax bases. The latter were calculated using the rates ruling when the temporary differences will reverse in the different countries where the group operates.

 

25


Deferred tax assets and liabilities are broken down as follows on 30 September 2023 and 31 December 2022:

 

(€‘000)

 

Description

   30/09/2023      31/12/2022
Restated
     Variation  

Deferred tax assets

     12,681        11,558        1,123  

Deferred tax assets arising on consolidation

     20,641        20,151        490  
  

 

 

    

 

 

    

 

 

 

TOTAL

     33,322        31,709        1,613  
  

 

 

    

 

 

    

 

 

 

 

(€‘000)

 

Description

   30/09/2023      31/12/2022
Restated
     Variation  

Deferred tax liabilities

     8,713        9,414        (701

Deferred tax liabilities arising on consolidation

     560        9,861        (9,301
  

 

 

    

 

 

    

 

 

 

TOTAL

     9,273        19,275        (10,002
  

 

 

    

 

 

    

 

 

 

[3.6] Other non-current financial assets

Other non-current financial assets amounting to €940 thousand at 30 September 2023. The amount refers to fair value of Interest Rate Swap at 30 September 2023 subscribed in first nine months of 2023 as described in note [3.17] Derivatives.

[3.7] Other non-current assets

Other non-current assets, amounting to:

 

   

€958 thousand at 30 September 2023;

 

   

€861 thousand at 31 December 2022.

Refer to guarantee deposits, mainly for rental contracts taken out by the group.

[3.8] Inventories

A breakdown of inventories at 30 September 2023 and 31 December 2022 is provided below:

 

(€‘000)

 

Description

   30/09/2023      31/12/2022
Restated
     Variation  

Raw materials and supplies

     6,755        6,272        483  

Work in progress and semi-finished products

     11,996        11,533        463  

Finished goods

     83,509        79,583        3,926  

Goods in transit

     1,166        831        335  

Allowance for inventory write-down

     (12,393      (11,492      (901
  

 

 

    

 

 

    

 

 

 

TOTAL

     91,033        86,727        4,306  
  

 

 

    

 

 

    

 

 

 

Inventories were measured using the cost of the production company for the consolidated companies.

The allowance for inventory write-downs, amounting to €12,393 thousand at 30 September 2023 and €11,492 thousand at 31 December 2022, changed as follows during the period:

 

(€‘000)

 

Description

   Amount  

Balance at 31/12/2022 restated

     11,492  

Exchange difference

     46  

Utilisations

     (795

Accruals

     1,651  
  

 

 

 

Balance at 30/09/2023

     12,393  
  

 

 

 

Utilisations of the allowance during the first nine months of 2023 is mainly referred to the scrapping of obsolete goods by Limacorporate S.p.A. and the accruals done by the subsidiaries and Limacorporate S.p.A..

 

26


[3.9] Trade receivables

Trade receivables at 30 September 2023 amount to €72,829 thousand, compared to €70,161 thousand at 31 December 2022, and are broken down as follows:

 

(€‘000)

 

Description

   Gross
Amount
     Loss
allowance
     Carrying Amount
31/12/2022

restated
 

Trade receivables - third parties

     72,527        2,387        70,140  

Trade receivables - related parties

     21        —         21  
  

 

 

    

 

 

    

 

 

 

TOTAL

     72,548        2,387        70,161  
  

 

 

    

 

 

    

 

 

 

 

(€‘000)

 

Description

   Gross
Amount
     Loss
allowance
     Carrying Amount
30/09/2023
 

Trade receivables - third parties

     76,337        3,508        72,829  

Trade receivables - related parties

     0        —         0  
  

 

 

    

 

 

    

 

 

 

TOTAL

     76,337        3,508        72,829  
  

 

 

    

 

 

    

 

 

 

The loss allowance amounts to €3,508 thousand and €2,387 thousand at 30 September 2023 and 31 December 2022, respectively.

The loss allowance is management’s estimate of the expected credit losses on trade receivables from customers. The estimate is based on the group’s expected credit losses, determined using past experience with similar receivables, current and historical overdue amounts, losses and collections, a careful monitoring of credit quality and forecasts of economic and market conditions.

Changes in the loss allowance in 2023 and 2022 are as follows:

 

(€‘000)

 

Description

   30/09/2023  

Balance at 31/12/2022 restated

     2,387  

Exchange difference

     33  

Accruals

     1,233  

Utilisations

     (145
  

 

 

 

Closing balance

     3,508  
  

 

 

 

The utilisations mainly refer to losses related to various positions against small different clients.

[3.10] Current tax assets

Tax assets amounting to €1,386 thousand and €2,087 thousand at 30 September 2023 and 31 December 2022, respectively and include direct taxes, particularly in relation to the parent’s IRES for €463 thousand and €1,619 thousand at 30 September 2023 and 31 December 2022, respectively.

 

27


[3.11] Other current assets

Other current assets amounting to €13,928 thousand and €14,192 thousand at 30 September 2023 and 31 December 2022, respectively, and are broken down as follows:

 

 

(€‘000)

 

Description

   30/09/2023      31/12/2022
Restated
     Variation  

Grants

     5,023        5,281        (258

Advances to suppliers

     1,032        1,327        (295

Advances to agents

     920        776        144  

VAT

     1,377        1,317        60  

VAT to be offset

     949        325        624  

Other tax assets

     221        827        (606

Insurance premiums and sureties

     841        574        267  

Hire and maintenance

     1,213        873        340  

Other sundry

     842        1,354        (512

Other

     1,511        1,538        (27
  

 

 

    

 

 

    

 

 

 

TOTAL

     13,928        14,192        (237
  

 

 

    

 

 

    

 

 

 

Assets for research grants refer mainly to:

 

   

PON-SIB grant (€4,630 thousand at 30 September 2023 and €4,630 at 31 December 2022);

 

   

MCBEES grant (€0 at 30 September 2023 and €258 thousand at 31 December 2022);

 

   

AIM grant (€40 thousand at 30 September 2023 and €40 thousand at 31 December 2022);

 

   

IAREPAM grant (€158 thousand at 30 September 2023 and €158 thousand at 31 December 2022);

 

   

PROST3SIS grant (€195 thousand at 30 September 2023 and €195 thousand at 31 December 2022).

Other assets also include guarantee deposits on gas and electricity consumption (€472 thousand at 30 September 2023 and 31 December 2022).

Hire and maintenance amounting to €1,213 thousand and €873 thousand at 30 September 2023 and 31 December 2022, respectively. The increase is mainly due to prepayments of the new maintenance agreement.

[3.12] Cash and cash equivalents

Cash and cash equivalents amounting to €27,127 thousand and €25,920 thousand at 30 September 2023 and 31 December 2022, respectively.

This caption shows the group’s liquidity at the reporting date.

Reference should be made to the statement of cash flows for an analysis of changes in cash and cash equivalents.

 

(€‘000)

 

Description

   30/09/2023      31/12/2022
Restated
     Variation  

Bank and postal accounts

     27,110        25,903        1,207  

Cash-in-hand and cash equivalents

     17        17        (0
  

 

 

    

 

 

    

 

 

 

TOTAL

     27,127        25,920        1,207  
  

 

 

    

 

 

    

 

 

 

 

28


[3.13] Equity

Equity attributable to the owners of the parent amounts to €316,024 thousand and €306,564 thousand at 30 September 2023 and 31 December 2022, respectively and is broken down as follows:

 

 

(€‘000)

 

Description

   30/09/2023      31/12/2022
Restated
     Variation  

Share capital

     9,868        9,868        0  

Share premium reserve

     14,425        14,425        0  

Legal reserve

     2,101        2,101        (0

Capital contributions

     74,347        28,051        46,296  

Merger reserve

     288,261        288,261        0  

Actuarial reserve

     31        31        0  

Translation reserve

     3,007        2,379        628  

Other reserves

     13,003        2,687        10,316  

Retained earnings (losses carried forward)

     (41,236      (21,966      (19,270

Loss for the year

     (47,784      (19,273      (28,511
  

 

 

    

 

 

    

 

 

 

Equity

     316,024        306,564        9,460  
  

 

 

    

 

 

    

 

 

 

Parent’s share capital at 30 September 2023 and 31 December 2022 is €9,868 thousand and is fully subscribed and paid up. It comprises of €9,868 thousand ordinary shares without a nominal amount.

The share premium reserve amounts to €14,425 thousand and it is unchanged during the period.

Legal reserve amount to €2,101 thousand at 30 September 2023 and €2,101 thousand at 31 December 2022. This reserve is not distributable. Merger reserve, amounting to €288,261 thousand at 30 September 2023 and 31 December 2022 and no changes during the period under analysis, comprises the effects of the reverse merger between the parent and Emil Holding III S.p.A. in October 2016 on equity.

Capital contribution for capital amounting to € 74,347 thousand at 30 September 2023 and € 28,051 thousand at 31 December 2022.

The transactions that affected this caption are summarised below:

 

  a.

€4,963 thousand for the contribution in kind made in 2021 by the shareholder for the acquisition of TechMah Medical.

The contribution in kind is directly related to the shared-based payment of certain milestones regarding the acquisition of TechMah Medical. Under the agreement signed in 2018, the subsidiary Lima USA allocated the founding shareholders of TechMah Medical a set number of new EmilNewCo Sarl (indirect parent of Limacorporate S.p.A. with a 100% interest) shares upon reaching set targets regarding the development of new products benefiting the group.

The above-mentioned allocation of shares in October 2021 led to a share capital increase for EmilNewCo and the recognition of an amount due from the founding shareholders of TechMah Medical equal to the liability recognised by Lima USA for the contractual milestones to be settled. The two transactions between the founding shareholders of Techmah Medical and Lima Group (EmilNewCo Sarl, Limacorporate S.p.A. and Lima USA) have been offset using claim notes, which generated the capital injection referred to above.

 

  b.

capital injection by the shareholder of €20,000 thousand in June 2020.

 

  c.

€3,088 thousand for the agreement with HSS (Hospital for Special Surgery). On 4 January 2019, Lima USA and HSS (the operator of the most prestigious US orthopaedic surgery hospital in New York) signed a collaboration agreement for the production of implants on hospital grounds, via the following agreements:

 

  I.

a six-year lease for the premises where Lima USA will produce the implants for HSS, of which payment for the first three years have been made by awarding HSS a fixed number of new Emil NewCo shares and the second three years will be paid by monthly instalments;

 

  II.

a supply contract which establishes that HSS will bear the cost of any leasehold improvements made by Lima USA and will receive a set number of new Emil NewCo shares in return.

The accounting effects of the above transaction with HSS are as follows:

 

   

recognition of other right-of-use assets for €1,793 thousand, lease liabilities of €875 thousand and other reserves of €918 thousand.

 

29


   

recognition of greater leasehold improvement costs of €2,170 thousand with a balancing increase of €2,170 thousand in other reserves.

 

  d.

Capital injection by the shareholder of €46,296 thousand in February 2023.

Actuarial reserve was set up as a result of application of IAS 19 for post-employment benefits and has a positive balance of €31 thousand at 30 September 2023 and 31 December 2022, respectively.

Translation reserve, with a positive balance of €3,007 thousand at 30 September 2023 and €2,379 thousand at 31 December 2022, reflects the changes in the group’s share of the equity of consolidated companies due to changes in exchange rates of such companies’ functional currencies compared to the presentation currency of the condensed consolidated interim financial statements.

The main items making up the other reserves are as follows:

 

   

the revaluation reserve, which arose from the merger of Lima S.p.A., amounts to €111 thousand and is recognised in compliance with Law no. 413 of 30 December 1991 in relation to deferred tax on the revalued amount of land and industrial buildings. There were no changes in the reserve during the three-year period.

 

   

the IFRS 2 reserve amounting to €15,028 thousand and €4,650 at 30 September 2023 and 31 December 2022, respectively, deriving from the accounting treatment of cash-settled share-based payment and equity-settled share-based payment arrangements, due to a new incentive plan signed by the company during the third part of 2022;

 

   

other sundry reserves of €1,764 thousand and €1,987 thousand at 30 September 2023 and 31 December 2022, respectively.

Retained earnings (losses carried forward) amount to a negative net balance of €41,236 thousand at 30 September 2023 and €21,966 thousand at 31 December 2022.

The following supplementary information is provided on the parent’s reserves:

1) Reserves or other provisions that do not contribute to the taxable profit of shareholders in the event of distribution regardless of when they are formed.

 

(€‘000)

 
     30/09/2023      31/12/2022
Restated
 

Emil Holding III merger reserve

     288,261        288,288  

Capital injections for capital increase

     74,347        28,051  

Share premium reserve

     14,425        14,425  
  

 

 

    

 

 

 

TOTAL

     377,033        330,764  
  

 

 

    

 

 

 

2) Reserves or other provisions that do contribute to the taxable profit of the parent in the event of distribution regardless of when they are formed.

 

(€‘000)

 
     30/09/2023      31/12/2022
Restated
 

Revaluation reserve as per Law no. 413/1991

     111        111  
  

 

 

    

 

 

 

TOTAL

     111        111  
  

 

 

    

 

 

 

 

30


  3)

Reserves included in share capital.

Reserves or other provisions that do contribute to the taxable profit of shareholders in the event of distribution, irrespective of when they were set up, for a free share capital increase by using the reserve as per the shareholders’ resolution of 15 October 1999.

 

(€‘000)

 
     30/09/2023      31/12/2022
Restated
 

Extraordinary reserve

     540        540  
  

 

 

    

 

 

 

TOTAL

     540        540  
  

 

 

    

 

 

 

[3.14] Provisions for risks and charges

Details of this caption and changing between 30 September 2023 and 31 December 2022 are set out below.

 

(€‘000)

 

Description

   31/12/2022
Restated
     Exchange
Difference
    Increases      Decreases     Reclassifications      30/09/2023  

Pension and similar provisions

     584        (0     183        —        —         768  

Other provisions

     16,572        1       12,675        (542     —         28,705  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 

TOTAL

     17,156        1       12,858        (542     —         29,473  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 

Agents’ termination indemnity (€768 thousand and €584 thousand at 30 September 2023 and 31 December 2022, respectively) is the estimated liability deriving from the application of ruling legislation and the contractual clauses in relation to the termination of agency contracts. Unlike accruals to the provision for risks, warranties and other provisions, accruals to agents’ termination indemnity are classified by nature among costs for services.

Other provisions, amounting to €28,705 thousand and €16,572 thousand at 30 September 2023 and 31 December 2022 respectively, are mainly comprised as follows:

 

   

the provision for charges of €1,521 thousand and €1,859 thousand at 30 September 2023 and 31 December 2022, respectively, of which €1,521 thousand and €1,460 thousand related to commission expense on revenue yet to be invoiced, €nil thousand and €nil thousand related to highly probable consultancy success fees the payment date of which is not yet known, both respectively at 30 September 2023 and 31 December 2022 and €nil thousand at 30 September 2023 and €399 thousand at 31 December 2022 related to highly probable non- competition agreements the payment date of which is not yet known;

 

   

The provision related to the payback system €17,774 thousand that increases from the prior period for an amount equal to €3,457 thousand;

 

   

compensation for damage caused by products of €545 thousand and €300 thousand at 30 September 2023 and 31 December 2022, respectively.

 

   

The provision of €8,533 thousand for some claims arose during the year

The market in which the Group operates is strictly controlled by laws and regulations such as, e.g., the EU Medical Devices Regulation (‘MDR’) in Europe and the Federal Food, Drug and Cosmetic Act (‘FDCA’) in USA. In order to demonstrate adherence to regulatory requirements and to maintain the ability to sell its products, the Group must obtain and maintain authorisations and certifications from the relevant authorities. Discussions are currently underway with the Australian authority, the Therapeutic Goods Administration (the ‘TGA’), which has been provided with clarification regarding an observation made by the TGA on the high revision rate of certain elements of the ‘SMR’ shoulder solution.

[3.15] Employee benefits

Employee benefits amounts to €1,258 thousand and €1,296 thousand at 30 September 2023 and 31 December 2022, respectively.

 

31


At 30 September 2023 this item mainly consists of post-employment benefits due upon termination of employment pursuant to current legislation in Italy. The actuarial model used to measure Italian post-employment benefits (“TFR”) is based on the same assumptions previously used for measurement at 31 December 2022, illustrated in the notes to the consolidated financial statements at 31 December 2022, to which reference should be made, as there were no significant changes in the demographic or economic assumptions underlying the actuarial calculation in the half of 2023 and 2022, respectively.

 

(€‘000)

 

Description

   30/09/2023      31/12/2022
Restated
     Variation  

Balance at 1 January

     1,296        1,442        (146

Exchange difference

     (32      (13      (19

Benefits settled/advances paid

     (183      (189      6  

Accruals

     1,393        1,716        (323

Cometa Fund, other pension funds

     (1,226      (1,599      373  

Post-employment benefits — Substitute tax on revaluation

     9           9  

Interest

     —         10        (10

Actuarial gain

     —         (71      71  
  

 

 

    

 

 

    

 

 

 

TOTAL

     1,258        1,296        (38
  

 

 

    

 

 

    

 

 

 

[3.16] Current and non-current financial liabilities

Non-current financial liabilities, amounting to €285,597 thousand at 30 September 2023 and €10,165 at 31 December 2022, comprise the portion of loans and borrowings due after one year and are broken down as follows:

 

(€‘000)

 

Description

   30/09/2023      31/12/2022
Restated
     Variation  

Non-current bank loans and borrowings

     191        363        (172

Non-current bank loans and borrowings (due after five years)

     2        2        0  

Bonds

     280,635        —         280,635  

Other financial liabilities

     —         5,248        (5,248

Derivatives

     265        —         265  

Lease liabilites as per IFRS 16

     4,504        4,552        (48
  

 

 

    

 

 

    

 

 

 

TOTAL

     285,597        10,165        275,432  
  

 

 

    

 

 

    

 

 

 

Derivatives, amounting to €265 thousand at 30 September 2023, refer to fair value of Interest Rate Cap subscribed in first nine months of 2023 as described in note [3.17] Derivatives.

 

32


Current financial liabilities, amounting to €20,102 thousand at 30 September 2023 and €336,659 at 31 December 2022, comprise the current portion of loans and borrowings and are broken down as follows:

 

(€‘000)

 

Description

   30/09/2023      31/12/2022
Restated
     Variation  

Credit cards

     454        383        71  

Current bank loans and borrowings

     12,000        54,000        (42,000

Bank loans and borrowings - current portion

     301        386        (85

Bonds - current portion

     —         274,039        (274,039

Accrued expenses on bonds - due within one year

     4,977        1,979        2,998  

Accrued financial expense - due within one year

     265        298        (33

Loans and borrowings with other financial backers

     185        2,310        (2,125

Lease liabilites as per IFRS 16

     1,920        3,265        (1,345
  

 

 

    

 

 

    

 

 

 

TOTAL

     20,102        336,660        (316,558
  

 

 

    

 

 

    

 

 

 

Current financial liabilities chiefly include the bond issued by Limacorporate S.p.A. in 2017 equal to €0 thousand and €274,039 thousand at 30 September 2023 and 31 December 2022, respectively, related to senior secured bonds redeemable in 2023 for a total nominal amount of €275 million. The bonds were initially recognised at fair value, net of directly related costs, and measured at amortised cost applying the effective interest rate method.

The bonds have coupons based on the 3-month Euribor plus a 3.75% spread, with a Euribor floor threshold of 0.00%. They are listed on the Euro MTF market of the Luxembourg Stock Exchange and the professional section of the ExtraMOT market of the Italian Stock Exchange.

The coupons mature every three months on 15 February, 15 May, 15 August and 15 November each year starting from 15 November 2017.

The following guarantees were issued in relation to the bonds:

 

   

pledge on the shares of Limacorporate S.p.A.;

 

   

pledge on the shares of some subsidiaries;

 

   

pledge on some of the current accounts of the parent and some subsidiaries;

 

   

special lien on plant, equipment and other items of property, plant and equipment of the parent;

 

   

lien on certain categories of assets of some subsidiaries;

 

   

guarantees on some categories of assets of the parent and some subsidiaries.

In relation to the refinancing put in place in 2017, as well as the issue of bonds, Limacorporate also finalised an agreement for a new super senior revolving credit facility for a maximum of €60 million. It may also be used partially, in several instalments with set repayment terms. If the financial covenants are complied with, the interest rate is the same as the bond, i.e., 3-month Euribor plus a 3.75% spread, with a Euribor floor threshold of 0.00%.

The same guarantees provided for the issue of the bonds were granted for this revolving credit facility; specifically:

 

   

pledge on the shares of Limacorporate S.p.A.;

 

   

pledge on the shares of some subsidiaries;

 

   

pledge on some of the current accounts of the parent and some subsidiaries;

 

   

special lien on plant, equipment and other items of property, plant and equipment of the parent;

 

   

lien on certain categories of assets of some subsidiaries;

 

   

guarantees on some categories of assets of the parent and some subsidiaries.

€54 million was used at 31 December 2022.

If more than 35% (as explained in financing agreement) of the available amount of the revolving facility is used (i.e., draw- downs exceeding €21 million), a covenant related to the ratio of “Super Senior Net Debt” (represented by the utilization of the revolving facility less cash and cash equivalents) and consolidated EBITDA which cannot exceed 1.83, is activated under the terms of the contract. Such covenant was complied with at 31 December 2022.

On 3 February 2023, the parent issued new senior secured bonds redeemable in February 2028 for a total nominal amount of €295 million. In addition to the bond issue, the parent also signed a new super senior revolving facility for a maximum of €65 million expiring in November 2027 (used for €12 million at 30 September 2023).

 

33


On 9 March 2023, the parent privately placed additional notes with the same terms and conditions as the bonds, for an amount of €15 million.

The pre-existing bonds and super senior revolving facility were fully redeemed and repaid.

The bonds have coupons based on the 3-month Euribor plus a 5.75% spread, with a Euribor floor threshold of 0.00%. They are listed on the Euro MTF market of the Luxembourg Stock Exchange.

The completion of the refinancing also saw a significant capital injection of €46,295 thousand by the parent’s shareholder.

A covenant exists on the new revolving facility similar, whereby if more than 40% (as explained in financing agreement) of the available amount of the revolving facility is used (i.e., draw-downs exceeding €26 million), a covenant related to the ratio of “Super Senior Net Debt” (represented by the utilization of the revolving facility less cash and cash equivalents) and consolidated EBITDA which cannot exceed 1.53, is activated under the terms of the contract. Such covenant was not tested as at 30 September 2023 since the testing condition had not been met.

Non-current financial liabilities (“Other current financial liabilities”) and current financial liabilities (“Other loan and borrowing”) also include liabilities for the purchase of business units related to the amount due in 2024 for the acquisition of a business unit from the group’s Sicilian distributor. The non-current amount is €nil at 30 September 2023 and €185 thousand at 31 December 2022. The current amount is €185 thousand at 30 September 2023 and €nil at 31 December 2022.

The caption also includes the non-current portion of the medium/long-term loans taken out by the parent for the SICAT and IAREPAM projects and by some branches in relation to the relief available for the Covid-19 pandemic, detailed as follows (residual amount includes current and no current portion of medium/long- term loans):

 

(€‘000)

Company

  

Description

   Original
amount
    

Rate

  

Expiry date

   Residual
amount at

30/09/2023
    

Guarantee

Limacorporate S.p.A.

  

SICAT sustainable growth fund 1st progress report

     274      Fixed    30/06/2026      105      None

Limacorporate S.p.A.

  

SICAT sustainable growth fund 2nd progress report

     339      Fixed    30/06/2026      138      None

Limacorporate S.p.A.

  

Sustainable grow th fund “Project IAREPAM - Artificial Intelligence for the Efficient Development of an Implant in Additive Manufacturing” 1st progress report

     6      Fixed    30/06/2031      6      None

Lima France

  

Covid-19 subsidised loan

     500      Fixed    31/05/2024      171      Government guarantee

Lima Austria

  

Covid-19 subsidised loan

     200     

0% until August 2022, then a

floating loan

   31/12/2024      75      None
     

 

 

          

 

 

    

Total

        1,319              495     
     

 

 

          

 

 

    

Current and non current bank loan and borrowing include the group medium-long term loans that are explained in part also in the table above and are the follows:

 

   

subsidised loan of €500 thousand granted by BNP Paribas to Lima France in May 2020 to be used to offset the negative economic effects of the Covid-19 pandemic. The interest subsidised rate was 0.45%; The residual amount at 30 September 2023 is €171.

 

   

subsidised loan of €200 thousand granted by Unicredit Bank of Austria to Lima Austria in August 2020. Like the above loans, the Austrian group company applied for this loan to offset the negative economic effects of the Covid-19 pandemic. The subsidised interest rate applied is 0.00% until August 2022 after which it will be the 3M Euribor + 0.75%; The residual amount at 30 September 2023 is €75 thousand.

Accrued financial expense and accrued expenses on bonds due within one year include interest accrued at each reporting date and not yet paid.

Other financial liabilities (non-current) and Other loans and borrowings (current)—include mainly the amounts yet to be paid in relation to the acquisition of TechMah Medical LLC (contingent consideration).

On 18th September 2023 the company was served a Complaint filed by the founding shareholders of TechMah Medical (“TechMah Founders”) versus Lima USA Inc. and Limacorporate S.p.A. for alleged breach of contract based on the milestones set out in the Investor and Founders Agreement entered into by TechMah Medical LLC, TechMah Founders, Lima USA Inc., and Limacorporate S.p.A. on 8th October 2021.

 

34


The Complaint contains high level allegations that Lima USA, Inc. and Limacorporate S.p.A. breached the Investor and Founders Agreement (“I&F Agreement”) by not using their “reasonable best efforts” to achieve some Regulatory Milestones and by failing to pay out certain Commercial Milestones the Founders assume have been met.

On 20th November 2023 the company filed a motion to dismiss, stating that Lima did not breach the I&F Agreement and has no liability to Plaintiffs.

On 22nd December 2023 the company was served an Amended Complaint by the TechMah Founders, which reiterated their previous allegations.

The company has filed a Defendants’ Answer To Verified Amended Complaint and Defendants Counterclaims which contains a request for compensatory damages in an amount to be determined at trial, but not less than $ 50 million.

As the matter is now going to be addressed by the court there is no contingent consideration to be recorded as a financial liability in the financial statements as at 30th September 2023. In view of these recent events and also based on the support of legal counsel, a certain amount has been provided together with other claims.

Finally, financial liabilities include lease liabilities deriving from the application of IFRS 16. The discount rate applied at 30 September 2023 and 31 December 2022 was revised and modified to take into consideration the higher interest rates compared to previous years.

Changing in the caption between 30 September 2023 and 31 December 2022 are set out below:

 

(€‘000)

 

Description

   31/12/2022
Restated
     Exchange
Difference
    Increases      Decreases     Other changes     Reclassifications     30/09/2023  

Lease liabilities as per IFRS 16 - non-current portion

     4,552        (6     2,194        (605     (157     (1,474     4,504  

Lease liabilities as per IFRS 16 - current portion

     3,265        (63     1        (2,758     —        1,474       1,920  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

TOTAL

     7,817        (68     2,195        (3,363     (157     —        6,424  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

Lease liabilities are detailed by due dates as follows:

 

(€‘000)

 

Descrizione

   30/09/2023      31/12/2022
Restated
 

Current liabilities - due within one year

     1,920        3,265  

Non-current liabilities - due from one to five years

     4,317        3,997  

Non-current liabilities - due after five years

     187        555  
  

 

 

    

 

 

 

TOTAL

     6,424        7,817  
  

 

 

    

 

 

 

[3.17] Derivatives

The derivatives refer to the interest rate swap and to the interest rate cap signed to hedge the bond issued in the first nine months of 2023.

The fair value of interest rate cap at 30 September 2023 is negative for €265 thousand and is included in non-current financial liabilities. The fair value of interest rate swap at 30 September 2023 is positive for €940 thousand and is included in non-current financial assets.

The derivatives are not listed. Therefore, their fair value is measured using financial techniques and compared to the counterpart’s measurement.

Although the derivatives were subscribed for hedging purposes, the Company decided not to apply hedge accounting, therefore fair value gains or losses on the derivative are recognized in profit or loss.

 

35


[3.18] Other non-current liabilities

Other non-current liabilities, amounting to €870 thousand and €649 thousand at 30 September 2023 and 31 December 2022 respectively and include incentive plans for some managers (€230 thousand and €73 thousand at 30 September 2023 and 31 December 2022, respectively) and the non-current portion of deferred income (€210 thousand and €221 thousand at 30 September 2023 and 31 December 2022, respectively), chiefly related to insurance costs.

The significant decrease during the half of 2022 is referred to the step down from the role of CEO which led to the partial liquidation of the VSP, and the remained part was reclassified on other liabilities (see paragraph [3.21]).

Reference should be made to note [4.7] Management Incentive plans for further information about such plans.

[3.19] Trade payables

Trade payables amount to €33,405 thousand and €36,564 thousand at 30 September 2023 and 31 December 2022 respectively and refer to short-term obligations to suppliers of goods and services. They refer to positions payable in the short term and there are no amounts due after one year.

There are no differences between the carrying amount and fair value of such payables.

Trade payables do not accrue interest. The terms and conditions for related parties do not differ from those applied for third party suppliers.

 

(€‘000)

 

Description

   30/09/2023      31/12/2022
Restated
 

Trade Payables

     33,143        36,214  

Payables to subsidiaries

     —         —   

Payables to parents

     262        350  
  

 

 

    

 

 

 

TOTAL

     33,405        36,564  
  

 

 

    

 

 

 

[3.20] Current tax liabilities

Tax liabilities amount to €1,917 thousand and €877 thousand at 30 September 2023 and 31 December 2022, respectively. Specifically, the caption is comprised of the parent’s IRAP payable (€1,093 thousand at 30 September 2023) while the remainder refers to current taxes payable by all of the foreign branches (€824 thousand at 30 September 2023).

 

36


[3.21] Other current liabilities

Other current liabilities are broken down in the following table. The main liabilities refer to payments on account, tax liabilities, social security charges payable and amounts due to employees:

 

(€‘000)

 

Description

   30/09/2023      31/12/2022
Restated
     Variation  

Wages and salaries

     1,910        1,848        62  

Employee and performance bonus

     9,619        8,911        708  

Directors’ fees

     411        302        109  

Statutory auditors’ fees

     53        34        19  

Liabilities for the purchase of business units

     194        194        0  

Payables to factors for collections received

     44        7        37  

Foreign commissions

     —         4        (4

Sundry other liabilities

     2,233        1,034        1,199  

Payments on account

     4,767        4,380        387  

IRPEF withholdings

     903        1,241        (338

Other tax liabilities

     351        1,852        (1,501

VAT

     2,138        1,280        858  

INPS - Inpdai - Previndai

     2,118        2,390        (272

INAIL

     37        19        18  

Cometa Fund and other pension funds

     280        292        (12

Enasarco for agents

     116        181        (65

Other social security charges payable

     377        612        (235

Accrued expenses:

        

Insurance premiums

     2        5        (3

Interests on non-current loans

     1        —         1  

Other sundry

     102        80        22  

Deferred income:

        

Grants related to assets

     19        72        (53

Rent

     0        1        (1

Other sundry

     —         3        (3
  

 

 

    

 

 

    

 

 

 

TOTAL

     25,673        24,742        931  
  

 

 

    

 

 

    

 

 

 

Payments on account amount to €4,767 thousand and €4,380 thousand at 30 September 2023 and 31 December 2022, respectively include the following:

 

   

PON SIB grant advance of €3,773 thousand, unchanged on the previous period;

 

   

MC BEES grant advance of €nil thousand at 30 September 2023 and €249 thousand at 31 December 2022;

 

   

PROST3SIS grant advance of €196 thousand at 30 September 2023 and €nil thousand at 31 December 2022;

 

   

IAREPAM grant advance of €11 thousand at 30 September 2023 and 31 December 2022;

 

   

LOGIN grant advances received from customers of €127 thousand and €nil thousand at 30 September 2023 and 31 December 2022 respectively;

 

   

advances received from customers of €354 thousand and €231 thousand at 30 September 2023 and 31 December 2022 respectively;

 

   

other payments on account of €306 thousand and €116 thousand at 30 September 2023 and 31 December 2022 respectively.

Liabilities for the purchase of business units of €194 thousand (unchanged from the previous period) refers to the acquisition of the Lima Brazil business unit. This liability dates back to 2011 when the Brazilian business unit was set up.

Other tax liabilities include taxes, fines and interest which arose from the parent signing a mutually-agreed assessment settlement procedure with the tax authorities (Friuli-Venezia Giulia regional tax authorities) for about €1,476 thousand, under which the first instalment was paid on 3 April 2023 and the second instalment was paid on 31 July (the parent opted for settlement in four quarterly instalments).

[3.22] Revenue and other revenue and income

Revenue amounts to €200,736 thousand on 30 September 2023, compared to €178,794 thousand on 30 September 2022.

 

37


Revenue derives from sales and distribution contracts with group customers essentially related to the sale of orthopaedic implants, mostly shoulders, hips and knees.

In accordance with IFRS 15, revenues are stated net of discounts and allowances and are constrained in order to only represent the ones that are highly probable to be collected. The constraints related to variable consideration refer to payback, amounting to € 3.5 million, established in connection with the activation of the Italian government payback provision as a retroactive rebate (i.e. variable consideration). Such variable consideration was estimated based on the publicly available information. The Italian payback law is a mechanism to obtain from suppliers a contribution to offset variances occurring when Italian government expenditures exceed their ceiling for the purchase of medical devices.

Revenueis broken down by geographical segment as follows:

 

(€‘000)

 

Revenue by GEOGRAPHICAL SEGMENT

   30/09/2023      30/09/2022
Restated
     Variation  

Europe

     128,849        103,676        25,173  

APAC

     28,710        28,063        647  

United States

     32,980        31,331        1,649  

Rest of world

     10,197        15,724        (5,527
  

 

 

    

 

 

    

 

 

 

Total sales revenue

     200,736        178,794        21,942  
  

 

 

    

 

 

    

 

 

 

Under Italian healthcare regulations, each region is allocated an annual budget for purchasing medical devices. Upon exceeding the assigned budget, the region can ask suppliers of medical devices to reimburse a portion of the excess amount in proportion to the annual market share of each supplier in the region involved (the payback system). Specifically, pursuant to Decree law no. 115 of 9 August 2022 (converted into Law no. 142/2022), the Ministry for Health, with Ministerial decree published on 15 September 2022 (“Decree 216/2022”), set the amounts exceeding the regional budgets for each year from 2015 to 2018 and, with Ministerial decree published on 6 October 2022 (“Decree 251/2022”), set out guidelines for the Italian regions to follow in requesting reimbursements under the payback system.

Under the payback system, each region issues payment orders to suppliers of medical devices. At the date of these consolidated financial statements, Limacorporate S.p.A. and Lima SM in liquidation received payment orders for reimbursements under the payback system for amounts totalling €8.8 million for 2015, 2016, 2017 and 2018 which were recognised as variable consideration under IFRS 15.

Should a supplier not pay the requested amounts within 30 days, Decree 216/2022 provides that such amounts be offset against any amounts due to such suppliers from each region and/or body partnered with regional healthcare authorities. In addition, under Decree law no. 4 of 11 January 2023, the due date for the payment of such amounts was deferred to 30 April 2023. Decree law no. 34 of 30 March 2023 as modified by Law Decree n 132 of 15th November 2023 then further deferred the payment to 30th November 2023.

On 24 November 2023 the Lazio regional administrative court has referred to the Italian Constitutional Court a series of points around the constitutional legitimacy of the legislation that disciplines the payback system for medical devices. As a consequence, al proceedings pending before the Lazio regional administrative court are, de facto, suspended until the Constitutional Court rules on the above.

Additionally, on 30 November 2023 the Lazio regional administrative court has issued a specific ruling to Limacorporate S.p.A., confirming that all requests for payment received from the regions are to be suspended until the Constitutional Court rules on the above.

 

38


In line with the approach adopted by other suppliers of medical devices, Limacorporate contested Decree 216/2022 and Decree 251/2022 before the Lazio regional administrative court, contesting, inter alia, whether the decrees comply with the constitution. The parent also contested the individual deeds through which the regions involved individually settled and requested the amounts deemed due to it.

Furthermore, as it cannot be excluded that the Italian Ministry for Health may deem that the regional budgets for each year from 2019 to 2022 have been exceeded and, thus, that the Italian regions may issue further payment orders for each of those years, the group has calculated its best estimate of amounts probably due, based on:

 

   

publicly available data on spending by the regions over the relevant budgets;

 

   

Limacorporate’s turnover in the various regions;

 

   

Limacorporate’s market share in the various regions.

Other revenue and income are broken down as follows:

 

(€‘000)

 

Description

   30/09/2023      30/09/2022
Restated
     Variation  

Service recharges

     2,639        1,950        690  

Lease income

     306        337        (31

Recharges to subsidiaries/associates

     10        18        (8

Gains

     735        508        435  

Release of the provision for risks

     —         5        223  

Other income

     224        487        (264

Grants related to income

     122        96        26  

Grants related to assets

     54        19        35  

Other revenue - previous years

     90        47        43  

Other revenue

     34        5        29  
  

 

 

    

 

 

    

 

 

 

TOTAL

     4,214        3,472        1,178  
  

 

 

    

 

 

    

 

 

 

The increase in revenue from recharges for services is linked to the rise in turnover and sales.

[3.23] Internal work capitalised

This caption amounts to €9,156 thousand on 30 September 2023 and €10,181 thousand on 30 September 2022. It may be broken down as follows:

 

(€‘000)

 

Description

   30/09/2023      30/09/2022
Restated
     Variation  

Increases in property, plant and equipment for capitalisation of equipment

     7,776        7,822        (46

ncreases in intangible assets for capitalisation of sundry costs

        545        (545

increases in property, plant and equipment for internal work

     1,380        1,814        (434
  

 

 

    

 

 

    

 

 

 

TOTAL

     9,156        10,181        (1,025
  

 

 

    

 

 

    

 

 

 

Increases in property, plant and equipment for capitalisation of equipment and internal work both refer to the capitalisation of equipment built internally. This equipment is provided to hospitals on a free loan basis to be used to implant the group’s products.

Increases in intangible assets for capitalisation of sundry costs (€nil thousand) refer to the capitalisation of internal and external costs incurred for product development projects.

 

39


[3.24] Raw materials, consumables, supplies and goods

This caption amounts to €50,902 thousand on 30 September 2023, compared to €42,250 thousand on 30 September 2022. It is broken down as follows:

 

(€‘000)

 

Description

   30/09/2023      30/09/2022
Restated
     Variation  

Purchase of raw materials

     9,240        7,121        2,119  

Purchase of semi-finished products

     19,029        16,164        2,866  

Purchase of finished goods

     10,164        7,185        2,979  

Individual tool components

     10,742        10,951        (210

Opening balance of raw materials, consumables, supplies and goods

     6,272        6,094        178  

Closing balance of raw materials, consumables, supplies and goods

     (6,755      (6,522      (232

Other purchases

     2,210        1,257        953  
  

 

 

    

 

 

    

 

 

 

TOTAL

     50,902        42,250        8,652  
  

 

 

    

 

 

    

 

 

 

[3.25] Services

Services amount to €63,036 thousand on 30 September 2023, compared to €60,200 thousand on 30 September 2022. The caption is broken down as follows:

 

(€‘000)

 

Description

   30/09/2023      30/09/2022
Restated
     Variation  

Outsourced processing and analyses

     2,495        2,483        12  

Transport costs for sales

     4,749        4,021        728  

Transport costs for purchases

     667        608        59  

Energy, power supply

     1,872        2,822        (951

Administrative services

     1,506        1,566        (59

Maintenance and repair

     1,691        1,479        212  

Maintenance of HW/SW/office equipment

     2,113        1,966        147  

Technical and commercial consultancy

     4,826        4,300        526  

Non-recurring consultancy

     1,080        1,880        (800

Conferences and trade fairs

     2,453        1,614        840  

WorkShop

     1,373        1,744        (370

Enasarco commissions and charges

     22,268        19,460        2,808  

Travel costs

     3,684        3,273        412  

Insurance costs

     2,961        2,660        301  

Directors’ fees

     572        2,551        (1,979

Royalties

     509        990        (481

Others

     8,216        6,784        1,432  
  

 

 

    

 

 

    

 

 

 

TOTAL

     63,036        60,200        2,837  
  

 

 

    

 

 

    

 

 

 

The increase in this caption is chiefly due to fees directly related to the growth in turnover and higher processing, transport costs and commissions also tied to the rise in sales.

Management remuneration at 30 September 2022 include € 941 thousand for management incentive plans (30 September 2023: € nil thousand). Reference should be made to section [4.7] Management Incentive plans for a description of such plans.

[3.26] Change in work in progress, semi-finished products and finished goods

This caption shows a positive balance of €3,890 thousand on 30 September 2023 (30 September 2022: €2,326 thousand).

 

40


[3.27] Personnel expenses

Personnel expenses amount to €67,412 thousand on 30 September 2023, compared to €56,313 thousand on 30 September 2022, and are broken down as follows:

 

(€‘000)

 

Description

   30/09/2023      30/09/2022
Restated
     Variation  

Wages and salaries

     56,225        45,747        10,802  

Social security contributions

     9,694        9,188        542  

Post-employment benefits

     1,393        1,319        74  

Other costs

     99        59        40  
  

 

 

    

 

 

    

 

 

 

TOTAL

     67,412        56,313        11,457  
  

 

 

    

 

 

    

 

 

 

[3.28] Amortisation, depreciation and impairment losses

Amortisation amount to €22,972 thousand on 30 September 2023, compared to €26,131 thousand on 30 September 2022, and include depreciation of right-of-use assets of €3,883 thousand on 30 September 2023 (30 September 2022: €4,007 thousand). Reference should be made to note [3.3] Property, plant and equipment for details on the individual categories.

The caption is broken down as follows:

 

(€‘000)

 

Description

   30/09/2023      30/09/2022
Restated
     Variation  

Amortisation of intangible assets

     3,314        6,244        (2,973

Depreciation of property, plant and equipment

     15,776        15,880        (72

Depreciation of leased assets

     3,883        4,007        (124
  

 

 

    

 

 

    

 

 

 

TOTAL

     22,972        26,131        (3,169
  

 

 

    

 

 

    

 

 

 

The impairment losses on trade receivables of €428 thousand (30 september 2022: €101 thousand) include the accrual for net impairment losses on trade receivables recognised pursuant to IFRS 9.

During the first nine months of 2023 the group impaired developments costs related to TechMah business, as consequence of the interruption of the project and the subscription of a new partnership with a software supplier on shoulder preoperative planning for an amount of €36,615 thousand.

As of the date of preparation of these condensed consolidated interim financial statements, the relevant losses are not expected to be reversed.

[3.29] Other operating costs

Other operating costs amount to €10,565 thousand on 30 September 2023, compared to €1,195 thousand in on 30 September 2022.

 

41


The caption is broken down as follows:

 

(€‘000)

 

Description

   30/09/2023      30/09/2022
Restated
     Variation  

Taxes and duties

     576        613        (37

Tax expense - previous years

     2        8        (7

Gifts and donations

     83        12        71  

Other costs

     258        522        (263

Losses on assets

     51        39        12  

Sundry costs - previous years

     1        1        1  

Provision for risks

     9,594        —         9,594  
  

 

 

    

 

 

    

 

 

 

TOTAL

     10,565        1,195        9,370  
  

 

 

    

 

 

    

 

 

 

[3.30] Net financial (income) expense

Net financial (income) expense amounts to €21,030 thousand negative on 30 September 2023, compared to €1,830 thousand positive on 30 September 2022, and is broken down as follows:

 

(€‘000)

 

Description

   30/09/2023      30/09/2022
Restated
     Variation  

Exchange gains

     3,111        13,481        (10,371

Other interest income

     7,524        107        7,417  

Financial income for adjusting liabilities to fair value

     940        6,201        (5,261

Financial Income

     11,574        19,789        (8,215

Exchange losses

     (5,386      (6,801      1,415  

Interest on bonds

     (19,548      (7,937      (11,610

Other interest and financial expenses

     (7,406      (3,221      (4,185

Financial expense for adjusting liabilities to fair value

     (265      —         (265

Financial Expenses

     (32,605      (17,959      (14,645
  

 

 

    

 

 

    

 

 

 

TOTAL

     (21,030      1,830        (22,860
  

 

 

    

 

 

    

 

 

 

The increase in financial expenses during the period is chiefly due to higher interests on bond.

Financial income include an amount for adjusting the derivatives’ fair value (€940 thousand at 30 September 2023 and €nil at 30 September 2022) and for adjusting to fair value the liability of Techmah’s acquisition (€nil thousand at 30 September 2023 and €6,201 thousand at 30 September 2022).

The change in other interest income refers to the release of financial expenses related to the financial liability of Techmah, which, as specified in Note 3.16, is zero as of September 30, 2023.

Exchange losses amount to €5,386 consist in €1,291 related to realised exchange losses and €4,095 refers to unrealised exchange losses.

Exchange gains amount to €3,111 consist in €1,057 related to realised exchange gains and €2,054 refers to unrealised exchange gains.

[3.31] Income tax (benefit) expense

Income tax (benefit) expense amounts to €(9,164) thousand on 30 September 2023 compared to an Income tax expense of € 266 thousand on 30 September 2022.

The decrease in deferred tax liabilities is mainly related to the write off of Techmah’s development costs.

 

42


[4.1] Operating segments

The disclosure about operating segments was prepared in accordance with IFRS 8 Operating segments which provides for the presentation of information in line with the measures adopted by the chief operating decision maker to make operating decisions.

At operating level, the group has a matrix organisational structure split by product line, distribution channel and geographical segment providing a coherent strategic vision of the business. This structure can be seen in the way management monitors and directs the group’s activities. Specifically, senior management reviews the group’s results as a whole as it does not have identifiable operating segments. Therefore, the group’s operations are presented as a single segment for IFRS 8 reporting purposes.

A breakdown of revenue earned in 2023 and 2022 by product line, distribution channel and geographical segment is shown below:

 

(€‘000)

 

Revenue by PRODUCT LINE

   30/09/2023      30/09/2022
Restated
     Variation  

Hip

     67,981        64,383        3,598  

Extremities

     81,935        72,674        9,261  

Knee

     43,502        35,185        8,317  

Fixation& Other

     7,319        6,553        766  
  

 

 

    

 

 

    

 

 

 

Total sales revenue

     200,736        178,794        21,941  
  

 

 

    

 

 

    

 

 

 

 

(€‘000)

 

Revenue by DISTRIBUTION CHANNEL

   30/09/2023      30/09/2022
Restated
     Variation  

Direct customers

     168,313        141,986        26,327  

Indirect channel

     32,423        36,808        (4,385
  

 

 

    

 

 

    

 

 

 

Total sales revenue

     200,736        178,794        21,942  
  

 

 

    

 

 

    

 

 

 

 

(€‘000)

 

Revenue by GEOGRAPHICAL SEGMENT

   30/09/2023      30/09/2022
Restated
     Variation  

Europe

     128,849        103,676        25,173  

APAC

     28,710        28,063        647  

United States

     32,980        31,331        1,649  

Rest of world

     10,197        15,724        (5,527
  

 

 

    

 

 

    

 

 

 

Total sales revenue

     200,736        178,794        21,942  
  

 

 

    

 

 

    

 

 

 

As required by IFRS 8, it is noted that the group does not have individual customers that generate revenue of 10% or more of its total revenue in 2023 and 2022.

[4.2] Financial instruments - Fair value and risk management

 

  A.

Accounting classification and fair value

The next table shows the carrying amount and fair value of each financial asset and liability, including their fair value hierarchy level. Information about the fair value of financial assets and liabilities not measured at fair value is not provided as their carrying amount reasonably approximates their fair value.

Trade receivables and other assets and trade payables and other liabilities classified as held for sale are not included in the table. Their carrying amount reasonably approximates their fair value.

 

43


(€000)

 
    Carrying Amount      Fair value  

30 September 2023

   Note   Fair value -
hedging
instruments
     Mandatorly at
FVTPL -
other
     FVOCI
debt
instruments
     FVOCI equity
instruments
     Financial
assets
measured

at fair
value
     Other
labilities
     Total      Level 1      Level 2      Level 3      Total  

Financial assets measured at fair value

                                  

Hedging interest rate swap

   [3.17]     940                       940           940           940  
       940        —         —         —         —         —         940        —         940        —         940  

Financial assets not measured at fair value

                                  

Trade receivables and other assets

   [3.9][3.11]                 87,285           87,285           87,285           87,285  

Cash and cash equivalents

   [3.12]                 27,127           27,127           27,127           27,127  
       —         —         —         —         114,412        —         114,412        —         114,412        —         114,412  

Financial liabilities measured at fair value

                                  

Hedging interest rate swap

   [3.17]     280                 —            280           280           280  

Liabilities for acquisitons - MT Ortho

   [3.16]                    185        185        —            185        185  

Liabiites for acquisitions - TechMah

   [3.16]                             —            —   
       280        —         —         —         —         185        465        —         280        185        465  

Financial liabilities not measured at fair value

                                  

Bank credit facilities

   [3.16]                    454        454           454           454  

Secured bank loans

   [316]                    12,000        12,000           12,000           12,000  

Unsecured bank loans

   [3.16]                    495        495           495           495  

Secured bonds - listed bonds

   [3.16]                    280,635        280,635           280,635           280,635  

Lease liabilities - IFRS 16

   [3.16]                    6,424        6,424           6,424           6,424  

Trade payables and otter Labilities

   [3.19][3.21]                    58,130        58,130           58,130           58,130  
       —         —         —         —         —         358,137        358,137        —         358,137        —         358,137  
    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

TOTAL

       1,221        —         —         —         114,412        358,322        473,955        —         473,770        185        473,955  
    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

  B.

Fair value measurement

i. Measurement techniques and significant unobservable inputs

The following tables present the measurement techniques and significant unobservable inputs used to determine the fair value of level 2 and 3 financial instruments in the statement of financial position.

Financial instruments measured at fair value

At 30 September 2023 the Management, as specified in note 3.16, assumes that there is no contingent consideration to be recorded as a financial liability of Techmah.

Financial instruments not measured at fair value

 

Type    Measurement technique
Secured bonds    Discounted cash flows:
Lease liabilities    This measurement technique
Secured bank loans    considers the present value of
Unsecured bank loans    estimated payments, discounted using a discount rate that reflects the risk.

 

  C.

Financial risk management

The group is exposed to the following risks deriving from its use of financial instruments:

 

   

credit risk;

 

   

liquidity risk;

 

   

market risk.

Risk management system

Overall responsibility for the design and oversight of the group’s risk management system lies with the parent’s board of directors. This committee is in charge of developing and monitoring the group’s risk management policies.

 

44


The group’s risk management policies are designed to identify and analyse any risks it is exposed to, establish appropriate limits and controls and monitor the risks and compliance with such limits. The committee regularly revisits the policies and related systems to align them with market developments and the group’s business. The group aims to create a disciplined and constructive control environment through training programmes, standards and management procedures so that its employees are familiar with their roles and responsibilities.

The board of directors ensures compliance with the risk polices and management procedures and checks that the risk management system is appropriate to deal with risks that could affect the group.

The group’s financial instruments comprise cash and cash equivalents, loans, trade receivables and payables, current and non-current assets and liabilities as well as derivatives.

In its normal business operations, the group is exposed to:

 

   

market risk, mainly currency and interest rate risks;

 

   

commercial or counterparty credit risks, related to the risk of default on commercial or financial obligations by various counterparties as part of normal business operations or lending, investment and hedging transactions;

 

   

liquidity risk, related to the availability of financial resources and access to the credit market and refers to the need to meet the group’s financial needs in the short term.

Financial risk management is carried out centrally and essentially ensures that there are enough financial resources to meet business development needs and that resources are suitably invested in profitable activities.

Market risk

Market risk can be broken down into the following components:

 

   

interest rate risk,

 

   

currency risk.

Interest rate risk

The group’s exposure to interest rate risk is chiefly related to cash and cash equivalents, bonds and bank loans and borrowings, especially the revolving credit facility that is managed centrally. The derivatives are referred of the interest rate swap and a cap contract put in place by the parent to hedge fluctuations in payments of interest on the bond issued in 2023. At 31 December 2022, 30 September 2022 and 31 December 2021 there weren’t derivatives. A 100bps increase in the interest rate applied to the first nine months of 2023 would have led to an increase in financial expense of roughly €0.5 million.

Currency risk

As the group sells its products in various countries, it is exposed to currency risk. This risk mainly derives from sales in currencies other than the Euro, like the US dollar, British pound, Japanese yen and Australian dollar.

The group regularly assesses its exposure to market financial risks. It does not manage such risks by using derivatives.

Credit risk

Credit risk is the risk that a customer or counterparty to a financial instrument may default on a contractual obligation generating a loss for the group. It mainly arises on trade receivables and debt instruments.

The group’s maximum exposure to this type of risk is the assets’ carrying amount.

Some of the markets on which the group operates have a higher level of risk, such as southern Italy, where the health system is deeply in debt, southern European countries, like Spain and Portugal, and eastern European countries, such as Croatia, the Czech Republic and Slovakia, where collection times are very long.

Most of the group’s receivables are due from public institutions, thus solely linked to the country risk. Moreover, payments from public administration have improved notably in some cases in recent years thanks to measures taken to cut public entity debt with private companies.

 

45


Credit risk is also mitigated by the fact that the group is increasing its sales in countries with shorter average collection times. Therefore, the weight of markets with higher credit risk will be reduced.

At 30 September 2023 and 2022, the group does not have exposures with individual customers for more than 10% of its total trade receivables.

The amount of financial assets for which recovery is doubtful is immaterial in terms of the total amount of receivables and is, in any case, covered by adequate accruals to the relevant allowances.

Liquidity risk

Liquidity risk derives from the ability to obtain financial resources at a sustainable cost to carry out the group’s normal business operations.

The group uses the usual tools to manage current trade receivables, as well as partially using the facilities available. Moreover:

 

   

the group has debt instruments and credit lines to deal with liquidity requirements;

there are no significant concentrations of liquidity risk with regard to financial assets.

[4.3] Significant non-recurring transactions

The condensed consolidated interim financial statements were not affected by significant non-recurring transactions.

[4.4] Guarantees

Reference should be made to section [3.16] of the notes to the condensed consolidated interim financial statements.

[4.5] Related party transactions

The group carries out transactions with the ultimate parent recognised in line with the provisions of IAS 24. They are all financial in nature and are performed with full transparency and on an arm’s length basis. They do not include typical and/or unusual transactions.

Details of related party transactions carried out during 30 September 2023 and 30 September 2022 are as follows:

 

(€‘000)

 
                   30.09.2023                              
     Payables      Receivables      Other non-
current
liabilities
     Other current
liabilities
     Sundry
recharges
     Services      Personnel
expenses
 

EMIL HOLDING II S.à.r.l.

     263        —         —         —         10        263        —   

Senior Management

     —         —         303        411        —         566        9,285  

Short-term

              411           566        —   

Post-empoyment

              —            —         —   

Other long - term

                    —         —   

Share based benefits

           303        —            —         9,285  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     263        —         303        411        10        829        9,285  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

No other significant related party transactions took place during the period.

The group operates in a market dominated by entities directly or indirectly controlled by the Italian government through state bodies, agencies, related parties and other organisations (entities related to government bodies). The parent does not carry out transactions with other entities related to government bodies, such as, for example, the sale and purchase of goods and materials, the supply or receipt of services, leasing of assets or use of public services.

 

46


Transactions with Emil Holding II S.à.r.l.

Financial transactions with the ultimate parent are part of the parent’s normal business operations and take place at conditions similar to those applied to transactions with non-related parties.

[4.6] Fees of directors, statutory auditors and key management personnel

The remuneration of managers and the fees paid to statutory auditors were as follows:

 

(€‘000)

 

Description

   30/09/2023      30/09/2022
Restated
     Variation  

Statutory auditors’ fees

     38        38        1  

Directors’ fees

     542        2,485        (1,943
  

 

 

    

 

 

    

 

 

 

TOTAL

     580        2,522        (1,942
  

 

 

    

 

 

    

 

 

 

[4.7] Management Incentive plans

In accordance with IFRS 2, the parent identified cash-settled share-based payment incentive plans for some managers.

 

   

The Bonus Payments

Starting from June 2022 the Controlling Entity and the Entity agreed with certain employees some compensation plans which provide that upon occurrence of certain events (the “Bonus Payment Trigger Events”) a payment of a certain amount based on the enterprise value of the Entity at the trigger event date (the “Trigger Event Enterprise Value”).

The Bonus Payment Trigger Events occur at the first of the following events:

 

   

the listing of Emil NewCo S.a.r.l. or any entity of the Lima Group of companies which holds, directly and indirectly, all or substantially all of the assets of the Lima Group, on a regulated stock exchange;

 

   

in case no listing pursuant to paragraph a) has taken place, (i) any sale or transfer by Emil Holding I to a third party purchaser (not related to any EQT Funds) of more than 50% of the ordinary shares held by Emil Holding I in Emil NewCo S.a.r.l. or (ii) any sale to a third party purchaser (not related to any EQT Funds) of more than 50% of the shares in any other entity which holds, directly or indirectly, all or substantially all of the business or assets of the Lima Group; or

 

   

an asset sale of all or substantially all of the assets of the Lima Group which results in the EQT Funds no longer holding any interest (except for unsubstantial assets) in the Lima Group.

Considering that the amount to be paid to the employees is based on the Trigger Event Enterprise Value of the Entity and is therefore based on the value of the Entity’s equity instrument, the Bonus Payment falls within the scope of the “IFRS 2 – Share Based Payments”.

In particular, the management accounted for the Bonus Payment as follows:

 

(i)

the agreements in which the Entity has the obligation to settle the payment as cash-settled share-based payments (the “Cash-settled Bonus Payments”);

 

(ii)

the agreements in which the obligation is settled by Emil Holding I as equity-settled share-based payments (the “Equity-settled Bonus Payments”).

In accordance with IFRS 2, the Equity-settled Bonus Payments are measured at the fair value of grant date. Instead, the Cash-settled Bonus Payments are measured at the fair value of grant date and then re-measured at each reporting date until settlement.

The fair value of the Bonus Payments is recognized as an expense during the vesting period.

In order to evaluate the fair value of the Bonus Payments, the management used a Monte Carlo valuation model.

 

   

The Grant Dates considered for the valuation are: June 6, 2022, June 18, 2022, June 28, 2022, and August 9, 2022, which are the grant dates of the major part of the agreements.

 

   

The management of the company has assumed that the exercise of the plan will occur following an Exit Event on December 31, 2023.

 

47


   

The riskfree interest rate is retrieved from public Information Provider and range from a minimun of 1.3% and maximum of 1.8% over the grant dates.

 

   

The volatility was estimated based on historical series of Equity Value from comparable companies. An adjustment was then applied in order to obtain the volatility relative to Enterprise Value, considering the framework derived from the Merton model.

 

   

Expected dividends rate is 0% for all the Bonus Payments.

 

   

Employee exit rate is 0% for all the Bonus Payments.

The fair value of the Cash-settled Bonus Payments at grant date amounted to € 380.1 thousand.

The fair value of the Equity-settled Bonus Payments at grant date amounted to € 16,348.0 thousand.

The movement of the interest rate curve and volatility is not expected to result in a significant change in the cash-settled bonus payment.

This plan led to a recognition of personnel expenses of €9,285 thousand at 30 September 2023.

[4.8] Events after the reporting date

With reference to the Investor and Founders Agreement described in the note 2.1, on 15th November 2023 the company filed a Motion to dismiss providing evidence that Lima did not breach the Investor and Founders Agreement Agreement and has no liability to Plaintiffs.

Enovis Corporation, an innovation-driven, medical technology growth company listed in NYSE, announced on September 25, 2023 a definitive agreement to acquire LimaCorporate S.p.A..

On 03 January 2024 Enovis Corporation (NYSE; ENOV) announced the completion of the acquisition of the shares of Limacorporate S.p.A. as anticipated on 25 September 2023. On the same date, Limacorporate S.p.A. fully reimbursed its bond and revolving credit facility. Such reimbursement was fully funded by an intercompany loan granted by Enovis Corporation.

On 09 January 2024 Limacorporate S.p.A. transferred the shares of Lima USA to Enovis Corporation.

31 January 2024

 

LOGO

 

48


LOGO

KPMG S.p.A.

Revisione e organizzazione contabile

Piazza Salvemini, 20

35131 PADOVA PD

Telefono +39 049 8249101

Email it-fmauditaly@kpmg.it

PEC kpmgspa@pec.kpmg.it

Independent Auditors’ Review Report

To the board of directors of Limacorporate S.p.A.

Results of Review of Condensed Consolidated Interim Financial Information

We have reviewed the accompanying condensed consolidated statement of financial position of Limacorporate S.p.A. and its subsidiaries (the Company) as of September 30, 2023 and 2022, the related condensed consolidated statements of income, changes in equity, and cash flows for the nine-month periods ended September 30, 2023 and 2022, and the related notes (collectively referred to as the condensed consolidated interim financial information).

Based on our reviews, we are not aware of any material modifications that should be made to the accompanying condensed consolidated interim financial information for it to be in accordance with International Accounting Standards 34, Interim Financial Reporting (IAS 34).

Basis for Review Results

We conducted our reviews in accordance with auditing standards generally accepted in the United States of America (GAAS) applicable to reviews of interim financial information. A review of condensed consolidated interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. A review of condensed consolidated interim financial information is substantially less in scope than an audit conducted in accordance with GAAS, the objective of which is an expression of an opinion regarding the financial information as a whole and accordingly, we do not express such an opinion. We are required to be independent of the Company and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our reviews. We believe that the results of the review procedures provide a reasonable basis for our conclusion.

Responsibilities of Management for the Condensed Consolidated Interim Financial Information

Management is responsible for the preparation and fair presentation of the condensed consolidated interim financial information in accordance with IAS 34 and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of condensed consolidated interim financial information that is free from material misstatement, whether due to fraud or error.

 

LOGO


LOGO

Limacorporate S.p.A.

Independent Auditors’ Review Report

September 30, 2023 and 2022

Report on Condensed Consolidated Balance Sheet as of December 31, 2022

We have previously audited, in accordance with GAAS, the consolidated statement of financial position as of December 31, 2022, and the related consolidated statements of income, comprehensive income, changes in equity, and cash flows for the year then ended (not presented herein); and we expressed an unmodified audit opinion on those audited consolidated financial statements in our report dated February 1, 2024. In our opinion, the accompanying condensed consolidated statement of financial position of the Company as of December 31, 2022 is consistent, in all material respects, with the audited consolidated financial statements from which it has been derived. The audit report includes an emphasis of matter paragraph that refers to the restatement of the 2022 financial statements for error corrections.

 

LOGO

KPMG S.p.A.

Padua, Italy

February 1, 2024

 

2

EX-99.3

Exhibit 99.3

ENOVIS CORPORATION

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

SEPTEMBER 30, 2023

 

1


UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET

As of September 30, 2023

($ in thousands)

 

     Enovis Historical
As of September 30, 2023
    Lima Historical
As of September 30, 2023
(Note 2)
    Transaction
Accounting
Adjustments
    Note 4   Financing
Adjustments
    Note 4   Pro Forma
Combined
 
ASSETS               

Current assets:

              

Cash and cash equivalents

   $ 32,129     $ 28,653     $ (777,790   (a)   $ 781,315     (a)   $ 64,307  

Trade receivables, less allowance for credit losses

     277,029       76,925       —          —          353,954  

Inventories, net

     470,913       96,153       38,459     (b)     —          605,525  

Prepaid expenses

     28,974       3,121       —          —          32,095  

Other current assets

     45,142       13,055       —          —          58,197  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Total current assets

     854,187       217,907       (739,331     $ 781,315         1,114,078  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Property, plant and equipment, net

     260,190       73,868       102,025     (m)     —          436,083  

Goodwill

     2,027,154       405,881       (145,426   (c)     —          2,287,609  

Intangible assets, net

     1,100,959       21,785       319,215     (d)     —          1,441,959  

Lease asset - right of use

     63,487       7,646       —          —          71,133  

Other assets

     94,940       37,203       7,957     (o)     (8,000   (n)     132,100  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Total assets

   $ 4,400,917     $ 764,290     $ (455,560     $ 773,315       $ 5,482,962  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 
LIABILITIES AND EQUITY               

Current liabilities:

              

Current portion of long-term debt

   $ —      $ 19,205     $ (19,205   (e)   $ 20,000     (j)   $ 20,000  

Accounts payable

     125,060       35,284       —          —          160,344  

Accrued liabilities

     230,224       31,170       80,000     (f)     —          341,394  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Total current liabilities

     355,284       85,659       60,795         20,000         521,738  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Long-term debt, less current portion

     395,000       296,903       (296,903   (e)     823,277     (j)     1,218,277  

Non-current lease liability

     49,176       4,757       —          —          53,933  

Other liabilities

     159,725       42,117       126,443     (k)     —          328,285  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Total liabilities

     959,185       429,436       (109,665       843,277         2,122,233  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Equity:

              

Common stock

     55       10,423       (10,423   (g)     —          55  

Additional paid-in capital

     2,952,975       417,403       (417,403   (h)     (61,962   (l)     2,891,013  

Retained earnings

     539,507       (92,972     81,931     (i)     (8,000   (n)     520,466  

Accumulated other comprehensive loss

     (52,915     —        —          —          (52,915
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Total shareholders’ equity

     3,439,622       334,854       (345,895       (69,962       3,358,619  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Noncontrolling interest

     2,110       —        —          —          2,110  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Total equity

     3,441,732       334,854       (345,895       (69,962       3,360,729  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Total liabilities and equity

   $ 4,400,917     $ 764,290     $ (455,560     $ 773,315       $ 5,482,962  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

See the accompanying notes to the Unaudited Pro Forma Condensed Combined Financial Information

 

2


UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS

For The Nine Months Ended September 30, 2023

($ in thousands)

 

     Enovis Historical
Nine Months Ended
September 30, 2023
    Lima Historical
Nine Months Ended
September 30, 2023
(Note 2)
    Transaction
Accounting
Adjustments
    Note 5     Financing
Adjustments
    Note 5     Pro Forma Combined  

Net sales

   $ 1,252,177     $ 220,370     $ —        $ —        $ 1,472,547  

Cost of sales

     525,787       70,284       12,003       (a), (f)       —          608,074  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Gross profit (loss)

     726,390       150,086       (12,003       —          864,473  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Selling, general and administrative expense

     619,294       136,575       5,597       (f)       —          761,466  

Research and development expense

     57,012       13,315       —          —          70,327  

Amortization of acquired intangibles

     98,256       3,590       12,910       (c)       —          114,756  

Insurance settlement loss (gain)

     —        —        —          —          —   

Restructuring and other charges

     11,782       41,259       —          —          53,041  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Total operating expenses

     786,344       194,739       18,507         —          999,590  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Operating income (loss)

     (59,954     (44,653     (30,510       —          (135,117
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Interest expense, net

     15,496       27,626       (27,886     (d)       42,408       (d)       57,644  

Debt extinguishment charges

     —        —        —          —          —   

Unrealized (gain) loss on investment in ESAB Corporation

     —        —        —          —          —   

Other (income) expense, net

     (665     (6,707     —          —          (7,372
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Income (loss) from continuing operations before taxes

     (74,785     (65,572     (2,624       (42,408       (185,389
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Income tax benefit

     (17,878     (9,929     (717     (e)       (11,591       (40,115
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Net income (loss) from continuing operations

     (56,907     (55,643     (1,907       (30,817       (145,274
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Income (loss) from discontinued operations, net of taxes

     21,096       —        —          —          21,096  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Net income (loss)

     (35,811     (55,643     (1,907       (30,817       (124,178
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Less: Net income attributable to noncontrolling interest from continued operations – net of taxes

     414       —        —          —          414  

Less: Net income attributable to noncontrolling interest from discontinued operations – net of taxes

     —        —        —          —          —   
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Net income (loss) attributable to Enovis Corporation

   $ (36,225   $ (55,643   $ (1,907     $ (30,817     $ (124,592
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Net income (loss) per share - basic

              

Continuing operations

     (1.05               (2.66

Discontinued operations

     0.39                 0.39  

Consolidated operations

     (0.67               (2.27

Net income (loss) per share - diluted

              

Continuing operations

     (1.05               (2.66

Discontinued operations

     0.39                 0.39  

Consolidated operations

     (0.67               (2.27

See the accompanying notes to the Unaudited Pro Forma Condensed Combined Financial Information

 

3


UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS

For the Year Ended December 31, 2022

($ in thousands)

 

     Envois Historical
Year Ended
December 31, 2022
    Lima Historical
Year Ended
December 31, 2022
(Note 2)
    Transaction
Accounting
Adjustments
    Note 5     Financing
Adjustments
    Note 5     Pro Forma Combined  

Net sales

   $ 1,563,101     $ 261,255     $ —        $ —        $ 1,824,356  

Cost of sales

     693,718       84,559       30,995       (a) (f)       —          809,272  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Gross profit

     869,383       176,696       (30,995       —          1,015,084  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Selling, general and administrative expense

     772,913       147,325       18,405       (b) (f)       —          938,643  

Research and development expense

     60,827       17,988       —          —          78,815  

Amortization of acquired intangibles

     126,301       9,101       12,899       (c)       —          148,301  

Insurance settlement gain

     (36,705     —        —          —          (36,705

Restructuring and other charges

     17,225       16,981       —          —          34,206  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Total operating expenses

     940,561       191,395       31,304         —          1,163,260  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Operating income (loss)

     (71,178     (14,699     (62,299       —          (148,176
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Interest expense, net

     24,052       15,795       (15,927     (d)       58,052       (d)       81,972  

Debt extinguishment charges

     20,396       —        —          8,000       (g)       28,396  

Unrealized (gain) loss on investment in ESAB Corporation

     (102,669     —        —          —          (102,669

Gain on cost basis investment

     (8,800     —        —          —          (8,800

Other (income) expense, net

     (2,088     (10,678     —          —          (12,766
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Income (loss) from continuing operations before taxes

     (2,069     (19,816     (46,372       (66,052       (134,309
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Income tax benefit

     36,120       6,861       (12,674     (e)       (15,867       14,440  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Net income (loss) from continuing operations

     (38,189     (26,677     (33,698       (50,185       (148,749
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Income (loss) from discontinued operations, net of taxes

     26,430       —        —          —          26,430  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Net income (loss)

     (11,759     (26,677     (33,698       (50,185       (122,319
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Less: Net income attributable to noncontrolling interest from continued operations – net of taxes

     567       —        —          —          567  

Less: Net income attributable to noncontrolling interest from discontinued operations – net of taxes

     966       —        —          —          966  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Net income (loss) attributable to Enovis Corporation

   $ (13,292   $ (26,677   $ (33,698     $ (50,185     $ (123,852
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Net income (loss) per share - basic

              

Continuing operations

     (0.72               (2.75

Discontinued operations

     0.47                 0.47  

Consolidated operations

     (0.25               (2.28

Net income (loss) per share - diluted

              

Continuing operations

     (0.72               (2.75

Discontinued operations

     0.47                 0.47  

Consolidated operations

     (0.25               (2.28

See the accompanying notes to the Unaudited Pro Forma Condensed Combined Financial Information

 

4


Note 1 – Basis of Presentation

The Acquisition is preliminarily being accounted for as a business combination using the acquisition method with Enovis as the accounting acquirer in accordance with Accounting Standards Codification (“ASC”) Topic 805, Business Combinations (“ASC 805”). Under this method of accounting, the aggregate transaction consideration will be allocated to Lima’s assets acquired and liabilities assumed based upon their estimated fair values at the date of completion of the Acquisition. The process of valuing the net assets of Lima immediately prior to the Acquisition is preliminary. Any differences between the estimated fair value of the consideration transferred and the estimated fair value of the assets acquired and liabilities assumed will be recorded as goodwill. Accordingly, the aggregate transaction consideration allocation and related adjustments reflected in this unaudited pro forma condensed combined financial information are preliminary and subject to revision based on a final determination of fair value.

The Company and certain of its subsidiaries entered into an Amendment of its Existing Credit Agreement to provide for the Term Loan Facility. The Company has additionally authorized the issuance of its $460,000,000 of 3.875% Convertible Senior Notes due 2028 as part of the offering, and will use a portion of the proceeds from this offering of Convertible Notes, together with approximately $400 million of borrowings from the Term Loan Facility and cash on hand, to fund the cash purchase price for the Lima Acquisition.

The unaudited pro forma condensed combined financial information presented is for informational purposes only and is not necessarily indicative of the financial position or results of operations that would have been realized if the Acquisition and Debt Financing had been completed on the dates set forth above, nor is it indicative of the future results or financial position of the Business. In addition, the unaudited pro forma condensed combined financial information does not reflect any anticipated synergies or dissynergies, operating efficiencies or cost savings that may result from the Acquisition.

All amounts presented within the notes to the unaudited pro forma condensed combined financial statements are presented in thousands of U.S. Dollars and have been prepared by applying Envois’ historical accounting policies. The unaudited pro forma condensed combined balance sheet as of September 30, 2023 gives effect to the Acquisition and the Debt Financing as if those transactions had been completed on September 30, 2023, and are applied to the unaudited condensed combined balance sheet of Enovis as of September 30, 2023.

The unaudited pro forma condensed combined statement of operations for the year ended December 31, 2022 and the nine months ended September 30, 2023 give effect to the Acquisition and the Debt Financing as if those transactions had occurred on January 1, 2022, the first day of fiscal year 2022 and are applied to the historical results of Enovis.

The assumptions and estimates underlying the adjustments to the pro forma financial statements are described in the accompanying notes.

The pro forma adjustments are preliminary, subject to further revision as additional information becomes available and additional analyses are performed. The pro forma adjustments have been made solely for the purpose of providing unaudited pro forma combined financial information and actual adjustments, when recorded, may differ materially.

The pro forma financial statements have been prepared for illustrative purposes only and may not be indicative of the operating results or financial condition that would have been achieved if the Transactions had been completed on the dates or for the periods presented, nor do they purport to project the results of operations or financial position for any future period or as of any future date. In addition to the pro forma adjustments, various other factors will have an effect on the financial condition and results of operations after the completion of the Transactions. The actual balance sheet and statements of operations may differ materially from the pro forma amounts reflected herein due to a variety of factors.

The historical financial statements of Enovis were prepared in accordance with U.S. GAAP and have been adjusted in the accompanying unaudited pro forma condensed combined financial information to give effect to pro forma adjustments which are necessary to account for the Acquisition and the Debt Financing. The unaudited pro forma adjustments are based upon available information and certain assumptions that management believes are reasonable.

 

5


Note 2 – Adjustments to the Historical Financial Information of Lima

The historical financial information of Lima was prepared in accordance with IFRS issued by the International Accounting Standards Board (IASB) and presented in EUR.

Reclassification adjustments have been made to Lima’s historical financial information to comply with Enovis’ presentation.

The historical financial information was translated from EUR to USD using the following historical exchange rates:

 

     EUR to USD  

Period end exchange rate as at September 30, 2023

   $ 1.06  

Average exchange rate for the 9 months ended September 30, 2023

     1.08  

Average exchange rate for the year ended December 31, 2022

     1.05  

 

6


UNAUDITED SCHEDULE OF ADJUSTED CONDENSED COMBINED STATEMENT OF FINANCIAL POSITION OF LIMA

As of September 30, 2023

(in thousands)

 

     IFRS                              U.S. GAAP  
     Lima historical
September 30,
2023
EUR
     IFRS to U.S.
GAAP differences
- EUR
    Note     Presentation
Reclassification
EUR
    Note     Lima adjusted
historical
September 30,
2023
EUR
     Lima adjusted
historical
September 30,
2023
USD
 
ASSETS                 

Current assets:

                

Cash and cash equivalents

   27,127      —        —        27,127      $ 28,653  

Trade receivables

     72,829        —          —          72,829        76,925  

Inventories

     91,033        —          —          91,033        96,153  

Prepaid expenses

     —         —          2,955       (aa     2,955        3,121  

Other current assets

     13,929        —          (1,569     (aa     12,360        13,055  

Current tax assets

     1,386        —          (1,386     (aa     —         —   
  

 

 

    

 

 

     

 

 

     

 

 

    

 

 

 

Total current assets

     206,304        —          —          206,304        217,907  
  

 

 

    

 

 

     

 

 

     

 

 

    

 

 

 

Property, plant and equipment

     77,173        (7,239     (b     —          69,934        73,868  

Goodwill

     384,268        —          —          384,268        405,881  

Intangible assets, net

     —         —          20,625       (bb     20,625        21,785  

Other intangible assets

     20,625        —        (a     (20,625     (bb     0        —   

Lease asset - right of use

     —         7,239       (b     —          7,239        7,646  

Other assets

     —         —          35,222       (cc     35,222        37,203  

Equity investments

     2        —          (2     (cc     —         —   

Deferred tax assets

     33,322        —          (33,322     (cc     —         —   

Other non-current financial assets

     940        —          (940     (cc     —         —   

Other non-current assets

     958        —          (958     (cc     —         —   
  

 

 

    

 

 

     

 

 

     

 

 

    

 

 

 

Total assets

   723,592      —        —        723,592      $ 764,290  
  

 

 

    

 

 

     

 

 

     

 

 

    

 

 

 

 

7


UNAUDITED SCHEDULE OF ADJUSTED CONDENSED COMBINED STATEMENT OF FINANCIAL POSITION OF LIMA

(continued)

As of September 30, 2023

(in thousands)

 

     IFRS                             U.S. GAAP  
     Lima historical
September 30,
2023

EUR
    IFRS to U.S.
GAAP differences
- EUR
    Note     Presentation
Reclassification

EUR
    Note     Lima adjusted
historical
September 30,
2023

EUR
    Lima adjusted
historical
September 30,
2023

USD
 

LIABILITIES AND EQUITY

              

Current liabilities:

              

Current portion of long-term debt

   —      —        18,182       (dd)     18,182     $ 19,205  

Trade payables

     33,405       —          —          33,405       35,284  

Accrued liabilities

     —        1,920       (b)       27,590       (ee)       29,510       31,170  

Current financial liabilities

     20,102       (1,920     (b)       (18,182     (dd)       —        —   

Current tax liabilities

     1,917       —          (1,917     (ee)       —        —   

Other current liabilities

     25,673       —          (25,673     (ee)       —        —   
  

 

 

   

 

 

     

 

 

     

 

 

   

 

 

 

Total current liabilities

     81,098       —          —          81,098       85,659  
  

 

 

   

 

 

     

 

 

     

 

 

   

 

 

 

Long-term debt, less current portion

     —        —          281,093       (ff)       281,093       296,903  

Non-current lease liability

     —        4,504       (b)       —          4,504       4,757  

Other liabilities

     —        —          39,874       (gg)       39,874       42,117  

Non current financial liabilities

     285,597       (4,504     (b)       (281,093     (ff)       —        —   

Employee benefits

     1,258       —          (1,258     (gg)       —        —   

Deferred tax liabilities

     9,273       —          (9,273     (gg)       —        —   

Provisions for risks and charges

     29,473       (1,000     (c)       (28,473     (gg)       —        —   

Other non-current liabilities

     870       —          (870     (gg)       —        —   
  

 

 

   

 

 

     

 

 

     

 

 

   

 

 

 

Total liabilities

   407,568     (1,000     —        406,568     $ 429,436  
  

 

 

   

 

 

     

 

 

     

 

 

   

 

 

 

Equity

              

Common stock

     —        —          9,868       (hh)       9,868       10,423  

Share capital

     9,868       —          (9,868     (hh)       —        —   

Additional paid-in capital

     —        —          395,176       (ii)       395,176       417,403  

Share premium reserve

     14,425       —          (14,425     (ii)       —        —   

Other reserves

     380,751       —          (380,751     (ii)       —        —   

Retained earnings

     —        —        (a)       (88,020     (jj)       (88,020     (92,972

Retained earnings (accumulated deficit)

     (41,236     —          41,236       (jj)       —        —   

Profit (loss) for the year

     (47,784     1,000       (c)       46,784       (jj)       —        —   

Accumulated other comprehensive loss

     —        —          —          —        —   
  

 

 

   

 

 

     

 

 

     

 

 

   

 

 

 

Total shareholders’ equity

     316,024       1,000         —          317,024       334,854  
  

 

 

   

 

 

     

 

 

     

 

 

   

 

 

 

Noncontrolling interest

     —        —          —          —        —   
  

 

 

   

 

 

     

 

 

     

 

 

   

 

 

 

Total equity

     316,024       1,000         —          317,024       334,854  
  

 

 

   

 

 

     

 

 

     

 

 

   

 

 

 

Total liabilities and equity

   723,592     —        —        723,592     $ 764,290  
  

 

 

   

 

 

     

 

 

     

 

 

   

 

 

 

 

8


UNAUDITED SCHEDULE OF ADJUSTED CONDENSED COMBINED STATEMENT OF OPERATIONS OF LIMA

For The Nine Months Ended September 30, 2023

(in thousands)

 

     IFRS                         U.S. GAAP  
     Lima nine months
ended September 30,
2023
    IFRS to U.S.
GAAP
differences - EUR
    Note   Presentation
Reclassification

EUR
    Note   Lima adjusted nine
months ended
September 30, 2023

EUR
    Lima adjusted nine
months ended
September 30,
2023

USD
 

Revenue

   200,736     —        (200,736   (aa)   —      $ —   

Other revenues and income

     4,214       —          (4,214   (aa, kk)     —        —   

Raw materials, consumables, supplies and goods

     50,902       —          (50,902   (bb, dd)     —        —   

Services

     63,036       8,283     (a,b)     (71,319   (bb, cc,
dd)
    —        —   

Change in W.I.P., semi-finished products and finished

     (3,890     —          3,890     (bb)     —        —   

Personnel expenses

     67,412       —          (67,412   (bb, cc)     —        —   

Amortisation and depreciation

     22,972       (3,883   (b)     (19,089   (ee)     —        —   

Impairment losses on trade receivables

     944       —          (944   (ff)     —        —   

Impairment losses on fixed assets

     38,082       —          (38,082   (gg)     —        —   

Other operating costs

     10,565       (1,000   (c)     (9,565   (cc)     —        —   

Internal work capitalised

     (9,156     —          9,156     (bb, cc)     —        —   

Financial income

     (11,574     —          11,574     (hh, ii)     —        —   

Financial expense

     32,605       175     (b)     (32,780   (hh, ii)     —        —   

Income taxes

     (9,164     —          9,164     (jj)     —        —   

Net sales

     —        —          203,401     (aa)     203,401       220,370  

Cost of sales

     —        —          64,872     (bb, ee)     64,872       70,284  

Selling, general and administrative expense

     —        —          126,059     (cc, ee,
ff)
    126,059       136,575  

Research and development expense

     —        —          12,290     (dd)     12,290       13,315  

Amortization of acquired intangibles

     —        —          3,314     (ee)     3,314       3,590  

Restructuring and other charges

     —        —          38,082     (gg)     38,082       41,259  

Interest expense, net

     —        —          25,499     (hh)     25,499       27,626  

Other (income) expense, net

     —        —          (6,191   (ii, kk)     (6,191     (6,707

Income tax benefit

   —      —        (9,164   (jj)   (9,164   $ (9,929

 

9


UNAUDITED SCHEDULE OF ADJUSTED CONDENSED COMBINED STATEMENT OF OPERATIONS OF LIMA

For The Year Ended December 31, 2022

(in thousands)

 

     IFRS                         U.S. GAAP  
     Lima Year Ended
December 31,
2022

EUR
    IFRS to U.S.
GAAP
differences -
EUR
    Note   Presentation
Reclassification

EUR
    Note   Lima adjusted
Year Ended
December 31, 2022

EUR
    Lima adjusted Year
Ended December
31, 2022

USD
 

Revenue

   245,669     —        (245,669   (aa)   —      $ —   

Other revenues and income

     5,798       —          (5,798   (aa, kk)     —        —   

Raw materials, consumables, supplies and goods

     56,391       —          (56,391   (bb, dd)     —        —   

Services

     81,645       11,655     (a,b)     (93,300   (bb, cc,
dd)
    —        —   

Change in W.I.P., semi-finished products and finished

     887       —          (887   (bb)     —        —   

Personnel expenses

     76,858       —          (76,858   (bb, cc)     —        —   

Amortisation and depreciation

     35,408       (5,335   (b)     (30,073   (ee)     —        —   

Impairment losses on trade receivables

     502       —          (502   (ff)     —        —   

Impairment losses on fixed assets

     16,152       —          (16,152   (gg)     —        —   

Other operating costs

     1,857       —          (1,857   (cc)     —        —   

Internal work capitalised

     (13,532     —          13,532     (bb, cc)     —        —   

Financial income

     (14,561     —          14,561     (hh, ii)     —        —   

Financial expense

     22,609       (220   (b)     (22,389   (hh, ii)     —        —   

Income taxes expense (benefit)

     6,526       —          (6,526   (jj)     —        —   

Net sales

     —        —          248,506     (aa)     248,506       261,255  

Cost of sales

     —        —          80,433     (bb, ee)     80,433       84,559  

Selling, general and administrative expense

     —        —          140,136     (cc, ee,
ff)
    140,136       147,325  

Research and development expense

     —        —          17,110     (dd)     17,110       17,988  

Amortization of acquired intangibles

     —        —          8,657     (ee)     8,657       9,101  

Restructuring and other charges

     —        —          16,152     (gg)     16,152       16,981  

Interest expense, net

     —        —          15,024     (hh)     15,024       15,795  

Other (income) expense, net

     —        —          (10,157   (ii, kk)     (10,157     (10,678

Income tax benefit

   —      —        6,526     (jj)   6,526     $ 6,861  

 

10


Statement of financial position IFRS to U.S. GAAP and Reclassification Adjustments

a - Under U.S. GAAP, only certain development costs that are proven to have alternative future use can be capitalized. As some of the costs incurred by Lima do not have alternative future use, such capitalized costs would be adjusted under U.S. GAAP, however, the balance will be valued in connection with purchase accounting and no adjustment is reflected herein for the IFRS to U.S. GAAP conversion.

b - As of January 1, 2019, Enovis and Lima adopted ASC 842, Leases and IFRS 16, Leases, respectively. U.S. GAAP follows finance lease and operating lease models for lessees, which impacts the pattern of expense recognition associated with the lease. Under IFRS, lessees account for all their leases under one accounting model, which is effectively equivalent to that of a finance lease under U.S. GAAP. To comply with U.S. GAAP, the unaudited Schedule of Adjusted Condensed Combined Statement of Financial Position as of September 30, 2023 includes a reclassification to Lease asset – right-of-use of €7.2 million, Accrued liabilities of €1.9 million, and Non-current lease liability of €4.5 million. The company is continuing to evaluate the classification of potential finance leases under US GAAP.

c - As of September 30, 2023, Lima’s Provisions for risks and charges includes an accrued liability for legal defense costs. As Enovis does not include such costs in estimates of loss accruals under ASC 450, an adjustment to reverse the effect of such legal defense costs is recorded on the unaudited Schedule of Adjusted Condensed Combined Statement of Financial Position as of September 30, 2023.

aa – Adjustment to reclassify a portion of Lima’s Other current assets to Prepaid expenses and Lima’s Current tax assets to Other current assets

bb – Adjustment to reclassify Lima’s Other intangible assets to Intangible assets, net

cc – Adjustment to reclassify Lima’s Equity investments, Deferred tax assets, Other non-current financial assets, and Other non-current assets to Other assets

dd – Adjustment to reclassify Lima’s Current financial liabilities to Current portion of long-term debt

ee – Adjustment to reclassify Lima’s Current tax liabilities, and Other liabilities to Accrued liabilities

ff – Adjustment to reclassify Lima’s Non-current financial liabilities to Long-term debt

gg – Adjustment to reclassify Lima’s Other non-current liabilities, Employee benefits, Deferred tax liabilities, and Provision for risks and charges to Other liabilities

hh – Adjustment to reclassify Lima’s Share capital to Common stock

ii – Adjustment to reclassify Lima’s Share premium reserve, and Other reserves to Additional paid-in capital

jj – Adjustment to reclassify Lima’s Retained earnings (accumulated deficit), and Profit (loss) for the year to Retained earnings

 

11


Statement of operations IFRS to U.S. GAAP and Reclassification Adjustments

a - To adjust for certain development costs capitalized by Lima into intangible assets, net. Lima capitalizes certain costs such as software licenses and research and development to intangible assets in accordance with IFRS. Under U.S. GAAP, only research and development costs that are proven to have alternative future use can be capitalized. As some of the costs incurred by Lima do not have alternative future use, such capitalized costs are adjusted. The impact of the adjustment on the unaudited Schedule of Adjusted Condensed Combined Statement of Operations for the nine months ended September 30, 2023 and year ended December 31, 2022 is calculated as the incremental expense that would have been recorded in accordance with U.S. GAAP during the respective periods. The adjustments result in an increase to Services for the nine months ended September 30, 2023 and year ended December 31, 2022 totaling €4.6 million and €6.1 million, respectively.

b - As of January 1, 2019, Enovis and Lima adopted ASC 842, Leases and IFRS 16, Leases, respectively. U.S. GAAP follows finance lease and operating lease models for lessees, which impacts the pattern of expense recognition associated with the lease. Under IFRS, lessees account for all their leases under one accounting model, which is effectively equivalent to that of a finance lease under U.S. GAAP. To comply with U.S. GAAP, the unaudited Schedule of Adjusted Condensed Combined Statement of Operations for the nine months ended September 30, 2023 and year ended December 31, 2022 includes a reclassification from Depreciation and Amortisation and Financial Expense to Services of €3.7 million and €5.6 million, respectively. The company is continuing to evaluate the classification of potential finance leases under US GAAP.

c - For the nine months ended September 30, 2023, Lima’s Other operating costs includes certain activity for legal defense costs. As Enovis does not include such costs in estimates of loss accruals under ASC 450, an adjustment to reverse the effect of such legal defense costs is recorded on the unaudited Schedule of Adjusted Condensed Combined Statement of Operations for the nine months ended September 30, 2023.

aa – Adjustment to reclassify Lima’s Revenue and a portion of Other revenues and income to Net sales. Reclassification to Net sales consists of revenue related to sales activities

bb – Adjustment to reclassify Lima’s Raw materials, Change in W.I.P., semi-finished products and finished, Services, Personnel, and Internal work capitalised to Cost of sales. Reclassification to Cost of sales consists of raw material costs, changes in W.I.P., semi-finished products and finished, personnel costs and services costs related to production

cc – Adjustment to reclassify Lima’s Services, Personnel, Internal work capitalised, and Other operating costs to Selling, general and administrative expense. Reclassification to Selling, general and administrative expense consist of service costs, salary and wages expense of employees

dd – Adjustment to reclassify Lima’s Raw materials and Services to Research and development expense. Reclassification to Research and development expense consist of raw material and services costs related to research and development activities

ee – Adjustment to reclassify Lima’s Amortisation and depreciation to Cost of Sales, Selling, general and administrative expense and Amortization of acquired intangibles

ff – Adjustment to reclassify Lima’s Impairment losses on trade receivables to Selling, general and administrative expense

gg – Adjustment to reclassify Lima’s Impairment losses on fixed assets to Restructuring and other charges

hh – Adjustment to reclassify a portion of Lima’s Financial income and Financial expense to Interest expense, net. Reclassification of Interest expenses consists of interest income and financial charges related to bonds and loans

ii – Adjustment to reclassify a portion of Lima’s Financial income and Financial expense to Other expense, net

jj – Adjustment to reclassify Lima’s Income tax expense (benefit) to Income tax expense (benefit)

kk – Adjustment to reclassify a portion of Lima’s Other revenues and income to Other expense, net

 

12


Note 3 – Preliminary Aggregate Transaction Consideration and Allocation

Estimated Aggregate Transaction Consideration

The following table summarizes the preliminary estimated aggregate transaction consideration for the Lima Business:

 

(in thousands)

   Amount  

Closing cash consideration

   $ 415,740  

Cash paid to settle Lima historical long-term debt

     351,009  

Estimated fair value of shares to be issued as contingent consideration (i)

     80,000  
  

 

 

 

Preliminary aggregate transaction consideration

   $ 846,749  
  

 

 

 

 

(i)

Reflects the preliminary fair value of the contingent consideration payable to Lima based on the historical share price of Enovis and will change through the closing date of the acquisition. As part of the purchase consideration, Enovis may issue up to 1,942,686 shares of Enovis common stock as a result of the arrangement within approximately 18 months after closing. The market price of the Enovis common stock may fluctuate between the timing of issuance, a 5% fluctuation in the market price of the common stock would have approximately a $3.5 million impact on the aggregate transaction consideration.

 

13


Preliminary Aggregate Transaction Consideration Allocation

The assumed accounting for the Acquisition, including the preliminary aggregate transaction consideration, is based on provisional amounts, and the associated purchase accounting is not final. The preliminary allocation of the purchase price to the acquired assets and assumed liabilities was based upon the preliminary estimate of fair values. For the preliminary estimate of fair value of assets acquired and liabilities assumed of Lima, management used publicly available benchmarking information, as well as a variety of other assumptions, including market participant assumptions. Management is expected to use widely accepted income-based, market-based, and cost-based valuation approaches in connection with the finalization of purchase accounting for the Acquisition. Actual results may differ materially from the assumptions within the accompanying unaudited pro forma condensed combined financial information. The unaudited pro forma adjustments are based upon available information and certain assumptions that management believes are reasonable under the circumstances. The purchase price adjustments applied to the historical financial information of Lima are preliminary and subject to change as additional information becomes available and as additional analyses are performed.

The following table summarizes the preliminary aggregate transaction consideration allocation, as if the Acquisition had been completed on September 30, 2023, with excess recorded to Goodwill:

 

(in thousands)

   Amount  

Preliminary aggregate transaction consideration

   $ 846,749  
  

 

 

 

Assets

  

Cash and cash equivalents

     28,653  

Trade receivables

     76,925  

Inventories

     134,612  

Prepaid expenses

     3,121  

Other current assets

     13,055  

Property, plant and equipment

     175,893  

Intangible assets

     341,000  

Lease asset - right of use

     7,646  

Other assets

     45,160  
  

 

 

 

Total assets

     826,065  

Liabilities

  

Accounts payable

     35,284  

Accrued liabilities

     31,170  

Non-current lease liability

     4,757  

Other liabilities

     168,560  
  

 

 

 

Total liabilities

     239,771  
  

 

 

 

Less: Estimated preliminary net assets acquired

     586,294  
  

 

 

 

Goodwill (see Footnote 4(c))

   $ 260,455  
  

 

 

 

 

14


Note 4 – Adjustments to the Unaudited Pro Forma Condensed Combined Balance Sheet

Adjustments included in the Transaction Accounting Adjustments column and Financing Adjustments column in the accompanying unaudited pro forma condensed combined balance sheet as of September 30, 2023 are as follows:

(a) Reflects adjustment to Cash and cash equivalents:

 

(in thousands)

   Amount  

Pro forma transaction accounting adjustments:

  

Estimated transaction costs (i)

   $ (11,041

Cash paid to settle Lima historical long-term debt

     (351,009

Cash paid for acquisition of Lima

     (415,740
  

 

 

 

Net pro forma transaction accounting adjustments to Cash and cash equivalents

   $ (777,790
  

 

 

 

Pro forma financing adjustments:

  

Cash from new Debt Financing, net of debt issuance costs and capped call fees (ii)

   $ 781,315  
  

 

 

 

Net pro forma adjustments to Cash and cash equivalents

   $ 3,525  
  

 

 

 

 

(i)

These costs consist of legal advisory, financial advisory, accounting and consulting costs expected to be incurred by Enovis. This is a preliminary estimate of costs and is subject to change upon close of the Transactions.

(ii)

New Debt Financing is reduced for debt issuance costs and original issue discount of $16.7 million as referenced in Footnote 4(j) and adjustments for capped call transaction of $56.0 million as referenced in Footnote 4(l).

(b) Represents a $38.5 million adjustment to the inventory balance to account for the preliminary adjustment to fair value of the inventory acquired as of the Acquisition Date. The estimated range of calculated value for inventory is based on preliminary estimates and assumptions. The final value determination of the acquired inventory may differ from this preliminary determination. The related assumptions and inputs will be refined as more data becomes available to determine the fair value indication.

(c) Preliminary adjustment to Goodwill, which represents the excess of the estimated aggregate transaction consideration over the preliminary fair value of the underlying assets acquired and liabilities assumed and the elimination of Lima’s historical Goodwill.

 

(in thousands)

   Amount  

Pro forma transaction accounting adjustments:

  

Goodwill resulting from the Acquisition (Note 3)

   $ 260,455  

Elimination of the Lima historical Goodwill

     (405,881
  

 

 

 

Net pro forma adjustments to Goodwill

   $ (145,426
  

 

 

 

 

15


(d) Reflects the preliminary purchase accounting adjustment for estimated intangibles based on the acquisition method of accounting. Adjustments to preliminary identifiable intangible assets in the unaudited pro forma condensed combined financial information consists of the following:

 

(in thousands)

   Preliminary
Fair Value
     Estimated
Useful Life
(Years)
 

Pro forma transaction accounting adjustments:

     

Estimated fair value – Technology

   $ 182,000        15  

Estimated fair value – Customer Relationships

     115,000        15  

Estimated fair value – Trade Name

     44,000        20  

Less: Historical Lima Intangible assets, net of amortization

     (21,785   
  

 

 

    

Net pro forma adjustments to Intangible assets, net

   $ 319,215     
  

 

 

    

(e) Reflects the settlement of historical Lima existing debt.

(f) Record estimated fair value of shares to be issued as contingent consideration.

(g) Reflects the elimination of Lima’s historical Common stock.

(h) Reflects the elimination of Lima’s historical Additional paid-in capital.

(i) Reflects the preliminary adjustment to Retained earnings, which includes the elimination of Lima’s historical Retained earnings.

 

(in thousands)

   Amount  

Pro forma transaction accounting adjustments:

  

Estimated transaction costs (i)

   $ (11,041

Less: Historical Lima Retained earnings elimination

     92,972  
  

 

 

 

Net pro forma adjustments to Retained earnings

   $ 81,931  
  

 

 

 

 

(i)

These costs consist of legal advisory, financial advisory, accounting and consulting costs expected to be incurred by Enovis. This is a preliminary estimate of costs and is subject to change upon close of the Transactions.

(j) Reflects the Debt Financing obtained from the Lenders, net of unamortized debt issuance costs. The adjustment to current and long-term debt is comprised of the following items:

 

(in thousands)

   Current portion
of long-term debt
     Long-term debt      Total  

Pro forma financing adjustments:

        

Convertible Notes

   $ —       $ 460,000      $ 460,000  

Term Loan

     20,000        380,000        400,000  

Less: Debt issuance costs and original issue discount

     —         (16,723      (16,723
  

 

 

    

 

 

    

 

 

 

Net pro forma financing adjustments

   $ 20,000      $ 823,277      $  843,277  
  

 

 

    

 

 

    

 

 

 

 

16


(k) Reflects the adjustments to record a deferred tax liability of $126.4 million resulting from pro forma fair value adjustments for the assets acquired and liabilities assumed. The estimate of the deferred tax was determined based on the estimated book basis of the net assets acquired after the application of acquisition accounting as compared to the tax basis of the net assets acquired using an estimated blended statutory tax rate of 27.3% for Intangible assets, net and estimated statutory tax rate of 27.9% for Property, plant and equipment, net and Inventories, net. Adjustments to established deferred tax assets and liabilities due to refined determination of statutory rates, changes in tax elections, as well as the changes in the estimates of the fair value of assets acquired and liabilities assumed may occur in conjunction with the finalization of the acquisition accounting and these changes in estimates could be material.

(l) Reflects a $61.9 million adjustment to record the capped call transactions entered into in connection with the issuance of the Convertible Notes. As these transactions meet certain accounting criteria, the capped call transactions are recorded in Shareholders’ equity and are not accounted for as derivatives.

(m) Reflects the preliminary purchase accounting adjustment of $102.0 million for Property, plant and equipment based on the acquisition method of accounting.

(n) Reflects the extinguishment of deferred financing fees associated with the bridge financing.

(o) Reflects a $7.9 million indemnification asset related to the settlement of certain litigation matters as agreed to in the purchase agreement. The estimated indemnification asset approximates the value of the related liability at September 30, 2023 and is recorded as an adjustment to Other current assets in the pro forma condensed combined balance sheet.

 

17


Note 5 – Pro Forma Adjustments to the Unaudited Condensed Combined Statement of Operations

Adjustments included in the Transaction Accounting Adjustments column and Financing Adjustments in the accompanying unaudited pro forma condensed combined statement of operations for the nine months ended September 30, 2023 and the fiscal year ended December 31, 2022 are as follows:

(a) Reflects $10.1 million for nine months ended September 30, 2023 and a $28.3 million for the year ended December 31, 2022 adjustments associated with the step-up in estimated fair value of Inventories, net recognized through Cost of sales during the 18 months after the acquisition.

A 10% change in the estimated fair value of Inventories, net would cause a corresponding increase or decrease in Cost of sales of approximately $1.0 million and $2.8 million for the nine months ended September 30, 2023 and the year ended December 31, 2022, respectively. Pro forma Cost of sales is preliminary and based on assumption that the inventory will be sold within 18 months of the closing date after the Transaction. The amount of Cost of sales following the Transaction may differ significantly between periods based upon the final value assigned and actual inventory turnover for each period.

(b) Reflects a $11.0 million adjustments to Selling, general and administrative expense (“SG&A”) related to expected transaction expenses.

(c) The following table reflects adjustments to Amortization of acquired intangibles related to amortization expense for the newly identified intangible assets, less the amortization expense on Lima’s historical intangible assets. Management is still in the process of evaluating the fair value of the intangible assets. Any resulting change in the fair value would have a direct impact to amortization expense, which could be material.

 

(in thousands)

   For the Nine
Months Ended

September 30, 2023
     For the Year Ended
December 31, 2022
 

Pro forma transaction accounting adjustments:

     

Amortization expense of Technology

   $ 9,100      $ 12,133  

Amortization expense of Customer Relationships

     5,750        7,667  

Amortization expense of Trade Name

     1,650        2,200  

Less: Historical amortization

     (3,590      (9,101
  

 

 

    

 

 

 

Net pro forma adjustments to Amortization of acquired intangibles

   $ 12,910      $ 12,899  
  

 

 

    

 

 

 

A 10% change in the valuation of technology intangible assets, customer relationship intangible assets, and trade name intangible assets would cause a corresponding increase or decrease in the amortization expense of approximately $1.7 million and $2.2 million for the nine months ended September 30, 2023 and the year ended December 31, 2022, respectively. Pro forma amortization is preliminary and based on the use of straight-line amortization. The amount of amortization following the Acquisition may differ significantly between periods based upon the final value assigned and amortization methodology used for each identifiable intangible asset.

(d) Reflects the expense related to the financing and amortization of issuance costs related to the Transactions:

 

(in thousands)

   For the Nine
Months Ended
September 30, 2023
     For the Year Ended
December 31, 2022
 

Pro forma transaction adjustments:

     

Remove historical Lima Interest expense

   $ (27,886    $ (15,927

Pro forma financing adjustments:

     

Interest expense from the financing transactions

   $ 42,408      $ 58,052  

The interest expense included in the unaudited pro forma condensed combined financial information was calculated using an effective interest rate, which considers transaction costs and issuance discounts, and reflects an approximate weighted-average interest rate of 6.9%. Actual interest rates may vary from those depicted in the pro forma amounts.

 

18


A sensitivity analysis on interest expense for the nine months ended September 30, 2023 and the year ended December 31, 2022 has been performed to assess the effect of a 12.5 basis point change of the hypothetical interest on the Debt Financing. The following table shows the change in the Interest expense for the Debt Financing described above:

 

(in thousands)

   For the Nine Months ended
September 30, 2023
     For the Year Ended
December 31, 2022
 

Interest expense assuming:

     

Increase of 0.125%

   $ 402      $ 569  

Decrease of 0.125%

   $ (402    $ (569

(e) Adjustment to reflect the income tax impact of the pro forma adjustments related to the Transactions using the estimated blended statutory tax rate of 27.3%. Income tax rates do not take into account any possible future tax events or changes in planned structure for the combined company. The effective tax rate of the combined company could be significantly different than what is presented in the pro forma financial information.

(f) Adjustment to reflect the incremental depreciation expense associated with the fair value step up of Property, plant and equipment. The following table reflects adjustments to Cost of sales and Selling, general and administrative expense related to depreciation expense for the increase in fair value of Property, plant and equipment. Management is still in the process of evaluating the fair value of the Property, plant and equipment assets. Any resulting change in the fair value would have a direct impact to depreciation expense, which could be material.

 

(in thousands)

   For the Nine Months
ended September 30, 2023
     For the Year Ended
December 31, 2022
 

Pro forma transaction adjustments – Cost of Sales:

     

Incremental depreciation expense associated with Property, plant and equipment

   $ 1,903      $ 2,636  

Net pro forma adjustments to Cost of sales

   $ 1,903      $ 2,636  

Pro forma transaction adjustments – Selling, general and administrative expense:

     

Incremental depreciation expense associated with Property, plant and equipment

   $ 5,597      $ 7,364  

Net pro forma adjustments to Selling, general and administrative expense

   $ 5,597      $ 7,364  

(g) Reflects an $8.0-million adjustment to Debt extinguishment charges related to bridge financing fees.

 

19


Note 6 – Pro Forma Earnings Per Share

The unaudited pro forma condensed combined basic and diluted earnings per share calculations are based on the condensed combined basic and diluted average shares of Enovis and Lima.

 

(in thousands, except per share data)

   For the Nine Months ended
September 30, 2023
     For the Year Ended
December 31, 2022
 

Pro Forma Weighted Average Shares

     

Basic weighted average number of common shares outstanding – historical

     54,549,369        54,065,420  

Pro Forma Earnings per Share

     

Pro forma Net income (loss) from continuing operations

     (145,274      (148,749

Basic – Pro Forma

   $ (2.66      (2.75

Diluted – Pro Forma

   $ (2.66      (2.75

 

20